

Drug Resistance and the Solid Tumor Microenvironment

Journal of the National Cancer Institute

99, 1441-1454

DOI: [10.1093/jnci/djm135](https://doi.org/10.1093/jnci/djm135)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Single-cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids. <i>Biotechnology and Bioengineering</i> , 2008, 101, 797-810.	1.7	21
2	Bacterial therapies: completing the cancer treatment toolbox. <i>Current Opinion in Biotechnology</i> , 2008, 19, 511-517.	3.3	70
3	Imaging angiogenesis and the microenvironment. <i>Apmis</i> , 2008, 116, 695-715.	0.9	139
4	Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. <i>Immunological Reviews</i> , 2008, 222, 299-315.	2.8	38
5	Multi-functional nanocarriers for targeted delivery of drugs and genes. <i>Journal of Controlled Release</i> , 2008, 130, 121-128.	4.8	165
6	Molecular aspects of tumour hypoxia. <i>Molecular Oncology</i> , 2008, 2, 41-53.	2.1	126
7	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. <i>Trends in Immunology</i> , 2008, 29, 235-241.	2.9	32
8	Solid tumor physiology and hypoxia-induced chemo/radio-resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 205-216.	1.2	181
9	Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3373-3380.	1.9	32
10	Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. <i>Drug Resistance Updates</i> , 2008, 11, 110-121.	6.5	163
11	Multi-functional nanocarriers to overcome tumor drug resistance. <i>Cancer Treatment Reviews</i> , 2008, 34, 592-602.	3.4	381
12	PEG-conjugated Hemoglobin Combination with Cisplatin Enforced the Antiangiogenic Effect in a Cervical Tumor Xenograft Model. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2008, 36, 487-497.	0.9	5
13	<i>In vitro</i> three-dimensional tumor microenvironment models for anticancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1-10.	2.5	105
14	A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 7110-7115.	3.2	42
15	Physiological Targeting to Improve Anticancer Drug Selectivity. <i>Australian Journal of Chemistry</i> , 2008, 61, 647.	0.5	24
17	Urokinase: the identity crisis continues. <i>Blood</i> , 2008, 112, 8-8.	0.6	0
18	Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. <i>Current Opinion in Supportive and Palliative Care</i> , 2008, 2, 153-160.	0.5	1
20	Hyaluronan-CD44 Interactions and Chemoresistance in Cancer Cells. , 2009, , 19-35.		2

#	ARTICLE	IF	CITATIONS
22	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. <i>Science</i> , 2009, 324, 1457-1461.	6.0	2,730
23	Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e4.	1.6	309
24	Targeting multiple kinases in glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 277-292.	1.9	39
25	Sensitivity of fluorophore-quencher labeled microbubbles to externally applied static pressure. <i>Medical Physics</i> , 2009, 36, 3455-3469.	1.6	5
26	Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts. <i>Clinical Cancer Research</i> , 2009, 15, 5389-5395.	3.2	53
27	Glucose Intolerance During Adjuvant Chemotherapy for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 537-537.	3.0	31
28	The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone. <i>Cancer Research</i> , 2009, 69, 940-947.	0.4	47
29	Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2424-2431.	1.9	54
30	Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling. <i>Cancer Research</i> , 2009, 69, 4484-4492.	0.4	125
31	Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?. <i>Cell Cycle</i> , 2009, 8, 3291-3296.	1.3	60
32	A Review of Mechanisms of Circumvention and Modulation of Chemotherapeutic Drug Resistance. <i>Current Cancer Drug Targets</i> , 2009, 9, 273-280.	0.8	45
34	Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 297, C66-C74.	2.1	45
35	Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor- β Pathways in Prostate Cancer. <i>Molecular Pharmacology</i> , 2009, 75, 429-436.	1.0	8
36	Accurate Analysis of Tumor Margins Using a Fluorescent pH Low Insertion Peptide (pHLIP). <i>International Journal of Molecular Sciences</i> , 2009, 10, 3478-3487.	1.8	28
37	Hyaluronan, CD44, and Emmprin Regulate Lactate Efflux and Membrane Localization of Monocarboxylate Transporters in Human Breast Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 1293-1301.	0.4	132
38	Abrogating Drug Resistance in Malignant Peripheral Nerve Sheath Tumors by Disrupting Hyaluronan-CD44 Interactions with Small Hyaluronan Oligosaccharides. <i>Cancer Research</i> , 2009, 69, 4992-4998.	0.4	90
39	Cancer Stem Cells and Tumor Response to Therapy: Current Problems and Future Prospects. <i>Seminars in Radiation Oncology</i> , 2009, 19, 96-105.	1.0	64
40	Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. <i>Journal of Controlled Release</i> , 2009, 137, 130-135.	4.8	41

#	ARTICLE	IF	CITATIONS
41	GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. <i>BMC Cancer</i> , 2009, 9, 241.	1.1	59
42	Acute and chronic in vivo therapeutic resistance. <i>Biochemical Pharmacology</i> , 2009, 77, 1665-1673.	2.0	37
43	Sequence dependence of cell growth inhibition by EGFR tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. <i>Head and Neck</i> , 2009, 31, 1263-1273.	0.9	5
44	Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells <i>in vitro</i> and in orthotopic mouse model. <i>International Journal of Cancer</i> , 2009, 125, 2547-2555.	2.3	34
45	Targeting slow-proliferating ovarian cancer cells. <i>International Journal of Cancer</i> , 2010, 126, 2448-2456.	2.3	28
46	Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 1112-1119.	1.9	18
47	Front Instabilities and Invasiveness of Simulated Avascular Tumors. <i>Bulletin of Mathematical Biology</i> , 2009, 71, 1189-1227.	0.9	49
48	Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. <i>British Journal of Cancer</i> , 2009, 100, 1073-1086.	2.9	131
49	Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines. <i>British Journal of Cancer</i> , 2009, 100, 1287-1291.	2.9	41
50	Accumulation of an anthraquinone and its platinum complexes in cancer cell spheroids: the effect of charge on drug distribution in solid tumour models. <i>Chemical Communications</i> , 2009, , 2673.	2.2	68
51	Tumour-targeted delivery of TRAIL using <i>Salmonella typhimurium</i> enhances breast cancer survival in mice. <i>British Journal of Cancer</i> , 2009, 101, 1683-1691.	2.9	152
52	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
53	Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. <i>European Journal of Cancer</i> , 2009, 45, 890-898.	1.3	36
54	CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. <i>European Journal of Cancer</i> , 2009, 45, 3326-3335.	1.3	21
55	Human tumor xenografts and mouse models of human tumors: re-discovering the models. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1295-1305.	2.5	13
56	A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. <i>Lab on A Chip</i> , 2009, 9, 545-554.	3.1	99
58	Hypoxia-Induced Decrease in p53 Protein Level and Increase in c-jun DNA Binding Activity Results in Cancer Cell Resistance to Etoposide. <i>Neoplasia</i> , 2009, 11, 976-IN3.	2.3	38
60	Patient-specific tumor biology-based selection of ovarian cancer therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 213-216.	0.2	1

#	ARTICLE	IF	CITATIONS
61	Ovarian cancer in 2010. Therapy: Open Access in Clinical Medicine, 2010, 7, 205-208.	0.2	0
62	Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Therapeutic Delivery, 2010, 1, 289-305.	1.2	21
63	Ovarian Cancer: The Role of Functional Imaging as an End Point in Clinical Trials. International Journal of Gynecological Cancer, 2010, 20, 971-978.	1.2	6
64	Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery. AAPS Journal, 2010, 12, 223-232.	2.2	95
65	Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla. European Radiology, 2010, 20, 491-496.	2.3	59
66	Fluorescent Copper(II) Bis(thiosemicarbazones): Synthesis, Structures, Electron Paramagnetic Resonance, Radiolabeling, In Vitro Cytotoxicity and Confocal Fluorescence Microscopy Studies. Chemistry - an Asian Journal, 2010, 5, 506-519.	1.7	59
67	Medical treatments: in association or alone, their role and their future perspectives. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 413-419.	1.4	9
68	Chromogranin A and the Tumor Microenvironment. Cellular and Molecular Neurobiology, 2010, 30, 1163-1170.	1.7	45
69	Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clinical and Experimental Metastasis, 2010, 27, 557-569.	1.7	75
70	Chitosan-Alginate Scaffold Culture System for Hepatocellular Carcinoma Increases Malignancy and Drug Resistance. Pharmaceutical Research, 2010, 27, 1939-1948.	1.7	86
71	Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. Journal of Controlled Release, 2010, 142, 167-173.	4.8	55
72	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Journal of Controlled Release, 2010, 145, 66-73.	4.8	78
73	Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer, 2010, 10, 157.	1.1	68
74	Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer, 2010, 10, 200.	1.1	39
75	The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer, 2010, 10, 255.	1.1	130
76	The stem cell code in oral epithelial tumorigenesis: "The cancer stem cell shift hypothesis"™. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 146-162.	3.3	31
77	Bax deficiency mediated drug resistance can be reversed by endoplasmic reticulum stress induced death signaling. Biochemical Pharmacology, 2010, 79, 1589-1599.	2.0	19
78	BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochemical Pharmacology, 2010, 80, 1160-1169.	2.0	24

#	ARTICLE	IF	CITATIONS
79	Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. <i>Experimental Cell Research</i> , 2010, 316, 3417-3424.	1.2	151
80	pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. <i>International Journal of Cancer</i> , 2010, 127, 207-219.	2.3	237
81	Effect of goniotalamin on the development of Ehrlich solid tumor in mice. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6742-6747.	1.4	57
82	Longitudinal Changes in Tumor Perfusion Pattern during the Radiation Therapy Course and its Clinical Impact in Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 502-508.	0.4	81
83	Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models. <i>Microcirculation</i> , 2010, 17, 206-225.	1.0	376
84	Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. <i>Journal of Internal Medicine</i> , 2010, 267, 515-525.	2.7	92
85	Tuning payload delivery in tumour cylindroids using gold nanoparticles. <i>Nature Nanotechnology</i> , 2010, 5, 465-472.	15.6	439
86	Galectins and Gliomas. <i>Brain Pathology</i> , 2010, 20, 17-27.	2.1	97
87	Front Instabilities and Invasiveness of Simulated 3D Avascular Tumors. <i>PLoS ONE</i> , 2010, 5, e10641.	1.1	31
88	A reduction in the interstitial fluid pressure per se, does not enhance the uptake of the small molecule weight compound 5-fluorouracil into 4T1 mammary tumours. <i>Drugs and Therapy Studies</i> , 2010, 1, 5.	0.6	2
89	Cáncer e o microambiente tumoral. , 2010, 89, 21-31.	0.0	4
90	Cavitation-enhanced delivery of macromolecules into an obstructed vessel. <i>Journal of the Acoustical Society of America</i> , 2010, 128, EL310-EL315.	0.5	16
91	Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound. <i>Journal of Oncology</i> , 2010, 2010, 1-13.	0.6	9
92	Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs. <i>Molecular Cancer Research</i> , 2010, 8, 809-820.	1.5	65
93	Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. <i>Cancer Research</i> , 2010, 70, 4499-4508.	0.4	68
94	Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 479-488.	1.3	17
95	Intraperitoneal therapy for peritoneal cancer. <i>Future Oncology</i> , 2010, 6, 1625-1641.	1.1	141
96	The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells. <i>Xenobiotica</i> , 2010, 40, 681-690.	0.5	15

#	ARTICLE	IF	CITATIONS
97	Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1477-1491.	1.5	36
98	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. <i>Cell Death and Disease</i> , 2010, 1, e87-e87.	2.7	155
99	Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. <i>Annals of Oncology</i> , 2010, 21, 1723-1727.	0.6	78
100	Re-challenge chemotherapy for relapsed non-small-cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 315-318.	0.9	20
101	TGFBI expression is associated with a better response to chemotherapy in NSCLC. <i>Molecular Cancer</i> , 2010, 9, 130.	7.9	61
102	Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. <i>Molecular Cancer</i> , 2010, 9, 191.	7.9	90
103	Cytotoxicity, Hydrophobicity, Uptake, and Distribution of Osmium(II) Anticancer Complexes in Ovarian Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 840-849.	2.9	120
104	The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 63-71.	1.8	70
105	Photodynamic therapy-driven induction of suicide cytosine deaminase gene. <i>Cancer Letters</i> , 2010, 290, 216-222.	3.2	7
107	Edema and fluid dynamics in connective tissue remodelling. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 518-523.	0.9	43
108	Mechanisms of Multidrug Resistance in Cancer. <i>Methods in Molecular Biology</i> , 2010, 596, 47-76.	0.4	555
109	Cell-Extracellular Matrix Interactions in Cancer. , 2010, , .		22
110	A microfluidic device for tissue biopsy culture and interrogation. <i>Analytical Methods</i> , 2010, 2, 1005.	1.3	29
111	Spatiotemporal analysis of tumor uptake patterns in dynamic ¹⁸ F-FDG-PET and dynamic contrast enhanced CT. <i>Acta Oncologica</i> , 2011, 50, 873-882.	0.8	12
112	Visualising the hypoxia selectivity of cobalt(III) prodrugs. <i>Chemical Science</i> , 2011, 2, 2135.	3.7	54
113	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 192-205.	2.0	61
114	Integrating pharmacogenetics into gemcitabine dosing—time for a change?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 439-444.	12.5	63
115	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. <i>Nature Chemical Biology</i> , 2011, 7, 787-793.	3.9	156

#	ARTICLE	IF	CITATIONS
116	<i>In vitro</i> and <i>In vivo</i> Anticancer Activity of Extracts, Fractions, and Eupomatenoid-5 Obtained from <i>Piper regnellii</i> Leaves. <i>Planta Medica</i> , 2011, 77, 1482-1488.	0.7	21
117	Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue. <i>Bioconjugate Chemistry</i> , 2011, 22, 1776-1783.	1.8	70
118	Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 749-763.	2.4	40
119	The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. <i>Imaging in Medicine</i> , 2011, 3, 333-343.	0.0	2
120	Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells. <i>Molecular Pharmaceutics</i> , 2011, 8, 185-203.	2.3	132
121	Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors. <i>Pharmacogenomics</i> , 2011, 12, 1337-1348.	0.6	16
122	Targeted photodynamic therapy – a promising strategy of tumor treatment. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 1097-1109.	1.6	228
123	Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines. <i>BMC Cancer</i> , 2011, 11, 51.	1.1	21
124	Polymeric Micelles for Neoadjuvant Cancer Therapy and Tumor-Primed Optical Imaging. <i>ACS Nano</i> , 2011, 5, 8721-8729.	7.3	64
125	Evolutionary Dynamics in Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 2094-2100.	2.3	73
126	Drug resistance in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 12-23.	12.5	286
127	Enhanced Release of Small Molecules from Near-Infrared Light Responsive Polymer Nanorod Composites. <i>ACS Nano</i> , 2011, 5, 2948-2956.	7.3	146
128	Tumors of the Central Nervous System, Volume 2., 2011, . .		3
130	Interventions that induce modifications in the tumor microenvironment. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2011, 15, 376-382.	0.6	10
131	Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. <i>Drug Resistance Updates</i> , 2011, 14, 191-201.	6.5	512
132	Intérêt des traceurs de l'hypoxie en radiothérapie. <i>Medecine Nucleaire</i> , 2011, 35, 621-624.	0.2	0
133	Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment. <i>Molecular Pharmaceutics</i> , 2011, 8, 2032-2038.	2.3	422
134	Rapid dissolution of ZnO nanocrystals in acidic cancer microenvironment leading to preferential apoptosis. <i>Nanoscale</i> , 2011, 3, 3657.	2.8	118

#	ARTICLE	IF	CITATIONS
135	Cavitation-Enhanced Extravasation for Drug Delivery. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 1838-1852.	0.7	106
137	Evaluation of the In vivo Radiosensitizing Activity of Etanidazole Using Tumor-bearing Chick Embryo. <i>Journal of Radiation Research</i> , 2011, 52, 208-214.	0.8	19
138	The microenvironment in health and cancer of the mammary gland. , 0, , 50-79.		0
139	Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells. <i>PLoS ONE</i> , 2011, 6, e19892.	1.1	37
140	Reversion of pH-Induced Physiological Drug Resistance: A Novel Function of Copolymeric Nanoparticles. <i>PLoS ONE</i> , 2011, 6, e24172.	1.1	23
141	Overexpression of GLUT1 in Colorectal Cancer is Independently Associated with Poor Prognosis. <i>International Journal of Biological Markers</i> , 2011, 26, 166-172.	0.7	41
143	Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. <i>Oncology Reports</i> , 2011, 25, 863-70.	1.2	9
144	New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. <i>Cancer Science</i> , 2011, 102, 1396-1402.	1.7	69
145	Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. <i>Cell Proliferation</i> , 2011, 44, 591-601.	2.4	65
146	Strategies to improve radiotherapy with targeted drugs. <i>Nature Reviews Cancer</i> , 2011, 11, 239-253.	12.8	889
147	An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. <i>Nature Reviews Cancer</i> , 2011, 11, 375-382.	12.8	151
148	Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. <i>Cancer Gene Therapy</i> , 2011, 18, 153-166.	2.2	21
149	Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1239-1253.	1.6	971
150	Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 955-964.	1.7	98
151	Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. <i>Journal of Controlled Release</i> , 2011, 155, 237-247.	4.8	112
152	Quiescent cells: A natural way to resist chemotherapy. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2011, 390, 3354-3361.	1.2	8
153	Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). <i>Experimental and Molecular Pathology</i> , 2011, 90, 215-225.	0.9	38
154	Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA. <i>International Journal of Pharmaceutics</i> , 2011, 419, 33-42.	2.6	28

#	ARTICLE	IF	CITATIONS
155	Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma. <i>European Journal of Pharmacology</i> , 2011, 667, 330-338.	1.7	37
156	Overcoming drug resistance in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 817-828.	1.5	194
157	The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. <i>Pharmaceutical Research</i> , 2011, 28, 2147-2156.	1.7	64
158	Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1055-1062.	1.1	17
159	Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1073-1083.	1.1	21
160	The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 389-398.	1.1	24
161	Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1179-1190.	1.1	32
162	Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. <i>International Journal of Pharmaceutics</i> , 2011, 413, 194-201.	2.6	78
163	Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. <i>Cancer Cell International</i> , 2011, 11, 3.	1.8	103
164	A systems-based mathematical modelling framework for investigating the effect of drugs on solid tumours. <i>Theoretical Biology and Medical Modelling</i> , 2011, 8, 45.	2.1	11
165	A Review of Three-Dimensional In Vitro Tissue Models for Drug Discovery and Transport Studies. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 59-74.	1.6	379
166	MR evaluation of response to targeted treatment in cancer cells. <i>NMR in Biomedicine</i> , 2011, 24, 648-672.	1.6	58
167	MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. <i>NMR in Biomedicine</i> , 2011, 24, 612-635.	1.6	15
168	Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. <i>International Journal of Cancer</i> , 2011, 129, 742-750.	2.3	28
169	Novel methods of enhanced retention in and rapid, targeted release from liposomes. <i>Current Opinion in Colloid and Interface Science</i> , 2011, 16, 203-214.	3.4	57
170	The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. <i>Biomaterials</i> , 2011, 32, 5673-5687.	5.7	187
171	Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 435-444.	1.7	106
172	Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2011, 39, 729-735.	1.7	62

#	ARTICLE	IF	CITATIONS
173	GLI2 Transcription Factor Mediates Cytokine Cross-talk in the Tumor Microenvironment. Journal of Biological Chemistry, 2011, 286, 21524-21534.	1.6	44
174	Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3686-3694.	0.8	76
175	Bax is necessary for PGC1 α pro-apoptotic effect in colorectal cancer cells. Cell Cycle, 2011, 10, 2937-2945.	1.3	26
176	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. Cancer Research, 2011, 71, 747-757.	0.4	127
177	Remodeling of Tumor Stroma and Response to Therapy. Cancers, 2012, 4, 340-353.	1.7	14
178	The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A. Xenobiotica, 2012, 42, 571-579.	0.5	2
179	Molecular Link Mechanisms between Inflammation and Cancer. Current Pharmaceutical Design, 2012, 18, 3831-3852.	0.9	344
180	Characterization of tumor vasculature distributions in central and peripheral regions based on Doppler ultrasound. Medical Physics, 2012, 39, 7490-7498.	1.6	8
181	Intratumoral Heterogeneity as a Therapy Resistance Mechanism. Advances in Pharmacology, 2012, 65, 335-359.	1.2	76
182	Mutational Pathway Determines Whether Drug Gradients Accelerate Evolution of Drug-Resistant Cells. Physical Review Letters, 2012, 109, 088101.	2.9	100
183	Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine, 2012, 7, 1235-1252.	1.7	33
184	Multidrug resistance-associated ABC transporters "too much of one thing, good for nothing. Biomolecular Concepts, 2012, 3, 319-331.	1.0	5
185	Matrix Stiffness: A Regulator of Cellular Behavior and Tissue Formation. , 2012, , 19-37.		57
186	Baseline Tumor Oxygen Saturation Correlates with a Pathologic Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Cancer Research, 2012, 72, 4318-4328.	0.4	111
187	A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents. Current Pharmaceutical Design, 2012, 18, 1395-1406.	0.9	50
188	Overcoming Drug Resistance and Treating Advanced Prostate Cancer. Current Drug Targets, 2012, 13, 1308-1323.	1.0	94
189	pH-Sensitive Polymeric Micelles for Programmable Drug and Gene Delivery. Current Pharmaceutical Design, 2012, 18, 3442-3451.	0.9	43
190	Systematic nanoparticle diffusivity estimation using multicellular tumor spheroid model. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
191	The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures. <i>Oncology Reports</i> , 2012, 27, 995-1002.	1.2	15
192	shRNA targeting Bmi1 impedes the self-renewal of cisplatin-enriched stem-like cells in human A549 cells. <i>Oncology Reports</i> , 2012, 28, 629-639.	1.2	5
193	Towards Control of Magnetic Fluids in Patients: Directing Therapeutic Nanoparticles to Disease Locations. <i>IEEE Control Systems</i> , 2012, 32, 32-74.	1.0	81
194	Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. <i>International Journal of Hyperthermia</i> , 2012, 28, 776-787.	1.1	61
195	Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2012, 10, 1147-1157.	1.5	89
196	Mechanisms of Tumor Vascular Priming by a Nanoparticulate Doxorubicin Formulation. <i>Pharmaceutical Research</i> , 2012, 29, 3312-3324.	1.7	14
197	Preliminary Studies with a New Hypoxia-Selective Cytotoxin, KS119W, <i>In Vitro</i> and <i>In Vivo</i> . <i>Radiation Research</i> , 2012, 178, 126-137.	0.7	10
198	Quantitative Immunohistochemistry for Evaluating the Distribution of Ki67 and Other Biomarkers in Tumor Sections and Use of the Method to Study Repopulation in Xenografts after Treatment with Paclitaxel. <i>Neoplasia</i> , 2012, 14, 324-IN6.	2.3	28
199	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 823-842.	2.7	59
200	Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9545-9571.	1.8	228
201	Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. <i>Nature Medicine</i> , 2012, 18, 1359-1368.	15.2	682
202	Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. <i>Biological Reviews</i> , 2012, 87, 701-730.	4.7	122
203	Cancer Cell Metabolism: One Hallmark, Many Faces. <i>Cancer Discovery</i> , 2012, 2, 881-898.	7.7	773
204	Bacteria-mediated in vivo delivery of quantum dots into solid tumor. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 769-774.	1.0	46
205	The dynamics of drug resistance: A mathematical perspective. <i>Drug Resistance Updates</i> , 2012, 15, 90-97.	6.5	94
206	Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. <i>Journal of Translational Medicine</i> , 2012, 10, 198.	1.8	31
207	Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. <i>Journal of Ovarian Research</i> , 2012, 5, 40.	1.3	14
208	A Review of Mechanisms of Contrast for Diffuse Optical Imaging of Cancer. <i>Journal of Near Infrared Spectroscopy</i> , 2012, 20, 185-202.	0.8	9

#	ARTICLE	IF	CITATIONS
209	Influence of a three-dimensional, microarray environment on human Cell culture in drug screening systems. <i>Biomaterials</i> , 2012, 33, 9087-9096.	5.7	83
210	Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. <i>Cancer Letters</i> , 2012, 326, 59-68.	3.2	32
211	Cancer chemotherapy: A critical analysis of its 60 years of history. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 181-199.	2.0	87
212	Improving drug penetration to curb tumor drug resistance. <i>Drug Discovery Today</i> , 2012, 17, 1139-1146.	3.2	27
213	A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[¹⁸ F]pentafluoropropyl)-acetamide ([¹⁸ F]EF5). <i>Nuclear Medicine and Biology</i> , 2012, 39, 1012-1018.	0.3	12
214	Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1059-1067.	1.0	2
215	Brain Tumor Models to Predict Clinical Outcome: Like the Phoenix?. <i>NeuroMethods</i> , 2012, , 3-20.	0.2	2
216	Polymer-Based Nanoparticulate Systems as Versatile Agents in the Prognosis and Therapy of Cancer. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2012, 82, 37-58.	0.4	1
218	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. <i>Radiation Oncology</i> , 2012, 7, 75.	1.2	25
219	The combination of olaparib and camptothecin for effective radiosensitization. <i>Radiation Oncology</i> , 2012, 7, 62.	1.2	26
220	The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus under a Hypoxic Microenvironment. <i>PLoS ONE</i> , 2012, 7, e39292.	1.1	16
221	Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches. <i>Frontiers in Pharmacology</i> , 2012, 3, 149.	1.6	98
222	Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches. , 0, , .		19
223	Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 2464-2471.	0.9	130
224	Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. <i>Journal of Pathology</i> , 2012, 227, 189-199.	2.1	109
225	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2012, 30, 3012-3019.	0.8	152
226	Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2012, 18, 4019-4025.	3.2	69
227	Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of Gefitinib. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 2763-2776.	1.6	29

#	ARTICLE	IF	CITATIONS
228	The determinants of tumour immunogenicity. <i>Nature Reviews Cancer</i> , 2012, 12, 307-313.	12.8	343
229	Micrometer-scale oxygen delivery rearranges cells and prevents necrosis in tumor tissue in vitro. <i>Biotechnology Progress</i> , 2012, 28, 515-525.	1.3	9
230	Evaluation of interstitial protein delivery in multicellular layers model. <i>Archives of Pharmacal Research</i> , 2012, 35, 531-541.	2.7	4
231	How to improve exposure of tumor cells to drugs – Promoter drugs increase tumor uptake and penetration of effector drugs. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 53-68.	6.6	78
232	Cancer stromal targeting (CAST) therapy. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 710-719.	6.6	99
233	Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2012, 21, 418-429.	7.7	1,664
234	A Tell-Tail Sign of Chromatin: Histone Mutations Drive Pediatric Glioblastoma. <i>Cancer Cell</i> , 2012, 21, 329-331.	7.7	19
235	Targeting Tumor Architecture to Favor Drug Penetration: A New Weapon to Combat Chemoresistance in Pancreatic Cancer?. <i>Cancer Cell</i> , 2012, 21, 327-329.	7.7	78
236	Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 388-398.	1.9	97
237	Sensitization of tumor cells by targeting histone deacetylases. <i>Biochemical Pharmacology</i> , 2012, 83, 987-994.	2.0	29
238	The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. <i>Biomaterials</i> , 2012, 33, 1437-1444.	5.7	241
239	Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. <i>Biomaterials</i> , 2012, 33, 5349-5362.	5.7	72
240	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. <i>Journal of Controlled Release</i> , 2012, 158, 379-385.	4.8	29
241	Early prediction of response to Vorinostat in an orthotopic rat glioma model. <i>NMR in Biomedicine</i> , 2012, 25, 1104-1111.	1.6	25
242	Targeted Drug Delivery and Penetration Into Solid Tumors. <i>Medicinal Research Reviews</i> , 2012, 32, 1078-1091.	5.0	108
243	Dose Dependence of Intratumoral Perivascular Distribution of Monoclonal Antibodies. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 860-867.	1.6	35
244	Methyl tert-butyl ether is anti-angiogenic in both <i>in vitro</i> and <i>in vivo</i> mammalian model systems. <i>Journal of Applied Toxicology</i> , 2013, 33, 820-827.	1.4	3
245	Dynamic ¹⁸ F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 173-180.	0.6	7

#	ARTICLE	IF	CITATIONS
246	Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 27-32.	0.6	14
247	Differential remodeling of cadherins and intermediate cytoskeletal filaments influence microenvironment of solid and ascitic sarcoma. <i>Molecular and Cellular Biochemistry</i> , 2013, 382, 293-306.	1.4	7
248	Assessment of navigation control strategy for magnetotactic bacteria in microchannel: toward targeting solid tumors. <i>Biomedical Microdevices</i> , 2013, 15, 1015-1024.	1.4	42
249	Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. <i>Cancer Letters</i> , 2013, 334, 263-273.	3.2	72
250	Sonophoric nanoprobe aided pH measurement in vivo using photoacoustic spectroscopy. <i>Analyst</i> , The, 2013, 138, 3126.	1.7	26
251	Role of integrated cancer nanomedicine in overcoming drug resistance. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1784-1802.	6.6	288
252	Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. <i>British Journal of Cancer</i> , 2013, 108, 1-8.	2.9	265
253	Nanopreparations to overcome multidrug resistance in cancer. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1748-1762.	6.6	294
254	Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors. <i>Journal of Therapeutic Ultrasound</i> , 2013, 1, 10.	2.2	93
255	Non-nuclear localization of Ki-67 in human colorectal cancer cells grown as multicellular layers. <i>Archives of Pharmacol Research</i> , 2013, 36, 634-640.	2.7	5
256	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects. <i>Annals of Surgical Oncology</i> , 2013, 20, 3504-3511.	0.7	123
257	Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2013, 28, 375-383.	1.0	49
258	Breast Cancer Metastasis and Drug Resistance. , 2013, , .		12
259	Investigation of possible endogenous hypoxia markers in colorectal cancer. <i>International Journal of Radiation Biology</i> , 2013, 89, 9-15.	1.0	12
260	Cell motility and drug gradients in the emergence of resistance to chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16103-16108.	3.3	80
261	Influence of tumour micro-environment heterogeneity on therapeutic response. <i>Nature</i> , 2013, 501, 346-354.	13.7	2,093
262	Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response. <i>Biotechnology and Bioengineering</i> , 2013, 110, 2063-2072.	1.7	32
263	Nanomedicine therapeutic approaches to overcome cancer drug resistance. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1866-1879.	6.6	598

#	ARTICLE	IF	CITATIONS
264	Micro and Nano Flow Systems for Bioanalysis. , 2013, , .		3
265	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
266	Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?. <i>Biomicrofluidics</i> , 2013, 7, 011811.	1.2	16
267	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1731-1747.	6.6	218
268	Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. <i>Biomaterials</i> , 2013, 34, 3489-3502.	5.7	314
269	pH-responsive and charge shielded cationic micelle of poly(L-histidine)- block -short branched PEI for acidic cancer treatment. <i>Journal of Controlled Release</i> , 2013, 172, 69-76.	4.8	112
270	Investigating the effects of ABC transporter-based acquired drug resistance mechanisms at the cellular and tissue scale. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 555.	0.6	10
271	Imaging of hypoxia with ¹⁸ F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 475-481.	0.9	55
272	Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1701-1710.	3.0	98
273	Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 1184.	0.6	31
274	Low-Glucose Conditions of Tumor Microenvironment Enhance Cytotoxicity of Tetrathiomolybdate to Neuroblastoma Cells. <i>Nutrition and Cancer</i> , 2013, 65, 702-710.	0.9	27
275	Hypoxia, Therapeutic Resistance, and Sphingosine 1-Phosphate. <i>Advances in Cancer Research</i> , 2013, 117, 117-141.	1.9	38
276	Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 285-311.	0.8	23
277	Pharmacokinetic considerations for targeted drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 139-147.	6.6	111
278	Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 211-227.	2.7	119
279	The Biology of Brain Metastasis. <i>Clinical Chemistry</i> , 2013, 59, 180-189.	1.5	73
280	New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 282-290.	1.9	95
281	Construction of oxygen and chemical concentration gradients in a single microfluidic device for studying tumor cell-drug interactions in a dynamic hypoxia microenvironment. <i>Lab on A Chip</i> , 2013, 13, 695-705.	3.1	122

#	ARTICLE	IF	CITATIONS
282	Gold nanoparticles: Emerging paradigm for targeted drug delivery system. <i>Biotechnology Advances</i> , 2013, 31, 593-606.	6.0	308
283	Size-Dependent Tumor Penetration and <i>in Vivo</i> Efficacy of Monodisperse Drug-Silica Nanoconjugates. <i>Molecular Pharmaceutics</i> , 2013, 10, 883-892.	2.3	145
284	Microfluidic oxygen imaging using integrated optical sensor layers and a color camera. <i>Lab on A Chip</i> , 2013, 13, 1593.	3.1	83
285	Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion. <i>Cancer Letters</i> , 2013, 331, 122-129.	3.2	34
286	The effect of interstitial pressure on tumor growth: Coupling with the blood and lymphatic vascular systems. <i>Journal of Theoretical Biology</i> , 2013, 320, 131-151.	0.8	183
287	Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 747-748, 19-27.	0.4	8
288	Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. <i>Biomaterials</i> , 2013, 34, 8301-8313.	5.7	23
289	Bioreducible PAA-g-PEG graft micelles with high doxorubicin loading for targeted antitumor effect against mouse breast carcinoma. <i>Biomaterials</i> , 2013, 34, 6818-6828.	5.7	64
290	A Preclinical Study to Explore Vasculature Differences Between Primary and Recurrent Tumors Using Ultrasound Doppler Imaging. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 860-869.	0.7	11
291	Barriers to Drug Delivery in Interventional Oncology. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1201-1207.	0.2	51
292	Riparian ecosystems in human cancers. <i>Evolutionary Applications</i> , 2013, 6, 46-53.	1.5	57
293	The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 606-617.	1.8	91
294	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody. <i>Proteomics</i> , 2013, 13, 866-877.	1.3	21
295	Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 36-45.	3.3	62
296	Modeling Breast Cancer Progression in 4-D. , 2013, , 177-188.		0
297	Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1 α inhibition in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1847-1857.	3.6	229
298	Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function. <i>Free Radical Biology and Medicine</i> , 2013, 60, 201-210.	1.3	19
299	Reversal of Multidrug Resistance by Mitochondrial Targeted Self-Assembled Nanocarrier Based on Stearylamine. <i>Molecular Pharmaceutics</i> , 2013, 10, 2426-2434.	2.3	30

#	ARTICLE	IF	CITATIONS
300	Three-dimensionally engineered biomimetic tissue models for <i>in vitro</i> drug evaluation: delivery, efficacy and toxicity. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 369-383.	2.4	45
301	Codelivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC. <i>Molecular Therapy</i> , 2013, 21, 1559-1569.	3.7	107
302	Hypoxic tumor microenvironment in advanced retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1598-1601.	0.8	26
303	Microdevices for Nanomedicine. <i>Molecular Pharmaceutics</i> , 2013, 10, 2127-2144.	2.3	22
304	Different strategies to overcome multidrug resistance in cancer. <i>Biotechnology Advances</i> , 2013, 31, 1397-1407.	6.0	215
305	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 56.	1.6	79
306	Aurein 2.3 functionality is supported by oblique orientated α -helical formation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 586-594.	1.4	21
307	Intracellular superoxide dismutase activity defines invasiveness of the murine T-lymphoma cell line L5187Y-ML25 <i>in vitro</i> and <i>in vivo</i> . <i>Leukemia Research</i> , 2013, 37, 89-92.	0.4	3
308	Multifunctional nanosystems for cancer therapy. , 2013, , 387-413.		3
309	LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. <i>Oncogene</i> , 2013, 32, 1682-1690.	2.6	89
310	Hydrogel nanosensors for biophotonic imaging of chemical analytes. <i>Nanomedicine</i> , 2013, 8, 1829-1838.	1.7	12
311	Improving Drug Uptake and Penetration into Tumors: Current and Forthcoming Opportunities. <i>Frontiers in Oncology</i> , 2013, 3, 161.	1.3	6
312	Tumor-Penetrating Peptides. <i>Frontiers in Oncology</i> , 2013, 3, 216.	1.3	161
313	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. <i>British Journal of Radiology</i> , 2013, 86, 20130281.	1.0	32
314	Microenvironmentâ€A Role in Tumour Progression and Prognosis. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2013, 7, 2096-9.	0.8	6
315	Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11397-11402.	3.3	91
316	Histological Advantages of the Tumor Graft. <i>Pancreas</i> , 2013, 42, 1275-1282.	0.5	11
317	Three-dimensional vasculature reconstruction of tumour microenvironment via local clustering and classification. <i>Interface Focus</i> , 2013, 3, 20130015.	1.5	7

#	ARTICLE	IF	CITATIONS
318	Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 542-552.	1.9	29
319	Tissue Distribution and Efficacy of Gold Nanorods Coupled with Laser Induced Photoplasmonic Therapy in Ehrlich Carcinoma Solid Tumor Model. <i>PLoS ONE</i> , 2013, 8, e76207.	1.1	43
320	The Tumor Microenvironment and Strategies to Improve Drug Distribution. <i>Frontiers in Oncology</i> , 2013, 3, 154.	1.3	106
321	Vascular Permeability and Drug Delivery in Cancers. <i>Frontiers in Oncology</i> , 2013, 3, 211.	1.3	246
322	Circadian rhythms in <i>Neurospora crassa</i> on a polydimethylsiloxane microfluidic device for real-time gas perturbations. <i>Biomicrofluidics</i> , 2013, 7, 44129.	1.2	7
323	Tailored immunoconjugate therapy depending on a quantity of tumor stroma. <i>Cancer Science</i> , 2013, 104, 231-237.	1.7	28
324	MR "eyes" for cancer: looking within an impenetrable disease. <i>NMR in Biomedicine</i> , 2013, 26, 745-755.	1.6	12
325	Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. <i>Biomicrofluidics</i> , 2013, 7, 11805.	1.2	44
326	Biological Microniches Characterizing Pathological Lesions. <i>Frontiers of Nanoscience</i> , 2013, 5, 139-173.	0.3	1
327	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MABs</i> , 2013, 5, 34-46.	2.6	46
328	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e25595.	2.1	83
329	New paradigm for tumor theranostic methodology using bacteria-based microrobot. <i>Scientific Reports</i> , 2013, 3, 3394.	1.6	189
330	Baseline tumour measurements predict survival in advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2013, 109, 1476-1481.	2.9	30
331	Development of Liposomal Anticancer Drugs. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 703-707.	0.6	27
332	Cobalt chloride inhibits tumor formation in osteosarcoma cells through upregulation of HIF-1 α . <i>Oncology Letters</i> , 2013, 5, 911-916.	0.8	10
333	Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho-LRP6 expression in Wnt/ β -catenin signaling. <i>Oncology Reports</i> , 2013, 30, 851-855.	1.2	21
334	<i>Salmonella typhimurium</i> Mediated Delivery of Apoptin in Human Laryngeal Cancer. <i>International Journal of Medical Sciences</i> , 2013, 10, 1639-1648.	1.1	29
335	Identification of Ovarian Cancer Metastatic miRNAs. <i>PLoS ONE</i> , 2013, 8, e58226.	1.1	78

#	ARTICLE	IF	CITATIONS
336	Influence of the Duration of Intravenous Drug Administration on Tumor Uptake. <i>Frontiers in Oncology</i> , 2013, 3, 192.	1.3	4
337	Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13979-14007.	1.8	95
338	Cell volume regulation in epithelial physiology and cancer. <i>Frontiers in Physiology</i> , 2013, 4, 233.	1.3	81
339	P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2013, 13, 326-346.	0.8	320
340	The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 115-133.	0.2	72
341	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. <i>OncoTargets and Therapy</i> , 2014, 7, 1689.	1.0	65
342	Tumor Bioengineering Using a Transglutaminase Crosslinked Hydrogel. <i>PLoS ONE</i> , 2014, 9, e105616.	1.1	32
343	MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1 α . <i>PLoS ONE</i> , 2014, 9, e115565.	1.1	93
344	Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment. <i>Marine Drugs</i> , 2014, 12, 719-733.	2.2	40
345	Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies. <i>Scientific World Journal</i> , The, 2014, 2014, 1-10.	0.8	44
346	Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma. <i>International Journal of Nanomedicine</i> , 2014, 9, 4169.	3.3	15
347	Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 115-126.	0.9	10
348	The Complexity of Colorectal Cancer Biology "Putting Bricks on the Path to Personalized Medicine. , 0, , .		1
349	Cellular and molecular immunology of lung cancer: therapeutic implications. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1711-1730.	1.3	10
350	Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. <i>Nanomedicine</i> , 2014, 9, 2587-2605.	1.7	31
351	Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine. <i>Autophagy</i> , 2014, 10, 562-571.	4.3	176
352	Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. <i>BMC Cancer</i> , 2014, 14, 738.	1.1	78
353	Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. <i>Oncogene</i> , 2014, 33, 5405-5414.	2.6	97

#	ARTICLE	IF	CITATIONS
354	Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-11.	0.9	86
355	Docetaxel-Encapsulating Small-Sized Polymeric Micelles with Higher Permeability and Its Efficacy on the Orthotopic Transplantation Model of Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23571-23588.	1.8	9
357	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects. <i>Cancers</i> , 2014, 6, 1-27.	1.7	32
358	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7
359	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 237-245.	0.4	24
360	Significance of MET overexpression in cytotoxic anticancer drug-resistant small cell lung cancer cells. <i>Cancer Science</i> , 2014, 105, 1032-1039.	1.7	36
361	RABbing cancer the wrong way. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11230-11231.	3.3	2
362	Maspin influences response to doxorubicin by changing the tumor microenvironment organization. <i>International Journal of Cancer</i> , 2014, 134, 2789-2797.	2.3	13
363	Nanomedicine. <i>Nanostructure Science and Technology</i> , 2014, , .	0.1	21
364	<i>Advances in Intravital Microscopy</i> . , 2014, , .		4
365	Spatial frequency analysis of high-density lipoprotein and iron-oxide nanoparticle transmission electron microscope image structure for pattern recognition in heterogeneous fields. <i>Journal of Biomedical Optics</i> , 2014, 19, 015004.	1.4	10
366	Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2014, 811, 207-233.	0.8	19
367	Correlation-based network analysis of cancer metabolism. <i>SpringerBriefs in Systems Biology</i> , 2014, , .	0.1	6
368	Revitalizing Personalized Medicine: Respecting Biomolecular Complexities Beyond Gene Expression. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-11.	1.3	5
369	AngioMap is a Novel Image Analysis Algorithm for Assessment of Plasma Cell Distribution Within Bone Marrow Vascular Niche. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 550-554.	0.6	4
370	Three-Dimensional Microfluidic Collagen Hydrogels for Investigating Flow-Mediated Tumor-Endothelial Signaling and Vascular Organization. <i>Tissue Engineering - Part C: Methods</i> , 2014, 20, 64-75.	1.1	115
371	Multimodal Nano-Systems for Cancer Diagnosis, Imaging, and Therapy. <i>Advances in Delivery Science and Technology</i> , 2014, , 351-388.	0.4	0
373	BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. <i>Radiation Oncology</i> , 2014, 9, 207.	1.2	50

#	ARTICLE	IF	CITATIONS
374	The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional Study. <i>European Urology</i> , 2014, 65, 227-234.	0.9	70
375	In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer. <i>Experimental and Molecular Pathology</i> , 2014, 97, 6-15.	0.9	31
376	Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 479-492.	2.4	101
377	Parameter non-identifiability of the Gyllenbergâ€“Webb ODE model. <i>Journal of Mathematical Biology</i> , 2014, 68, 41-55.	0.8	4
378	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	2.7	5
379	Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts. <i>International Journal of Pharmaceutics</i> , 2014, 464, 168-177.	2.6	46
380	Evolution of acquired resistance to anti-cancer therapy. <i>Journal of Theoretical Biology</i> , 2014, 355, 10-20.	0.8	213
381	Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. <i>Current Breast Cancer Reports</i> , 2014, 6, 110-120.	0.5	38
382	Stress-induced cleavage of Myc promotes cancer cell survival. <i>Genes and Development</i> , 2014, 28, 689-707.	2.7	86
383	Anti-tumor efficacy of ultrasonic cavitation is potentiated by concurrent delivery of anti-angiogenic drug in colon cancer. <i>Cancer Letters</i> , 2014, 347, 105-113.	3.2	37
385	Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells. <i>Pharmaceutical Research</i> , 2014, 31, 1882-1892.	1.7	64
386	Dynamic Interactions Between Cancer Stem Cells and Their Stromal Partners. <i>Current Pathobiology Reports</i> , 2014, 2, 41-52.	1.6	47
387	Towards an integrated systems-based modelling framework for drug transport and its effect on tumour cells. <i>Journal of Biological Engineering</i> , 2014, 8, 3.	2.0	7
388	Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 118, 101-110.	2.5	21
389	Ion channels and transporters in the development of drug resistance in cancer cells. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130109.	1.8	93
390	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202
391	3D cell culture systems modeling tumor growth determinants in cancer target discovery. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 29-41.	6.6	369
392	EpCAM-Targeted Therapy for Human Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1314-1322.	0.7	44

#	ARTICLE	IF	CITATIONS
393	The challenge of intratumour heterogeneity in precision medicine. <i>Journal of Internal Medicine</i> , 2014, 276, 41-51.	2.7	66
394	Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors. <i>Assay and Drug Development Technologies</i> , 2014, 12, 207-218.	0.6	1,793
395	The potential of heparanase as a therapeutic target in cancer. <i>Biochemical Pharmacology</i> , 2014, 89, 12-19.	2.0	98
397	Implications of intratumour heterogeneity for treatment stratification. <i>Journal of Pathology</i> , 2014, 232, 264-273.	2.1	53
398	Optimization of liquid overlay technique to formulate heterogenic 3D cell cultures models. <i>Biotechnology and Bioengineering</i> , 2014, 111, 1672-1685.	1.7	113
399	Variation in diffusion of gases through PDMS due to plasma surface treatment and storage conditions. <i>Biomedical Microdevices</i> , 2014, 16, 91-96.	1.4	98
400	Lighting up tumours. <i>Nature Materials</i> , 2014, 13, 122-124.	13.3	34
401	Design and Synthesis of N-Acylated Aza-Goniothalamine Derivatives and Evaluation of Their in vitro and in vivo Antitumor Activity. <i>ChemMedChem</i> , 2014, 9, 2725-2743.	1.6	29
402	Improving chemoradiation efficacy by PI3-K/AKT inhibition. <i>Cancer Treatment Reviews</i> , 2014, 40, 1182-1191.	3.4	39
403	Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic Strategies. <i>Oncology Research and Treatment</i> , 2014, 37, 584-589.	0.8	75
404	Single particle tracking reveals biphasic transport during nanorod magnetophoresis through extracellular matrix. <i>Soft Matter</i> , 2014, 10, 4118-4125.	1.2	17
405	Small rigid platforms functionalization with quaternary ammonium: Targeting extracellular matrix of chondrosarcoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1887-1895.	1.7	15
406	Probing hypoxia-induced staurosporine resistance in prostate cancer cells with a microfluidic culture system. <i>Analyst</i> , 2014, 139, 3274-3280.	1.7	26
407	Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. <i>Bioconjugate Chemistry</i> , 2014, 25, 2093-2100.	1.8	68
408	New approaches to selectively target cancer-associated matrix metalloproteinase activity. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 1043-1057.	2.7	65
409	Nitric Oxide Releasing α -Tocopheryl Polyethylene Glycol Succinate for Enhancing Antitumor Activity of Doxorubicin. <i>Molecular Pharmaceutics</i> , 2014, 11, 4118-4129.	2.3	86
410	Rapid uptake of glucose and lactate, and not hypoxia, induces apoptosis in three-dimensional tumor tissue culture. <i>Integrative Biology (United Kingdom)</i> , 2014, 6, 399-410.	0.6	36
411	Advancements of Mass Spectrometry in Biomedical Research. <i>Advances in Experimental Medicine and Biology</i> , 2014, , .	0.8	6

#	ARTICLE	IF	CITATIONS
412	Surface ligands in synthesis, modification, assembly and biomedical applications of nanoparticles. Nano Today, 2014, 9, 457-477.	6.2	169
413	Multifunctional Tumor pH-Sensitive Self-Assembled Nanoparticles for Bimodal Imaging and Treatment of Resistant Heterogeneous Tumors. Journal of the American Chemical Society, 2014, 136, 5647-5655.	6.6	452
414	Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Clinical Pharmacology and Therapeutics, 2014, 96, 224-238.	2.3	60
415	pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma. ACS Nano, 2014, 8, 8027-8039.	7.3	113
416	Absolute MR thermometry using nanocarriers. Contrast Media and Molecular Imaging, 2014, 9, 283-290.	0.4	4
417	Comparison of the Hypoxia PET Tracer ¹⁸ F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. Journal of Nuclear Medicine, 2014, 55, 1192-1197.	2.8	18
418	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
419	Membrane organization determines barrier properties of endothelial cells and short-chain sphingolipid-facilitated doxorubicin influx. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1301-1307.	1.2	4
420	The Drug Discovery by NanoMedicine and its Clinical Experience. Japanese Journal of Clinical Oncology, 2014, 44, 515-525.	0.6	75
421	Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. Journal of Controlled Release, 2014, 192, 47-56.	4.8	93
422	Cancer Secretomes and Their Place in Supplementing Other Hallmarks of Cancer. Advances in Experimental Medicine and Biology, 2014, 806, 409-442.	0.8	38
423	Susceptibility of sheep, human, and pig erythrocytes to haemolysis by the antimicrobial peptide Modelin 5. European Biophysics Journal, 2014, 43, 423-432.	1.2	13
424	Defining normoxia, physoxia and hypoxia in tumoursâ€”implications for treatment response. British Journal of Radiology, 2014, 87, 20130676.	1.0	694
425	Engineering strategies to mimic the glioblastoma microenvironment. Advanced Drug Delivery Reviews, 2014, 79-80, 172-183.	6.6	118
426	MicroRNAs in hypoxia and acidic tumor microenvironment. Science Bulletin, 2014, 59, 2223-2231.	1.7	7
427	A polydimethylsiloxaneâ€”polycarbonate hybrid microfluidic device capable of generating perpendicular chemical and oxygen gradients for cell culture studies. Lab on A Chip, 2014, 14, 3762-3772.	3.1	117
428	Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Archives of Toxicology, 2014, 88, 1205-1248.	1.9	61
429	Bacterial Delivery of Staphylococcus aureus α -Hemolysin Causes Regression and Necrosis in Murine Tumors. Molecular Therapy, 2014, 22, 1266-1274.	3.7	78

#	ARTICLE	IF	CITATIONS
430	Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment. <i>Interface Focus</i> , 2014, 4, 20140028.	1.5	34
431	SIRT1 and AMPK Mediate Hypoxia-Induced Resistance of Nonâ€“Small Cell Lung Cancers to Cisplatin and Doxorubicin. <i>Cancer Research</i> , 2014, 74, 298-308.	0.4	100
432	Chitosan-Based Thermoreversible Hydrogel as an in Vitro Tumor Microenvironment for Testing Breast Cancer Therapies. <i>Molecular Pharmaceutics</i> , 2014, 11, 2134-2142.	2.3	34
433	Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors. <i>Molecular Pharmaceutics</i> , 2014, 11, 2511-2526.	2.3	44
434	Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. <i>Cancer Cell</i> , 2014, 25, 102-117.	7.7	109
435	3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. <i>Experimental Cell Research</i> , 2014, 323, 131-143.	1.2	219
436	Hypoxia-induced tumor malignancy and drug resistance: Role of microRNAs. <i>Biomarkers and Genomic Medicine</i> , 2014, 6, 1-11.	0.2	17
437	Animal Models and the Tumor Microenvironment: Studies of Tumorâ€“Host Symbiosis. <i>Seminars in Oncology</i> , 2014, 41, 146-155.	0.8	16
438	Monitoring the Effects of Anti-angiogenesis on the Radiation Sensitivity of Pancreatic Cancer Xenografts Using Dynamic Contrast-Enhanced Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 412-418.	0.4	9
439	Lipid A controls the robustness of intratumoral accumulation of attenuated <i>Salmonella</i> in mice. <i>International Journal of Cancer</i> , 2014, 135, 647-657.	2.3	18
440	Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. <i>Oncogene</i> , 2014, 33, 1341-1347.	2.6	29
441	Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?. <i>Theranostics</i> , 2014, 4, 81-89.	4.6	792
442	Resveratrol Reduces the Hypoxia-Induced Resistance to Doxorubicin in Breast Cancer Cells. <i>Journal of Nutritional Science and Vitaminology</i> , 2014, 60, 122-128.	0.2	33
443	The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer. <i>Journal of Tissue Engineering</i> , 2014, 5, 204173141454418.	2.3	33
444	Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. <i>Oncology Letters</i> , 2014, 8, 1739-1744.	0.8	20
445	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e17.	1.6	51
446	Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy. <i>Microbial Cell Factories</i> , 2015, 14, 199.	1.9	21
447	Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. <i>Cancer Science</i> , 2015, 106, 1438-1447.	1.7	42

#	ARTICLE	IF	CITATIONS
448	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. <i>Cancer Informatics</i> , 2015, 14s4, CIN.S19338.	0.9	59
449	Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells. <i>Chemistry - A European Journal</i> , 2015, 21, 15308-15319.	1.7	79
450	Hypoxia alters the recruitment of tropomyosins into the actin stress fibres of neuroblastoma cells. <i>BMC Cancer</i> , 2015, 15, 712.	1.1	8
451	Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. <i>Cancer Cell International</i> , 2015, 15, 71.	1.8	451
452	Evidence-based support for the use of proton pump inhibitors in cancer therapy. <i>Journal of Translational Medicine</i> , 2015, 13, 368.	1.8	50
453	Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 108.	3.5	54
454	Effects of oxygen on the antigenic landscape of prostate cancer cells. <i>BMC Research Notes</i> , 2015, 8, 687.	0.6	7
455	Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity. <i>EJNMMI Research</i> , 2015, 5, 57.	1.1	6
456	Tumor Intracellular Environment Responsive Materials Shielded Nano Complexes for Highly Efficient Light Triggered Gene Delivery without Cargo Gene Damage. <i>Advanced Functional Materials</i> , 2015, 25, 3472-3482.	7.8	59
457	<i>In vivo</i> study of novel nanocomposite for prostate cancer treatment. <i>Journal of Physics: Conference Series</i> , 2015, 617, 012001.	0.3	0
458	Role of peptide self-assembly in antimicrobial peptides. <i>Journal of Peptide Science</i> , 2015, 21, 530-539.	0.8	90
459	Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	10
460	Genetic Heterogeneity in Colorectal Cancer and its Clinical Implications. <i>Acta Medica Portuguesa</i> , 2015, 28, 370-375.	0.2	10
461	Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. <i>Journal of Cancer</i> , 2015, 6, 717-726.	1.2	91
462	Three-Dimensional (3D) Cell Cultures in Cell-based Assays for in-vitro Evaluation of Anticancer Drugs. <i>Journal of Analytical & Bioanalytical Techniques</i> , 2015, 06, .	0.6	35
463	Inhibition of cell proliferation in gastric cancer cell lines on exposure to rubriflordilactone A. <i>Bangladesh Journal of Pharmacology</i> , 2015, 11, 63.	0.1	0
464	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	1.7	61
465	Mechanisms of Drug Resistance in Veterinary Oncology – A Review with an Emphasis on Canine Lymphoma. <i>Veterinary Sciences</i> , 2015, 2, 150-184.	0.6	28

#	ARTICLE	IF	CITATIONS
466	Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids. <i>Molecules</i> , 2015, 20, 18016-18030.	1.7	28
467	Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid. <i>Frontiers in Oncology</i> , 2015, 5, 165.	1.3	60
468	Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. <i>PLoS ONE</i> , 2015, 10, e0131429.	1.1	70
469	Environmental Interactions and Epistasis Are Revealed in the Proteomic Responses to Complex Stimuli. <i>PLoS ONE</i> , 2015, 10, e0134099.	1.1	11
470	Stromal Carcinoma Associated Fibroblasts Promote Drug Resistance of Human Pancreatic Cancer Cells by Modulation of ROS via CXCR4/CXCL12 Signaling. <i>International Journal of Translational Science</i> , 2015, 2015, 107-130.	0.2	0
471	Anticancer and Anti-Inflammatory Activities of a Standardized Dichloromethane Extract from <i>Piper umbellatum</i> L. Leaves. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	25
472	<i>Spirulina platensis</i> Lacks Antitumor Effect against Solid Ehrlich Carcinoma in Female Mice. <i>Advances in Pharmacological Sciences</i> , 2015, 2015, 1-8.	3.7	17
473	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 35040-35050.	0.8	48
474	Roles of Tumor Microenvironment in Hepatocellular Carcinoma. <i>Current Cancer Therapy Reviews</i> , 2015, 11, 82-93.	0.2	20
475	cRGD targeted and charge conversion-controlled release micelles for doxorubicin delivery. <i>RSC Advances</i> , 2015, 5, 22957-22964.	1.7	15
476	Enhance Cancer Cell Recognition and Overcome Drug Resistance Using Hyaluronic Acid and Î±-Tocopheryl Succinate Based Multifunctional Nanoparticles. <i>Molecular Pharmaceutics</i> , 2015, 12, 2189-2202.	2.3	76
477	Phosphanegold(I) thiolates, Ph ₃ PAu[SC(OR)=NC ₆ H ₄ Me-4] for R=Me, Et and iPr, induce apoptosis, cell cycle arrest and inhibit cell invasion of HT-29 colon cancer cells through modulation of the nuclear factor-Î²B activation pathway and ubiquitination. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 855-873.	1.1	26
478	^{99m} Tc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab. <i>Annals of Nuclear Medicine</i> , 2015, 29, 519-527.	1.2	9
479	Myo19 is an Outer Mitochondrial Membrane Motor and Effector of Starvation Induced Filopodia. <i>Journal of Cell Science</i> , 2016, 129, 543-56.	1.2	46
480	Nitric oxide release by N-(2-chloroethyl)-N-nitrosoureas: a rarely discussed mechanistic path towards their anticancer activity. <i>RSC Advances</i> , 2015, 5, 2137-2146.	1.7	9
481	Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 1081-1095.	1.1	14
482	Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 254-262.	1.0	53
483	Bladder Tumor Heterogeneity: The Impact on Clinical Treatment. <i>Urologia Internationalis</i> , 2015, 95, 1-8.	0.6	22

#	ARTICLE	IF	CITATIONS
484	Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. <i>International Journal of Pharmaceutics</i> , 2015, 479, 399-407.	2.6	56
485	Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 404-411.	1.0	4
486	Design of Hybrid MnO ₂ Polymer-Lipid Nanoparticles with Tunable Oxygen Generation Rates and Tumor Accumulation for Cancer Treatment. <i>Advanced Functional Materials</i> , 2015, 25, 1858-1872.	7.8	182
487	Secretory prostate apoptosis response (Par)4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death. <i>FEBS Open Bio</i> , 2015, 5, 8-19.	1.0	20
488	Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating. <i>Journal of Controlled Release</i> , 2015, 199, 180-189.	4.8	27
489	Three-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation. <i>Scientific Reports</i> , 2014, 4, 6468.	1.6	181
490	Simultaneous ¹²⁵ I integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	78
491	Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 172-182.	3.3	15
492	Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. <i>Biomaterials</i> , 2015, 45, 99-114.	5.7	56
493	Introduction to the molecular basis of cancer metabolism and the Warburg effect. <i>Molecular Biology Reports</i> , 2015, 42, 819-823.	1.0	65
494	Resistance to Targeted ABC Transporters in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , .	0.1	3
495	Tumor Microenvironment Activated Photothermal Strategy for Precisely Controlled Ablation of Solid Tumors upon NIR Irradiation. <i>Advanced Functional Materials</i> , 2015, 25, 1574-1580.	7.8	129
496	Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors. <i>Physics in Medicine and Biology</i> , 2015, 60, 1477-1496.	1.6	16
498	Synthetic tumor networks for screening drug delivery systems. <i>Journal of Controlled Release</i> , 2015, 201, 49-55.	4.8	55
499	Autophagic responses to hypoxia and anticancer therapy in head and neck cancer. <i>Pathology Research and Practice</i> , 2015, 211, 101-108.	1.0	14
500	Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. <i>Cancer Treatment Reviews</i> , 2015, 41, 105-113.	3.4	78
501	Proton channels and exchangers in cancer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 2715-2726.	1.4	158
502	High-Content Analysis with Cellular and Tissue Systems Biology. , 2015, , 369-392.e7.		9

#	ARTICLE	IF	CITATIONS
503	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. <i>Biomaterials</i> , 2015, 52, 126-139.	5.7	261
504	Quantitative Determination of Irinotecan and the Metabolite SN-38 by Nanoflow Liquid Chromatography-Tandem Mass Spectrometry in Different Regions of Multicellular Tumor Spheroids. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 577-586.	1.2	26
505	Protamine-carboxymethyl cellulose magnetic nanocapsules for enhanced delivery of anticancer drugs against drug resistant cancers. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 969-981.	1.7	61
507	Advancements in the delivery of epigenetic drugs. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1501-1512.	2.4	22
508	Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e3.	1.6	65
509	Targeted and controlled drug delivery using a temperature and ultra-violet responsive liposome with excellent breast cancer suppressing ability. <i>RSC Advances</i> , 2015, 5, 27630-27639.	1.7	18
510	A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy. <i>Journal of Theoretical Biology</i> , 2015, 380, 569-584.	0.8	24
511	Macrophage Polarization and the Effect of MicroRNA-155 Administered in Water-in-Oil-in-Water Multiple Emulsion Formulations. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	1
512	¹⁵ O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1144-1149.	2.8	17
513	IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. <i>ACS Nano</i> , 2015, 9, 7976-7991.	7.3	136
514	Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponse Therapy. <i>Chemical Reviews</i> , 2015, 115, 10637-10689.	23.0	827
515	Analysis of Hypoxia-Inducible Factor-1 α Expression Relative to Other Key Factors in Malignant Canine Mammary Tumours. <i>Journal of Comparative Pathology</i> , 2015, 153, 101-110.	0.1	9
516	Effect of FosPeg [®] mediated photoactivation on P-gp / ABCB1 protein expression in human nasopharyngeal carcinoma cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2015, 148, 82-87.	1.7	9
517	Labile ruthenium(II) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation. <i>Dalton Transactions</i> , 2015, 44, 15602-15610.	1.6	33
518	Applications of Dynamical Systems in Biology and Medicine. <i>The IMA Volumes in Mathematics and Its Applications</i> , 2015, , .	0.5	16
519	Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality. <i>Cancer Drug Discovery and Development</i> , 2015, , 345-361.	0.2	0
520	Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. <i>PLoS Computational Biology</i> , 2015, 11, e1004142.	1.5	100
521	Spatial and Functional Heterogeneities Shape Collective Behavior of Tumor-Immune Networks. <i>PLoS Computational Biology</i> , 2015, 11, e1004181.	1.5	35

#	ARTICLE	IF	CITATIONS
522	A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy. <i>Journal of Controlled Release</i> , 2015, 209, 101-109.	4.8	42
523	Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities. <i>Journal of Clinical Oncology</i> , 2015, 33, 1779-1786.	0.8	66
524	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 67.e9-67.e13.	0.8	22
525	Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor. <i>Biochemical Pharmacology</i> , 2015, 94, 79-90.	2.0	22
526	A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. <i>Science Translational Medicine</i> , 2015, 7, 284ra58.	5.8	76
527	Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. <i>Archives of Pharmacal Research</i> , 2015, 38, 239-248.	2.7	48
528	Association of angiogenic factors with prognosis in esophageal cancer. <i>BMC Cancer</i> , 2015, 15, 121.	1.1	28
529	Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. <i>Journal of Translational Medicine</i> , 2015, 13, 78.	1.8	31
530	Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model. <i>Journal of Controlled Release</i> , 2015, 207, 101-111.	4.8	84
531	Macrophages and Therapeutic Resistance in Cancer. <i>Cancer Cell</i> , 2015, 27, 462-472.	7.7	1,130
532	Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 1044-1060.	0.6	4
533	Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. <i>European Urology Focus</i> , 2015, 1, 54-63.	1.6	15
534	Architecture of Chimeric Spheroids Controls Drug Transport. <i>Cancer Microenvironment</i> , 2015, 8, 101-109.	3.1	13
535	Tailoring Oxygen Sensitivity with Halide Substitution in Difluoroboron Dibenzoylmethane Polylactide Materials. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 23633-23643.	4.0	72
536	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. <i>Small GTPases</i> , 2015, 6, 123-133.	0.7	37
537	Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. <i>Journal of Controlled Release</i> , 2015, 220, 160-168.	4.8	22
538	Evaluating Biomaterial- and Microfluidic-Based 3D Tumor Models. <i>Trends in Biotechnology</i> , 2015, 33, 667-678.	4.9	99
539	Minimal residual disease in cancer therapy "Small things make all the difference. <i>Drug Resistance Updates</i> , 2015, 21-22, 1-10.	6.5	34

#	ARTICLE	IF	CITATIONS
540	Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. <i>Journal of Controlled Release</i> , 2015, 217, 27-41.	4.8	101
541	Genetic instability in the tumor microenvironment: a new look at an old neighbor. <i>Molecular Cancer</i> , 2015, 14, 145.	7.9	48
542	Nano-enabled delivery of diverse payloads across complex biological barriers. <i>Journal of Controlled Release</i> , 2015, 219, 548-559.	4.8	54
543	Quantifying and reducing uncertainties in cancer therapy. , 2015, 9412, .		2
544	Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. <i>Journal of Controlled Release</i> , 2015, 219, 269-277.	4.8	54
545	Monocytic delivery of therapeutic oxygen bubbles for dual-modality treatment of tumor hypoxia. <i>Journal of Controlled Release</i> , 2015, 220, 738-750.	4.8	57
546	A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. <i>Technology</i> , 2015, 03, 54-63.	1.4	5
547	Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. <i>Drug Resistance Updates</i> , 2015, 23, 69-78.	6.5	202
548	Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. <i>Nanomedicine</i> , 2015, 10, 1993-1995.	1.7	95
549	Investigation into the hypoxia-dependent cytotoxicity of anticancer drugs under oxygen gradient in a microfluidic device. <i>Microfluidics and Nanofluidics</i> , 2015, 19, 1271-1279.	1.0	24
550	Improving drug delivery to solid tumors: Priming the tumor microenvironment. <i>Journal of Controlled Release</i> , 2015, 201, 78-89.	4.8	411
551	Resistance through repopulation. <i>Nature</i> , 2015, 517, 152-153.	13.7	34
552	Nanotechnology to Combat Multidrug Resistance in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 245-272.	0.1	5
553	Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. <i>Biotechnology Advances</i> , 2015, 33, 224-241.	6.0	35
554	Prediction of individual response to anticancer therapy: historical and future perspectives. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 729-757.	2.4	48
555	WNT Signaling: an Emerging Mediator of Cancer Cell Metabolism?. <i>Molecular and Cellular Biology</i> , 2015, 35, 2-10.	1.1	119
556	Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA. <i>Scientific Reports</i> , 2014, 4, 6878.	1.6	118
557	Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. <i>Targeted Oncology</i> , 2015, 10, 189-198.	1.7	33

#	ARTICLE	IF	CITATIONS
558	Does Adriamycine, Cytoxan with Taxol Treatment Affect FBS and Lipid Profile in Breast Cancer Patients. Archives of Medicine, 2016, 8, .	0.2	0
559	Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	16
560	Promoter methylation patterns of <i>ABCB1</i> , <i>ABCC1</i> and <i>ABCG2</i> in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget, 2016, 7, 73347-73369.	0.8	31
561	Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-11.	1.9	56
562	Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells International, 2016, 2016, 1-17.	1.2	131
563	The Role of Rhoj in Endothelial Cell Biology and Tumor Pathology. BioMed Research International, 2016, 2016, 1-9.	0.9	11
564	Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-8.	0.7	48
565	Metformin Synergistically Enhances Cisplatin-Induced Cytotoxicity in Esophageal Squamous Cancer Cells under Glucose-Deprivation Conditions. BioMed Research International, 2016, 2016, 1-8.	0.9	16
566	Potential antitumor activity of novel DODAC/PHO-S liposomes. International Journal of Nanomedicine, 2016, 11, 1577.	3.3	17
567	Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3 β / β -catenin Signaling. Theranostics, 2016, 6, 1205-1219.	4.6	132
568	Hypoxia on the Expression of Hepatoma Upregulated Protein in Prostate Cancer Cells. Frontiers in Oncology, 2016, 6, 144.	1.3	13
569	A Versatile Axle for the Construction of Disassemblage Rotaxanes. Molecules, 2016, 21, 1043.	1.7	2
570	Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. PLoS Computational Biology, 2016, 12, e1004969.	1.5	55
571	Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1 α Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC. Frontiers in Physiology, 2016, 7, 420.	1.3	51
572	Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. Molecular and Clinical Oncology, 2016, 4, 326-368.	0.4	4
573	Fibroblasts, an inconspicuous but essential player in colon cancer development and progression. World Journal of Gastroenterology, 2016, 22, 5301.	1.4	39
574	Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation. Oncotarget, 2016, 7, 40621-40629.	0.8	95
575	The Role of Monocarboxylate Transporters and Their Chaperone CD147 in Lactate Efflux Inhibition and the Anticancer Effects of Terminalia chebula in Neuroblastoma Cell Line N2-A. European Journal of Medicinal Plants, 2016, 12, 1-18.	0.5	6

#	ARTICLE	IF	CITATIONS
576	The chemotherapeutic drug boanmycin induces cell senescence and senescence-associated secretory phenotype factors, thus acquiring the potential to remodel the tumor microenvironment. <i>Anti-Cancer Drugs</i> , 2016, 27, 84-88.	0.7	3
577	How can nanomedicines overcome cellular-based anticancer drug resistance?. <i>Journal of Materials Chemistry B</i> , 2016, 4, 5078-5100.	2.9	32
578	Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses. <i>Biotechnology and Bioengineering</i> , 2016, 113, 2474-2484.	1.7	26
579	Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma. <i>BJU International</i> , 2016, 118, 598-603.	1.3	42
580	Natural Polyphenols in Cancer Chemoresistance. <i>Nutrition and Cancer</i> , 2016, 68, 879-891.	0.9	48
581	Preparation of Engineered <i>Salmonella Typhimurium</i> -Driven Hyaluronic Acid-Based Microbeads with Both Chemotactic and Biological Targeting Towards Breast Cancer Cells for Enhanced Anticancer Therapy. <i>Advanced Healthcare Materials</i> , 2016, 5, 288-295.	3.9	31
582	Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. <i>Genome Biology</i> , 2016, 17, 190.	3.8	35
583	Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging. <i>Scientific Reports</i> , 2016, 6, 29999.	1.6	14
584	Impact of Hyperglycemia and Age on Outcomes in Patients With Acute Myeloid Leukemia. <i>Oncology Nursing Forum</i> , 2016, 43, 595-601.	0.5	6
585	Efficient DNA binding of NF- κ B requires the chaperone-like function of NPM1. <i>Nucleic Acids Research</i> , 2016, 45, gkw1285.	6.5	46
586	Extracellular electrical recording of pH-triggered bursts in C6 glioma cell populations. <i>Science Advances</i> , 2016, 2, e1600516.	4.7	22
587	Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. <i>Scientific Reports</i> , 2016, 6, 25424.	1.6	27
588	Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC. <i>Oncology Letters</i> , 2016, 12, 3241-3249.	0.8	18
589	Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations. <i>Biology Direct</i> , 2016, 11, 43.	1.9	56
590	Targeting the Microenvironment in Advanced Colorectal Cancer. <i>Trends in Cancer</i> , 2016, 2, 495-504.	3.8	80
591	An Autonomous and Adaptive Bacteria-based Drug Delivery System. , 2016, , .		2
592	Polymer-Based and pH-Sensitive Nanobiosensors for Imaging and Therapy of Acidic Pathological Areas. <i>Pharmaceutical Research</i> , 2016, 33, 2358-2372.	1.7	18
593	Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. <i>Current Opinion in Cell Biology</i> , 2016, 42, 80-93.	2.6	117

#	ARTICLE	IF	CITATIONS
594	Multiplexed Epitope-Based Tissue Imaging for Discovery and Healthcare Applications. <i>Cell Systems</i> , 2016, 2, 225-238.	2.9	201
595	Caffeic acid-coated multifunctional magnetic nanoparticles for the treatment and bimodal imaging of tumours. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 160, 210-216.	1.7	28
596	Tumor microenvironment-specific nanoparticles activatable by stepwise transformation. <i>Journal of Controlled Release</i> , 2016, 234, 68-78.	4.8	25
597	Tumor cell culture on collagen-chitosan scaffolds as three-dimensional tumor model: A suitable model for tumor studies. <i>Journal of Food and Drug Analysis</i> , 2016, 24, 620-626.	0.9	16
598	Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 104-111.	0.6	23
599	Alkyl and aryl sulfonyl p-pyridine ethanone oximes are efficient DNA photo-cleavage agents. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 158, 30-38.	1.7	19
600	Diffusion and Uptake of Tobacco Mosaic Virus as Therapeutic Carrier in Tumor Tissue: Effect of Nanoparticle Aspect Ratio. <i>Journal of Physical Chemistry B</i> , 2016, 120, 6120-6129.	1.2	31
601	Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. <i>Cancer Letters</i> , 2016, 376, 278-283.	3.2	56
602	Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 2049-2058.	2.3	39
603	Nanoliposomal irinotecan for treating pancreatic cancer. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 541-547.	0.5	3
604	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 1865-1874.	3.2	700
605	Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. <i>Pharmaceutical Research</i> , 2016, 33, 1657-1670.	1.7	7
606	Cancer chemoresistance; biochemical and molecular aspects: a brief overview. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 20-30.	1.9	123
607	Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. <i>Molecular Pharmaceutics</i> , 2016, 13, 2010-2025.	2.3	37
608	Evaluation of a Simplified Intravoxel Incoherent Motion (IVIM) Analysis of Diffusion-Weighted Imaging for Prediction of Tumor Size Changes and Imaging Response in Breast Cancer Liver Metastases Undergoing Radioembolization. <i>Medicine (United States)</i> , 2016, 95, e3275.	0.4	23
609	Doxorubicin hydrochloride-oleic acid conjugate loaded nanostructured lipid carriers for tumor specific drug release. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 145, 95-103.	2.5	38
610	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1-12.	1.1	152
611	Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 287-295.	1.5	55

#	ARTICLE	IF	CITATIONS
612	Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors. <i>Advanced Healthcare Materials</i> , 2016, 5, 2788-2798.	3.9	51
614	An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome. <i>Acta Biomaterialia</i> , 2016, 44, 341-354.	4.1	34
615	Breaching the Hyaluronan Barrier with PH20 α Facilitates Intratumoral Permeation and Enhances Antitumor Efficiency: A Comparative Investigation of Typical Therapeutic Agents in Different Nanoscales. <i>Advanced Healthcare Materials</i> , 2016, 5, 2872-2881.	3.9	19
616	Transitioning from multi-phase to single-phase microfluidics for long-term culture and treatment of multicellular spheroids. <i>Lab on A Chip</i> , 2016, 16, 3548-3557.	3.1	33
617	Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. <i>Cancer Cell</i> , 2016, 30, 257-272.	7.7	158
618	Multifunctional Phosphorescent Conjugated Polymer Dots for Hypoxia Imaging and Photodynamic Therapy of Cancer Cells. <i>Advanced Science</i> , 2016, 3, 1500155.	5.6	111
619	Observation of reversible, rapid changes in drug susceptibility of hypoxic tumor cells in a microfluidic device. <i>Analytica Chimica Acta</i> , 2016, 936, 179-184.	2.6	15
620	Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?. <i>Bioconjugate Chemistry</i> , 2016, 27, 2225-2238.	1.8	726
621	An outline of main factors of drug resistance influencing cancer therapy. <i>Journal of Chemotherapy</i> , 2016, 28, 457-464.	0.7	20
622	SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer. <i>Oncology Reports</i> , 2016, 35, 2561-2568.	1.2	36
623	Nanomedicine targeting the tumor microenvironment: Therapeutic strategies to inhibit angiogenesis, remodel matrix, and modulate immune responses. <i>Journal of Cellular Immunotherapy</i> , 2016, 2, 69-78.	0.6	46
624	Combination therapeutics of doxorubicin with Fe ₃ O ₄ @chitosan@phytic acid nanoparticles for multi-responsive drug delivery. <i>RSC Advances</i> , 2016, 6, 88248-88254.	1.7	8
625	Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. <i>Journal of Controlled Release</i> , 2016, 241, 68-80.	4.8	114
626	Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. <i>Pharmaceutical Research</i> , 2016, 33, 2722-2735.	1.7	3
627	Direct Pharmacological Inhibition of β -Catenin by RNA Interference in Tumors of Diverse Origin. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2143-2154.	1.9	43
628	High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 737-742.	1.0	29
629	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. <i>Scientific Reports</i> , 2016, 6, 37027.	1.6	58
630	Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. <i>Scientific Reports</i> , 2016, 6, 36750.	1.6	82

#	ARTICLE	IF	CITATIONS
631	3D tumor spheroids: an overview on the tools and techniques used for their analysis. <i>Biotechnology Advances</i> , 2016, 34, 1427-1441.	6.0	579
632	Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer. <i>Scientific Reports</i> , 2016, 6, 24706.	1.6	40
633	Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2016, 76, 6828-6838.	0.4	75
634	Effects of chronic exposure to acidic environment on the response of tumor cells to radiation. <i>International Journal of Radiation Biology</i> , 2016, 92, 502-507.	1.0	1
635	Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. <i>Chinese Journal of Cancer</i> , 2016, 35, 61.	4.9	32
636	Phenylboronic acid-decorated gelatin nanoparticles for enhanced tumor targeting and penetration. <i>Nanotechnology</i> , 2016, 27, 385101.	1.3	30
637	Effect of hypoxia on chemosensitivity to 5-fluorouracil in SH-SY5Y neuroblastoma cells. <i>Bioscience Horizons</i> , 2016, 9, hzw005.	0.6	5
638	Fluorescent and quantitative mitochondrial redox imaging of tumor targeted by Octa-RGD probe. <i>Journal of Innovative Optical Health Sciences</i> , 2016, 09, 1642002.	0.5	0
639	Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation. <i>Cell Cycle</i> , 2016, 15, 1908-1918.	1.3	49
640	Iron participated in breast cancer chemoresistance by reinforcing IL-6 paracrine loop. <i>Biochemical and Biophysical Research Communications</i> , 2016, 475, 154-160.	1.0	26
641	Spectral mapping of 3D multi-cellular tumor spheroids: time-resolved confocal microscopy. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 18381-18390.	1.3	20
642	Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. <i>Journal of Controlled Release</i> , 2016, 236, 15-21.	4.8	46
643	The five Rs of chemotherapy. <i>Lancet Oncology</i> , The, 2016, 17, 703-705.	5.1	6
644	Cancer in the aftermath of Nepal's earthquakes. <i>Lancet Oncology</i> , The, 2016, 17, 705-706.	5.1	9
645	Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. <i>Molecular Pharmaceutics</i> , 2016, 13, 2214-2223.	2.3	44
646	NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?. <i>Journal of Nanobiotechnology</i> , 2016, 14, 17.	4.2	35
647	IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer. , 2016, 9836, .		4
648	Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer <i>in vitro</i> model. <i>Nanomedicine</i> , 2016, 11, 331-344.	1.7	21

#	ARTICLE	IF	CITATIONS
649	Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1381-1386.	3.3	64
650	Chemo-directed specific targeting of nanoparticle-doxorubicin complexes to tumor in animal model. Journal of Drug Delivery Science and Technology, 2016, 31, 167-175.	1.4	3
651	Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. Cancer Research, 2016, 76, 1320-1334.	0.4	36
652	Nanostructured lipid-carraageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux. Drug Development and Industrial Pharmacy, 2016, 42, 1351-1359.	0.9	24
653	Developing multi-cellular tumor spheroid model (MCTS) in the chitosan/collagen/alginate (CCA) fibrous scaffold for anticancer drug screening. Materials Science and Engineering C, 2016, 62, 215-225.	3.8	39
654	Novel Morphologic and Genetic Analysis of Cancer Cells in a 3D Microenvironment Identifies STAT3 as a Regulator of Tumor Permeability Barrier Function. Cancer Research, 2016, 76, 1044-1054.	0.4	19
655	Î±-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles. Colloids and Surfaces B: Biointerfaces, 2016, 140, 246-253.	2.5	49
656	In vitro evaluation of anticancer properties of exopolysaccharides from Lactobacillus acidophilus in colon cancer cell lines. In Vitro Cellular and Developmental Biology - Animal, 2016, 52, 163-173.	0.7	70
657	The promise of protein glycosylation for personalised medicine. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1583-1595.	1.1	79
658	The role of tumor microenvironment in melanoma therapy resistance. Melanoma Management, 2016, 3, 23-32.	0.1	18
659	Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Molecular Medicine Reports, 2016, 13, 2476-2484.	1.1	85
660	Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemotherapy and Pharmacology, 2016, 77, 441-457.	1.1	175
661	Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. Molecular Cancer Therapeutics, 2016, 15, 1145-1152.	1.9	27
662	Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles. Toxicology in Vitro, 2016, 33, 45-53.	1.1	36
663	Bioengineering three-dimensional culture model of human lung cancer cells: an improved tool for screening EGFR targeted inhibitors. RSC Advances, 2016, 6, 24083-24090.	1.7	17
664	pH-Sensitive Nanosystems. , 2016, , 49-81.		3
665	Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1279-1290.	1.7	78
666	Improving nanoparticle diffusion through tumor collagen matrix by photo-thermal gold nanorods. Nanoscale, 2016, 8, 12524-12530.	2.8	85

#	ARTICLE	IF	CITATIONS
667	“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 3-18.	6.6	399
668	Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. <i>Lab on A Chip</i> , 2016, 16, 312-325.	3.1	141
669	Tumor microenvironment and cancer therapy resistance. <i>Cancer Letters</i> , 2016, 380, 205-215.	3.2	246
670	Chemotherapy promotes tumour cell hybridization in vivo. <i>Tumor Biology</i> , 2016, 37, 5025-5030.	0.8	21
671	Tumor-Priming Smoothed Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 84-93.	1.9	27
672	Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine. <i>British Journal of Radiology</i> , 2016, 89, 20150210.	1.0	9
673	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. <i>International Journal of Clinical Oncology</i> , 2016, 21, 126-132.	1.0	18
674	Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. <i>Molecular Cancer Research</i> , 2016, 14, 3-13.	1.5	230
675	In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier. <i>Biomaterials</i> , 2016, 75, 71-81.	5.7	66
676	Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 599-606.	1.4	3
677	Extremely low frequency electromagnetic field sensitizes cisplatin-resistant human ovarian adenocarcinoma cells via P53 activation. <i>Cytotechnology</i> , 2016, 68, 1403-1413.	0.7	27
678	In vitro cancer cell-ECM interactions inform in vivo cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2016, 97, 270-279.	6.6	162
679	Emulsion technologies for multicellular tumour spheroid radiation assays. <i>Analyst</i> , 2016, 141, 100-110.	1.7	62
680	Simultaneous visualization of tumour oxygenation, neovascularization and contrast agent perfusion by real-time three-dimensional optoacoustic tomography. <i>European Radiology</i> , 2016, 26, 1843-1851.	2.3	57
681	Tumor microenvironment and therapeutic response. <i>Cancer Letters</i> , 2017, 387, 61-68.	3.2	1,267
682	Cell Mediated Photothermal Therapy of Brain Tumors. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 99-106.	2.1	31
683	Near-IR-Absorbing Gold Nanoframes with Enhanced Physiological Stability and Improved Biocompatibility for In Vivo Biomedical Applications. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 3873-3884.	4.0	33
684	In vivo aggregation-induced transition between T_{1} and T_{2} relaxations of magnetic ultra-small iron oxide nanoparticles in tumor microenvironment. <i>Nanoscale</i> , 2017, 9, 3040-3050.	2.8	50

#	ARTICLE	IF	CITATIONS
685	Colloid electrochemistry of conducting polymer: towards potential-induced in-situ drug release. <i>Electrochimica Acta</i> , 2017, 228, 407-412.	2.6	14
686	Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?. <i>Seminars in Cancer Biology</i> , 2017, 43, 111-118.	4.3	48
687	Hypoxic behavior in cells under controlled microfluidic environment. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 759-771.	1.1	10
688	Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties. <i>Journal of Controlled Release</i> , 2017, 251, 49-67.	4.8	104
689	Nanomedicine as a potent strategy in melanoma tumor microenvironment. <i>Pharmacological Research</i> , 2017, 126, 31-53.	3.1	25
690	Targeting of crosstalk between tumor and tumor microenvironment by Î²-D mannuronic acid (M2000) in murine breast cancer model. <i>Cancer Medicine</i> , 2017, 6, 640-650.	1.3	37
691	Towards cell-based therapeutics: A bio-inspired autonomous drug delivery system. <i>Nano Communication Networks</i> , 2017, 12, 25-33.	1.6	5
692	Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. <i>Nature</i> , 2017, 543, 428-432.	13.7	423
693	Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 347-363.	5.6	52
694	Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes. <i>Oncology Letters</i> , 2017, 13, 206-214.	0.8	18
695	Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression. <i>Cell Reports</i> , 2017, 18, 2228-2242.	2.9	129
696	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	178
697	Therapeutic implications of tumor interstitial acidification. <i>Seminars in Cancer Biology</i> , 2017, 43, 119-133.	4.3	82
698	Epigenetic control of gene expression: Potential implications for cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 166-172.	2.0	113
699	Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 959-969.	1.1	43
700	A non-equilibrium thermodynamic model for tumor extracellular matrix with enzymatic degradation. <i>Journal of the Mechanics and Physics of Solids</i> , 2017, 104, 32-56.	2.3	32
701	A multimodal instrument for real-time in situ study of ultrasound and cavitation mediated drug delivery. <i>Review of Scientific Instruments</i> , 2017, 88, 034302.	0.6	5
702	Effect of Combined Anticancer Drugs Treatment on Heterogeneous Brain Tumors. <i>International Journal of Applied and Computational Mathematics</i> , 2017, 3, 3877-3896.	0.9	1

#	ARTICLE	IF	CITATIONS
703	Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia. <i>Chemical Reviews</i> , 2017, 117, 6160-6224.	23.0	682
704	Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis. <i>Biomaterials</i> , 2017, 133, 176-207.	5.7	79
705	Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. <i>ACS Nano</i> , 2017, 11, 4916-4925.	7.3	218
706	Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis. <i>British Journal of Cancer</i> , 2017, 116, 1329-1339.	2.9	35
707	Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy. <i>Pharmacological Research</i> , 2017, 126, 109-122.	3.1	59
708	3D tumor microtissues as an in vitro testing platform for microenvironmentally-triggered drug delivery systems. <i>Acta Biomaterialia</i> , 2017, 57, 47-58.	4.1	32
709	A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts. <i>Scientific Reports</i> , 2017, 7, 1325.	1.6	53
710	Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy. <i>Integrative Biology (United Kingdom)</i> , 2017, 9, 555-565.	0.6	40
711	Comparison of Tumor Penetration of Podophyllotoxin- α -Carboxymethylcellulose Conjugates with Various Chemical Compositions in Tumor Spheroid Culture and In Vivo Solid Tumor. <i>Bioconjugate Chemistry</i> , 2017, 28, 1505-1518.	1.8	26
712	A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery. <i>Autophagy</i> , 2017, 13, 359-370.	4.3	15
713	Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. <i>Cancer Letters</i> , 2017, 388, 34-42.	3.2	115
714	Quantitating drug-target engagement in single cells in vitro and in vivo. <i>Nature Chemical Biology</i> , 2017, 13, 168-173.	3.9	81
715	Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. <i>Nanoscale</i> , 2017, 9, 1334-1355.	2.8	132
716	Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 983-995.	2.4	35
717	Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery. <i>ACS Nano</i> , 2017, 11, 6691-6702.	7.3	121
718	Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway. <i>Anti-Cancer Drugs</i> , 2017, 28, 187-196.	0.7	10
719	Current progress in antivascular tumor therapy. <i>Drug Discovery Today</i> , 2017, 22, 1503-1515.	3.2	35
720	First plasma and tissue pharmacokinetic study of the YSNSG cyclopeptide, a new integrin antagonist, using microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 178-187.	1.9	2

#	ARTICLE	IF	CITATIONS
721	Î±-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery. ACS Applied Materials & Interfaces, 2017, 9, 19215-19230.	4.0	71
722	Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chemical Society Reviews, 2017, 46, 3830-3852.	18.7	719
723	Polysaccharide matrices used in 3D in vitro cell culture systems. Biomaterials, 2017, 141, 96-115.	5.7	86
724	Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Current Oncology Reports, 2017, 19, 47.	1.8	100
725	Systemic Drug Delivery in Gastric Cancer. , 2017, , 189-201.		0
726	Assembly of breast cancer heterotypic spheroids on hyaluronic acid coated surfaces. Biotechnology Progress, 2017, 33, 1346-1357.	1.3	17
727	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume". Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
728	pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy. Acta Biomaterialia, 2017, 58, 168-180.	4.1	436
729	Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer. International Journal of Pharmaceutics, 2017, 528, 322-333.	2.6	29
730	Tumour blood vessel normalisation by prolyl hydroxylase inhibitor repaired sensitivity to chemotherapy in a tumour mouse model. Scientific Reports, 2017, 7, 45621.	1.6	22
731	A549 and MRC-5 cell aggregation in a microfluidic <i>Lab-on-a-chip</i> system. Biomicrofluidics, 2017, 11, 024110.	1.2	22
732	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. Cancer Research, 2017, 77, 2869-2880.	0.4	17
733	Evaluating the influence of mechanical stress on anticancer treatments through a multiphase porous media model. Journal of Theoretical Biology, 2017, 421, 179-188.	0.8	25
734	A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discovery, 2017, 22, 494-506.	1.4	26
735	New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacologica Sinica, 2017, 38, 614-622.	2.8	475
736	Use of hepatobiliary phase images in Gd-EOB-DTPA-enhanced MRI of breast cancer hepatic metastasis to predict response to chemotherapy. Clinical Imaging, 2017, 43, 127-131.	0.8	6
737	Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1531-1541.	1.2	20
738	Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. International Journal of Pharmaceutics, 2017, 523, 203-216.	2.6	81

#	ARTICLE	IF	CITATIONS
739	Peptide nanoparticle with pH-sensing cargo solubility enhances cancer drug efficiency. <i>Nano Today</i> , 2017, 13, 15-22.	6.2	11
740	The structural modification of natural products for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 121-140.	2.5	169
741	Matrix stiffening promotes a tumor vasculature phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 492-497.	3.3	295
742	Breast tumor stroma: A driving force in the development of resistance to therapies. <i>Chemical Biology and Drug Design</i> , 2017, 89, 309-318.	1.5	58
743	Biomimetic synthesis of sericin and silica hybrid colloidosomes for stimuli-responsive anti-cancer drug delivery systems. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 151, 102-111.	2.5	18
744	Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. <i>Oncology Reports</i> , 2017, 38, 3011-3018.	1.2	25
745	Exploration of Zinc Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer Nanomedicine. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 39971-39984.	4.0	140
746	Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model. <i>Scientific Reports</i> , 2017, 7, 14167.	1.6	34
747	Improving Tumor Specificity and Anticancer Activity of Dasatinib by Dual-Targeted Polymeric Micelles. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 36642-36654.	4.0	77
748	MicroRNA-320 regulates autophagy in retinoblastoma by targeting hypoxia inducible factor-1 α . <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 2367-2372.	0.8	27
749	Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy. <i>Bulletin of Mathematical Biology</i> , 2017, 79, 2986-3012.	0.9	22
750	cRGD/TAT Dual-Ligand Reversibly Cross-Linked Micelles Loaded with Docetaxel Penetrate Deeply into Tumor Tissue and Show High Antitumor Efficacy in Vivo. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 35651-35663.	4.0	48
751	Real-time monitoring system for evaluating the acid-producing activity of oral squamous cell carcinoma cells at different environmental pH. <i>Scientific Reports</i> , 2017, 7, 10092.	1.6	11
752	Engineering and physical sciences in oncology: challenges and opportunities. <i>Nature Reviews Cancer</i> , 2017, 17, 659-675.	12.8	204
753	Rapid Generation and Detection of Biomimetic Oxygen Concentration Gradients In Vitro. <i>Scientific Reports</i> , 2017, 7, 13487.	1.6	8
754	Synthesis and Evaluation of Radiolabeled Phosphoramidate Mustard with Selectivity for Hypoxic Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1269-1274.	1.3	15
755	Chemoprotection Across the Tumor Border: Cancer Cell Response to Doxorubicin Depends on Stromal Fibroblast Ratios and Interstitial Therapeutic Transport. <i>Cellular and Molecular Bioengineering</i> , 2017, 10, 463-481.	1.0	11
756	Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. <i>Nanomedicine</i> , 2017, 12, 2137-2148.	1.7	63

#	ARTICLE	IF	CITATIONS
757	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administrationâ€™ Approved Drugs. <i>Pharmacological Reviews</i> , 2017, 69, 479-496.	7.1	58
758	In vivo quantitative imaging of tumor pH by nanosonophore assisted multispectral photoacoustic imaging. <i>Nature Communications</i> , 2017, 8, 471.	5.8	98
759	LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 1004-1009.	2.5	15
760	Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. <i>Experimental Eye Research</i> , 2017, 162, 48-61.	1.2	11
761	Microscale Mass Spectrometry Analysis of Extracellular Metabolites in Live Multicellular Tumor Spheroids. <i>Analytical Chemistry</i> , 2017, 89, 9069-9076.	3.2	31
762	A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2017, 7, 5725.	1.6	37
763	Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. <i>Nano Today</i> , 2017, 15, 56-90.	6.2	103
764	Hyperbranched Phosphorescent Conjugated Polymer Dots with Iridium(III) Complex as the Core for Hypoxia Imaging and Photodynamic Therapy. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 28319-28330.	4.0	84
765	Prodrug-embedded angiogenic vessel-targeting nanoparticle: A positive feedback amplifier in hypoxia-induced chemo-photo therapy. <i>Biomaterials</i> , 2017, 144, 188-198.	5.7	57
766	Opioid Tripeptides Hybridized with <i>trans</i> -1- <i>n</i> -Cinnamylpiperazine as Proliferation Inhibitors of Pancreatic Cancer Cells in Two- and Three-Dimensional in vitro Models. <i>ChemMedChem</i> , 2017, 12, 1637-1644.	1.6	4
767	MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. <i>Scientific Reports</i> , 2017, 7, 16763.	1.6	11
768	Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids. <i>Scientific Reports</i> , 2017, 7, 16645.	1.6	41
769	A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance. <i>Integrative Biology (United Kingdom)</i> , 2017, 9, 912-924.	0.6	38
770	Reprogramming Tumor-Associated Macrophages To Reverse EGFR ^{T790M} Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. <i>Nano Letters</i> , 2017, 17, 7684-7690.	4.5	90
771	Mesoporous carbon nanomaterials in drug delivery and biomedical application. <i>Drug Delivery</i> , 2017, 24, 94-107.	2.5	130
772	Metabolic Profiling of healthy and cancerous tissues in 2D and 3D. <i>Scientific Reports</i> , 2017, 7, 15285.	1.6	72
773	Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. <i>Cancer Science</i> , 2017, 108, 2470-2477.	1.7	24
774	HIF-1 \pm - Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy. <i>Scientific Reports</i> , 2017, 7, 14978.	1.6	62

#	ARTICLE	IF	CITATIONS
775	Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance. <i>Nature Communications</i> , 2017, 8, 15884.	5.8	54
776	AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer. <i>Cell Death and Disease</i> , 2017, 8, e2894-e2894.	2.7	37
777	Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 25152-25163.	4.0	87
778	An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. <i>Cell Death and Disease</i> , 2017, 8, e2932-e2932.	2.7	76
779	Microfluidic technologies for anticancer drug studies. <i>Drug Discovery Today</i> , 2017, 22, 1654-1670.	3.2	63
780	Stimuli-Responsive “Cluster Bomb” for Programmed Tumor Therapy. <i>ACS Nano</i> , 2017, 11, 7201-7214.	7.3	145
781	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4434-4447.	0.4	52
782	DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. <i>Cancer Research</i> , 2017, 77, 198-206.	0.4	96
783	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1457-1474.	2.4	77
784	Adaptive mechanisms of resistance to anti-neoplastic agents. <i>MedChemComm</i> , 2017, 8, 53-66.	3.5	12
785	Molecular imaging of the tumor microenvironment. <i>Advanced Drug Delivery Reviews</i> , 2017, 113, 24-48.	6.6	175
786	Mathematical model of tumor volume dynamics in mice treated with electrochemotherapy. <i>Medical and Biological Engineering and Computing</i> , 2017, 55, 1085-1096.	1.6	2
787	Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 536-548.	3.2	27
788	Folic acid-conjugated soybean protein-based nanoparticles mediate efficient antitumor ability <i>in vitro</i> . <i>Journal of Biomaterials Applications</i> , 2017, 31, 832-843.	1.2	18
789	Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. <i>Journal of Controlled Release</i> , 2017, 263, 79-89.	4.8	165
790	<i>In situ</i> measurement of ECM rheology and microheterogeneity in embedded and overlaid 3D pancreatic tumor stroma co-cultures via passive particle tracking. <i>Journal of Innovative Optical Health Sciences</i> , 2017, 10, 1742003.	0.5	6
791	Relationship among reaction rate, release rate and efficiency of nanomachine-based targeted drug delivery. <i>Technology and Health Care</i> , 2017, 25, 1119-1130.	0.5	3
792	Novel function of E26 transformation-specific domain-containing protein ELK3 in lymphatic endothelial cells. <i>Oncology Letters</i> , 2017, 15, 55-60.	0.8	1

#	ARTICLE	IF	CITATIONS
793	The extravascular penetration of tirapazamine into tumours: a predictive model of the transport and efficacy of hypoxia specific cytotoxic analogues and the potential use of cucurbiturils to facilitate delivery. <i>International Journal of Computational Biology and Drug Design</i> , 2017, 10, 343.	0.3	1
794	Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice. <i>Frontiers in Pharmacology</i> , 2017, 8, 531.	1.6	16
795	Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening. <i>Frontiers in Physiology</i> , 2017, 8, 605.	1.3	132
796	5.17 Three-Dimensional Bioengineered Cancer Models. , 2017, , 303-328.		2
797	Doxorubicin-loaded poly (lactic-co-glycolic acid) nanoparticles coated with chitosan/alginate by layer by layer technology for antitumor applications. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 1791-1802.	3.3	66
798	Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells. <i>Viruses</i> , 2017, 9, 174.	1.5	9
799	Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1 α , EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. <i>Archives of Medical Science</i> , 2017, 6, 1303-1314.	0.4	26
800	Nanoparticles for tumor targeting. , 2017, , 221-267.		6
801	Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1854.	1.8	62
802	Tumor Microenvironment on a Chip: The Progress and Future Perspective. <i>Bioengineering</i> , 2017, 4, 64.	1.6	56
803	Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. <i>Bioengineering</i> , 2017, 4, 78.	1.6	23
804	STAT3 but Not HIF-1 α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. <i>Cancers</i> , 2017, 9, 137.	1.7	26
805	The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1586.	1.8	301
806	Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue. <i>Journal of Nanobiotechnology</i> , 2017, 15, 67.	4.2	36
807	Development of hyaluronic acid microcargo for therapeutic bacteriobots. , 2017, , .		0
808	Nanobiotechnology for Breast Cancer Treatment. , 0, , .		12
809	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	1.4	10
810	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 595-606.	1.3	24

#	ARTICLE	IF	CITATIONS
811	Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. <i>Bioconjugate Chemistry</i> , 2018, 29, 914-927.	1.8	15
812	Targeting the Proteostasis Network for Mycobacterial Drug Discovery. <i>ACS Infectious Diseases</i> , 2018, 4, 478-498.	1.8	55
813	Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. <i>Translational Oncology</i> , 2018, 11, 426-435.	1.7	21
814	Metadherin contributes to epithelial-mesenchymal transition and paclitaxel resistance induced by acidic extracellular pH in nasopharyngeal carcinoma. <i>Oncology Letters</i> , 2018, 15, 3858-3863.	0.8	11
815	Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. <i>Annals of Biomedical Engineering</i> , 2018, 46, 899-911.	1.3	5
816	Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer. <i>Translational Oncology</i> , 2018, 11, 732-742.	1.7	32
817	Mathematical Oncology. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 945-953.	0.9	37
818	Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial. <i>ACS Central Science</i> , 2018, 4, 567-581.	5.3	49
819	A microfluidic gradient generator to simulate the oxygen microenvironment in cancer cell culture. <i>Microelectronic Engineering</i> , 2018, 195, 107-113.	1.1	22
820	Camptothecin-loaded fusogenic nanodroplets as ultrasound theranostic agent in stem cell-mediated drug-delivery system. <i>Journal of Controlled Release</i> , 2018, 278, 100-109.	4.8	23
821	Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. <i>Journal of Controlled Release</i> , 2018, 275, 67-77.	4.8	50
822	A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy. <i>Biomaterials</i> , 2018, 178, 706-719.	5.7	130
823	Nanomaterial-assisted sensitization of oncotherapy. <i>Nano Research</i> , 2018, 11, 2932-2950.	5.8	19
824	Spheroids-on-a-chip: Recent advances and design considerations in microfluidic platforms for spheroid formation and culture. <i>Sensors and Actuators B: Chemical</i> , 2018, 263, 151-176.	4.0	175
825	Size-controlled, colloidally stable and functional nanoparticles based on the molecular assembly of green tea polyphenols and keratins for cancer therapy. <i>Journal of Materials Chemistry B</i> , 2018, 6, 1373-1386.	2.9	56
826	Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release. <i>Royal Society Open Science</i> , 2018, 5, 170986.	1.1	35
827	Tissue specificity of in vitro drug sensitivity. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 158-166.	2.2	23
828	Tumor Microenvironment-Enabled Nanotherapy. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701156.	3.9	158

#	ARTICLE	IF	CITATIONS
829	Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 793-803.	1.8	94
831	Fluorescence-Activated Cell Sorting of Murine Mammary Cancer Stem-Like Cell Subpopulations with HIF Activity. <i>Methods in Molecular Biology</i> , 2018, 1742, 247-263.	0.4	5
832	Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7-ethyl-10-hydroxycamptothecin. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701140.	3.9	12
833	In Situ shRNA Synthesis on DNA-Poly(lactide) Nanoparticles to Treat Multidrug Resistant Breast Cancer. <i>Advanced Materials</i> , 2018, 30, 1705737.	11.1	62
834	Dual-targeted nanomedicines for enhanced tumor treatment. <i>Nano Today</i> , 2018, 18, 65-85.	6.2	90
835	Tumor Microenvironment Responsive Oxygen-Self-Generating Nanoplatform for Dual-Imaging Guided Photodynamic and Photothermal Therapy. <i>ChemistrySelect</i> , 2018, 3, 4366-4373.	0.7	31
836	Spatially Uniform Tumor Treatment and Drug Penetration by Regulating Ultrasound with Microbubbles. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 17784-17791.	4.0	38
837	Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 825-844.	2.8	85
838	The influence and manipulation of acid/base properties in drug discovery. <i>Drug Discovery Today: Technologies</i> , 2018, 27, 41-47.	4.0	6
839	A nitroreductase and acidity detecting dual functional ratiometric fluorescent probe for selectively imaging tumor cells. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 3266-3272.	1.5	20
840	Reduction-active polymeric prodrug micelles based on β -cyclodextrin polyrotaxanes for triggered drug release and enhanced cancer therapy. <i>Carbohydrate Polymers</i> , 2018, 193, 153-162.	5.1	34
841	Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1196-1206.	1.9	87
842	How the Warburg effect supports aggressiveness and drug resistance of cancer cells?. <i>Drug Resistance Updates</i> , 2018, 38, 1-11.	6.5	340
843	Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. <i>ACS Nano</i> , 2018, 12, 3295-3310.	7.3	143
844	Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling. <i>Scientific Reports</i> , 2018, 8, 3638.	1.6	12
845	Notch signaling molecule is involved in the invasion of MiaPaCa2 cells induced by CoCl ₂ via regulating epithelial-mesenchymal transition. <i>Molecular Medicine Reports</i> , 2018, 17, 4965-4972.	1.1	9
846	Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030510.	2.9	57
847	The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 111-122.	1.2	51

#	ARTICLE	IF	CITATIONS
848	Identification and Quantification of Drug-Resistant Cells in Colorectal Tumor and Distal Margin. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 141-145.	0.3	0
849	Not only tumor but also therapy heterogeneity. <i>Annals of Oncology</i> , 2018, 29, 13-18.	0.6	20
850	Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model. <i>Molecular Imaging and Biology</i> , 2018, 20, 437-447.	1.3	27
851	Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. <i>Journal of Theoretical Biology</i> , 2018, 436, 120-134.	0.8	24
852	Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs. <i>Journal of Theoretical Biology</i> , 2018, 438, 21-33.	0.8	2
853	The key role of extracellular vesicles in the metastatic process. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 64-77.	3.3	119
854	Characterization of tumor vascular permeability using natural dextrans and CEST MRI. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1001-1009.	1.9	33
855	A modified 384-well device for versatile use in 3D cancer cell (co)cultivation and screening for investigations of tumor biology in vitro. <i>Engineering in Life Sciences</i> , 2018, 18, 132-139.	2.0	8
856	A topological analysis of targeted In-111 uptake in SPECT images of murine tumors. <i>Journal of Mathematical Biology</i> , 2018, 76, 1559-1587.	0.8	7
857	Light-enhanced hypoxia-responsive nanoparticles for deep tumor penetration and combined chemo-photodynamic therapy. <i>Chemical Communications</i> , 2018, 54, 13127-13130.	2.2	41
858	Interaction study of cancer cells and fibroblasts on a spatially confined oxygen gradient microfluidic chip to investigate the tumor microenvironment. <i>Analyst, The</i> , 2018, 143, 5431-5437.	1.7	15
859	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2018, 35, 195-292.	1.2	12
861	Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. <i>Theranostics</i> , 2018, 8, 5986-5994.	4.6	91
862	Synergistic Effects of NOTCH/β3-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells. <i>Frontiers in Oncology</i> , 2018, 8, 460.	1.3	22
863	Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking <i>In Vitro</i> Models in Anti-Cancer Drug Development. <i>Theranostics</i> , 2018, 8, 5259-5275.	4.6	138
864	Glutathione Triggered Near Infrared Fluorescence Imaging-Guided Chemotherapy by Cyanine Conjugated Polypeptide. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 4208-4218.	2.6	9
865	Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia-telangiectasia mutated and nuclear factor-κB pathways in gastric cancer cells. <i>Oncology Reports</i> , 2018, 40, 2334-2342.	1.2	9
866	Effect of fibroblast coculture on the proliferation, viability and drug response of colon cancer cells. <i>Oncology Letters</i> , 2019, 17, 2409-2417.	0.8	29

#	ARTICLE	IF	CITATIONS
867	DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. <i>Scientific Reports</i> , 2018, 8, 17862.	1.6	47
868	Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801198.	3.9	49
869	Dual Role of Magnetic Nanoparticles as Intracellular Hotspots and Extracellular Matrix Disruptors Triggered by Magnetic Hyperthermia in 3D Cell Culture Models. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 44301-44313.	4.0	40
870	Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1455.	1.6	21
871	A Role of Tumor-Released Exosomes in Paracrine Dissemination and Metastasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3968.	1.8	53
872	Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 642-649.	0.8	21
873	Radiofrequency-Triggered Drug Release from Nanoliposomes with Millimeter-Scale Resolution Using a Superimposed Static Gating Field. <i>Small</i> , 2018, 14, e1802563.	5.2	30
874	A drug screening assay on cancer cells chronically adapted to acidosis. <i>Cancer Cell International</i> , 2018, 18, 147.	1.8	27
875	Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1077, 87-113.	0.8	3
876	Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy. <i>Metabolites</i> , 2018, 8, 2.	1.3	51
877	Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance. <i>Pharmaceutics</i> , 2018, 10, 196.	2.0	15
878	Drug-Homogeneity Index in Mass-Spectrometry Imaging. <i>Analytical Chemistry</i> , 2018, 90, 13257-13264.	3.2	6
879	An ecosystem framework for understanding and treating disease. <i>Evolution, Medicine and Public Health</i> , 2018, 2018, 270-286.	1.1	11
880	Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives. <i>ACS Nano</i> , 2018, 12, 10636-10664.	7.3	320
881	Overcoming multiple drug resistance in cancer using polymeric micelles. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 1127-1142.	2.4	39
882	Precision medicine and bladder cancer heterogeneity. <i>Bulletin Du Cancer</i> , 2018, 105, 925-931.	0.6	19
883	A Continuum Mechanics Model of Enzyme-Based Tissue Degradation in Cancer Therapies. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 3184-3226.	0.9	6
884	Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5113-5126.	3.3	81

#	ARTICLE	IF	CITATIONS
885	Quantitative Proteomic Analysis of 2D and 3D Cultured Colorectal Cancer Cells: Profiling of Tankyrase Inhibitor XAV939-Induced Proteome. <i>Scientific Reports</i> , 2018, 8, 13255.	1.6	22
886	Selecting immuno-oncology-based drug combinations what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
887	LncRNA CamK-A Regulates Ca ²⁺ -Signaling-Mediated Tumor Microenvironment Remodeling. <i>Molecular Cell</i> , 2018, 72, 71-83.e7.	4.5	119
888	A tumor targeted near-infrared light-controlled nanocomposite to combat with multidrug resistance of cancer. <i>Journal of Controlled Release</i> , 2018, 288, 34-44.	4.8	26
889	Nanoformulations of doxorubicin: how far have we come and where do we go from here?. <i>Nanotechnology</i> , 2018, 29, 332002.	1.3	26
890	Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2009-2021.	1.7	27
891	Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 3751-3758.	0.8	13
892	Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells. <i>Advanced Science</i> , 2018, 5, 1700859.	5.6	54
893	Profiling of N-linked glycans from 100 cells by capillary electrophoresis with large-volume dual preconcentration by isotachopheresis and stacking. <i>Journal of Chromatography A</i> , 2018, 1565, 138-144.	1.8	46
894	Vascularized microfluidic platforms to mimic the tumor microenvironment. <i>Biotechnology and Bioengineering</i> , 2018, 115, 2793-2806.	1.7	49
895	Valproic acid inhibits the protective effects of stromal cells against chemotherapy in breast cancer: Insights from proteomics and systems biology. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9270-9283.	1.2	13
896	Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. <i>Stem Cells International</i> , 2018, 2018, 1-16.	1.2	593
897	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with ⁸⁹ Zr-Labeled Trastuzumab-DM1: A Comparison with ⁸⁹ Zr-Labeled Trastuzumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3383-3393.	2.3	16
898	Quantitative imaging of receptor-ligand engagement in intact live animals. <i>Journal of Controlled Release</i> , 2018, 286, 451-459.	4.8	36
899	Oxygen-generating Hybrid Polymeric Nanoparticles with Encapsulated Doxorubicin and Chlorin e6 for Trimodal Imaging-Guided Combined Chemo-Photodynamic Therapy. <i>Theranostics</i> , 2018, 8, 1558-1574.	4.6	175
900	Modeling continuous levels of resistance to multidrug therapy in cancer. <i>Applied Mathematical Modelling</i> , 2018, 64, 733-751.	2.2	11
901	Multiscale models for transport and biodistribution of therapeutics in cancer. <i>Computer Aided Chemical Engineering</i> , 2018, , 209-237.	0.3	4
902	Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 733-746.	0.8	8

#	ARTICLE	IF	CITATIONS
903	Efficacy of inverso isomer of CendR peptide on tumor tissue penetration. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 825-832.	5.7	16
904	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncolmmunology</i> , 2018, 7, e1488564.	2.1	26
905	The Role of Desmoplasia and Stromal Fibroblasts on Anti-cancer Drug Resistance in a Microengineered Tumor Model. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 419-433.	1.0	28
906	Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 173.	1.3	123
907	Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1027-1039.	5.1	170
908	Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models. <i>International Journal of Molecular Sciences</i> , 2018, 19, 147.	1.8	102
909	The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1907.	1.8	27
910	Antitumor necrosis factor α antibodies as a novel therapy for hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 529-536.	0.8	7
911	MMP-Responsive α -Smart β ™ Drug Delivery and Tumor Targeting. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 766-781.	4.0	185
912	Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. <i>BMC Cancer</i> , 2018, 18, 164.	1.1	25
913	The role of spatial variations of abiotic factors in mediating intratumour phenotypic heterogeneity. <i>Journal of Theoretical Biology</i> , 2018, 451, 101-110.	0.8	27
914	pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 17792-17808.	4.0	50
915	Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. <i>Theranostics</i> , 2018, 8, 533-548.	4.6	188
916	Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1412-1414.	2.8	47
917	Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. <i>Biomaterials</i> , 2018, 182, 145-156.	5.7	93
918	Targeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem Cells. <i>Theranostics</i> , 2018, 8, 1350-1360.	4.6	47
919	An anion receptor that facilitates transmembrane proton α -anion symport by deprotonating its sulfonamide N α -H proton. <i>Chemical Communications</i> , 2018, 54, 10351-10354.	2.2	15
920	Fabrication of magnetic nanochains linked with <sc>CTX</sc> and curcumin for dual modal imaging detection and limitation of early tumour. <i>Cell Proliferation</i> , 2018, 51, e12486.	2.4	15

#	ARTICLE	IF	CITATIONS
921	A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors. <i>Cancer Research</i> , 2018, 78, 5949-5957.	0.4	18
922	Inventions and Innovations in Preclinical Platforms for Cancer Research. <i>Inventions</i> , 2018, 3, 43.	1.3	10
923	CT Imaging of Enzymatic Activity in Cancer Using Covalent Probes Reveal a Size-Dependent Pattern. <i>Journal of the American Chemical Society</i> , 2018, 140, 12010-12020.	6.6	53
924	Analysis of the Myc-induced pancreatic β cell islet tumor microenvironment using imaging ToF-SIMS. <i>Biointerphases</i> , 2018, 13, 06D402.	0.6	11
925	Dual Chemodrug-Loaded Single-Walled Carbon Nanohorns for Multimodal Imaging-Guided Chemo-Photothermal Therapy of Tumors and Lung Metastases. <i>Theranostics</i> , 2018, 8, 1966-1984.	4.6	79
926	Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. <i>PLoS ONE</i> , 2018, 13, e0191109.	1.1	100
927	Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H ⁺ -ATPase expression and activity. <i>Oncology Letters</i> , 2018, 15, 7279-7290.	0.8	7
928	Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance. <i>Oncimmunology</i> , 2018, 7, e1468951.	2.1	7
929	A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1-38.	2.5	293
930	Integrated phosphorescence-based photonic biosensor (iPOB) for monitoring oxygen levels in 3D cell culture systems. <i>Biosensors and Bioelectronics</i> , 2019, 123, 131-140.	5.3	34
931	Delitpyrones: β -Pyrone Derivatives from a Freshwater <i>Delitschia</i> sp.. <i>Planta Medica</i> , 2019, 85, 62-71.	0.7	14
932	Numerical investigation of drug transport from blood vessels to tumour tissue using a Tumour-Vasculature-on-a-Chip. <i>Chemical Engineering Science</i> , 2019, 208, 115155.	1.9	11
933	Two-Dimensional (2D) and Three-Dimensional (3D) Cell Culturing in Drug Discovery. , 0, , .		24
934	Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 31743-31754.	4.0	32
935	Enhancement of cisplatin efficacy by lipid- CaO_2 nanocarrier-mediated comprehensive modulation of the tumor microenvironment. <i>Biomaterials Science</i> , 2019, 7, 4260-4272.	2.6	48
936	Zunyimycin C inhibits the proliferation of lung cancer cells by inducing apoptosis through an AKT-related mechanism. <i>Medicinal Chemistry Research</i> , 2019, 28, 1828-1837.	1.1	0
937	Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 209-219.	1.0	8
938	Photoacoustic imaging as a tool to probe the tumour microenvironment. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	57

#	ARTICLE	IF	CITATIONS
939	Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multidrug-resistant breast cancer. <i>Nanotheranostics</i> , 2019, 3, 266-283.	2.7	41
940	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cell Reports</i> , 2019, 28, 512-525.e6.	2.9	59
941	An Integrated Microfluidics Approach for Personalized Cancer Drug Sensitivity and Resistance Assay. <i>Advanced Biology</i> , 2019, 3, 1900001.	3.0	6
942	pH-sensitive carbon quantum dots doxorubicin nanoparticles for tumor cellular targeted drug delivery. <i>Polymers for Advanced Technologies</i> , 2019, 30, 2664-2673.	1.6	34
943	The trip of a drug inside the body: From a lipid-based nanocarrier to a target cell. <i>Journal of Controlled Release</i> , 2019, 309, 59-71.	4.8	9
944	Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. <i>International Journal of Medical Sciences</i> , 2019, 16, 981-989.	1.1	104
945	Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2074-2084.	1.9	24
946	Preferential Tumor Accumulation of Polyglycerol Functionalized Nanodiamond Conjugated with Cyanine Dye Leading to Near-Infrared Fluorescence In Vivo Tumor Imaging. <i>Small</i> , 2019, 15, e1901930.	5.2	37
947	Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. <i>Nature Nanotechnology</i> , 2019, 14, 799-809.	15.6	555
948	Nano-engineered lymphocytes for alleviating suppressive tumor immune microenvironment. <i>Applied Materials Today</i> , 2019, 16, 273-279.	2.3	5
949	A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction. <i>Nano Letters</i> , 2019, 19, 7918-7926.	4.5	22
950	The effects and mechanisms of epigallocatechin-3-gallate on reversing multidrug resistance in cancer. <i>Trends in Food Science and Technology</i> , 2019, 93, 221-233.	7.8	17
951	Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo. <i>Cancers</i> , 2019, 11, 1512.	1.7	28
952	Mathematical model of hypoxia and tumor signaling interplay reveals the importance of hypoxia and cell-to-cell variability in tumor growth inhibition. <i>BMC Bioinformatics</i> , 2019, 20, 507.	1.2	2
953	Development and Evaluation of Paclitaxel-Loaded Aerosol Nanocomposite Microparticles and Their Efficacy Against Air-Grown Lung Cancer Tumor Spheroids. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 6570-6580.	2.6	16
954	Heat Shock Protein 60 in Human Diseases and Disorders. <i>Heat Shock Proteins</i> , 2019, , .	0.2	6
955	A Cancer Invasion Model Combined with Cancer-Associated Fibroblasts Aggregates Incorporating Gelatin Hydrogel Microspheres Containing a p53 Inhibitor. <i>Tissue Engineering - Part C: Methods</i> , 2019, 25, 711-720.	1.1	45
956	Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. <i>Annals of the New York Academy of Sciences</i> , 2019, 1455, 34-58.	1.8	64

#	ARTICLE	IF	CITATIONS
957	Potentialization of anticancer agents by identification of new chemosensitizers active under hypoxia. <i>Biochemical Pharmacology</i> , 2019, 162, 224-236.	2.0	4
958	Anti-cancer effects of ethanol extract of <i>Reynoutria japonica</i> Houtt. radix in human hepatocellular carcinoma cells via inhibition of MAPK and PI3K/Akt signaling pathways. <i>Journal of Ethnopharmacology</i> , 2019, 245, 112179.	2.0	10
959	Poly(lactide)/poly(ethylene glycol) fibrous mats for local paclitaxel delivery: comparison of drug release into liquid medium and to HEMA-based hydrogel model. <i>Monatshefte für Chemie</i> , 2019, 150, 1691-1696.	0.9	5
960	Anti-MUC1/CD44 Dual-Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells. <i>ACS Applied Bio Materials</i> , 2019, 2, 4622-4633.	2.3	35
961	Quantitative evaluation of liposomal doxorubicin and its metabolites in spheroids. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7087-7094.	1.9	11
962	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
963	The multi-factorial nature of clinical multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100645.	6.5	324
964	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. <i>Cells</i> , 2019, 8, 1083.	1.8	153
965	Systems biology approaches to measure and model phenotypic heterogeneity in cancer. <i>Current Opinion in Systems Biology</i> , 2019, 17, 35-40.	1.3	17
966	Tumor self-responsive upconversion nanomedicines for theranostic applications. <i>Nanoscale</i> , 2019, 11, 17535-17556.	2.8	30
967	BZD9L1 sirtuin inhibitor as a potential adjuvant for sensitization of colorectal cancer cells to 5-fluorouracil. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987897.	1.4	14
968	CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1579-1591.	1.1	24
969	Tumor-Microenvironment-Activatable Nanoreactor Based on a Polyprodrug for Multimodal-Imaging-Medicated Enhanced Cancer Chemo/Phototherapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 40704-40715.	4.0	29
970	Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy. <i>Biomaterials Science</i> , 2019, 7, 262-271.	2.6	22
971	Modulation of Intracellular Oxygen Pressure by Dual-Drug Nanoparticles to Enhance Photodynamic Therapy. <i>Advanced Functional Materials</i> , 2019, 29, 1806708.	7.8	98
972	Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. <i>Small</i> , 2019, 15, e1804591.	5.2	34
973	Enhancing magnetic resonance/photoluminescence imaging-guided photodynamic therapy by multiple pathways. <i>Biomaterials</i> , 2019, 199, 52-62.	5.7	38
974	Hypoxia-Modified Cancer Cell Metabolism. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 4.	1.8	359

#	ARTICLE	IF	CITATIONS
975	Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 93-101.	2.7	99
976	Unprecedented O ₂ compression and H ⁺ fragilization in Lewis solutions. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 2234-2250.	1.3	27
977	Microfluidic modelling of the tumor microenvironment for anti-cancer drug development. <i>Lab on A Chip</i> , 2019, 19, 369-386.	3.1	182
978	Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. <i>Theranostics</i> , 2019, 9, 4508-4524.	4.6	37
979	Inhibition of ERK Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. <i>Cell Reports</i> , 2019, 27, 3587-3601.e4.	2.9	29
980	Light sheet fluorescence microscopy versus confocal microscopy: in quest of a suitable tool to assess drug and nanomedicine penetration into multicellular tumor spheroids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 195-203.	2.0	56
981	Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. <i>Cancers</i> , 2019, 11, 870.	1.7	33
982	Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1571.	3.3	97
983	High Co-loading Capacity and Stimuli-Responsive Release Based on Cascade Reaction of Self-Destructive Polymer for Improved Chemo-Photodynamic Therapy. <i>ACS Nano</i> , 2019, 13, 7010-7023.	7.3	116
984	Shape Effect of Nanoparticles on Tumor Penetration in Monolayers Versus Spheroids. <i>Molecular Pharmaceutics</i> , 2019, 16, 2902-2911.	2.3	30
985	Current progress in long-term and continuous cell metabolite detection using microfluidics. <i>TrAC - Trends in Analytical Chemistry</i> , 2019, 117, 263-279.	5.8	35
986	Electrochemical mapping of oxygenation in the three-dimensional multicellular tumour hemi-spheroid. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2019, 475, 20180647.	1.0	4
987	FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 230.	3.5	33
988	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 619-636.	1.7	71
989	The quantitative relationship between isotopic and net contributions of lactate and glucose to the tricarboxylic acid (TCA) cycle. <i>Journal of Biological Chemistry</i> , 2019, 294, 9615-9630.	1.6	25
990	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. <i>Frontiers in Pharmacology</i> , 2019, 10, 450.	1.6	26
991	pH-Sensitive Ratiometric Fluorescent Probe for Evaluation of Tumor Treatments. <i>Materials</i> , 2019, 12, 1632.	1.3	13
992	A Dual Fluorescent 3-D Multicellular Coculture of Breast Cancer MCF-7 and Fibroblast NIH-3T3 Cells for High Throughput Cancer Drug Screening. <i>Biochemical Engineering Journal</i> , 2019, 148, 152-161.	1.8	11

#	ARTICLE	IF	CITATIONS
993	Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPIn-LoPE and the Chemotherapy Drug, Doxorubicin. <i>Pharmaceutics</i> , 2019, 11, 219.	2.0	21
994	Amphiphilic Block Copolymer Poly (Acrylic Acid)-B-Polycaprolactone as a Novel pH-sensitive Nanocarrier for Anti-Cancer Drugs Delivery: In-vitro and In-vivo Evaluation. <i>Polymers</i> , 2019, 11, 820.	2.0	24
995	Nanomedicine in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 213-247.	0.0	0
996	Natural products as multidrug resistance modulators in cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 176, 268-291.	2.6	225
997	Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ER1 ² /Bcl-2 signalling. <i>Cell Death and Disease</i> , 2019, 10, 375.	2.7	88
998	Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2256.	1.8	97
999	Collagen Type Iâ€“Gelatin Methacryloyl Composites: Mimicking the Tumor Microenvironment. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 2887-2898.	2.6	18
1000	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
1001	<p>Nanomedicine-based formulations containing ω-3 polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases<p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 2809-2828.	3.3	31
1002	Reactive oxygen species and near-infrared light dual-responsive indocyanine green-loaded nano hybrids for overcoming tumour multidrug resistance. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 185-193.	1.9	22
1003	Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment. <i>Chemical Communications</i> , 2019, 55, 4254-4257.	2.2	21
1004	Glucose starvation induces resistance to metformin through the elevation of mitochondrial multidrug resistance protein 1. <i>Cancer Science</i> , 2019, 110, 1256-1267.	1.7	16
1005	Integration of single-cell RNA-seq data into population models to characterize cancer metabolism. <i>PLoS Computational Biology</i> , 2019, 15, e1006733.	1.5	70
1006	Differential long noncoding RNAs expression in cancer-associated fibroblasts of non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2019, 20, 143-153.	0.6	9
1007	<p>Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy<p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1011-1026.	3.3	13
1008	Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF^{V600E} A375 Melanoma Cells. <i>Chemical Research in Toxicology</i> , 2019, 32, 645-658.	1.7	5
1009	Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization. <i>Molecular Carcinogenesis</i> , 2019, 58, 1118-1133.	1.3	19
1010	NFεB targeting for overcoming tumor resistance and normal tissues toxicity. <i>Journal of Cellular Physiology</i> , 2019, 234, 17187-17204.	2.0	84

#	ARTICLE	IF	CITATIONS
1011	Reactive oxygen species and cancer: A complex interaction. <i>Cancer Letters</i> , 2019, 452, 132-143.	3.2	154
1012	Limiting tumor seeding as a therapeutic approach for metastatic disease. , 2019, 199, 117-128.		7
1013	Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type. <i>Pharmaceutical Research</i> , 2019, 36, 66.	1.7	18
1014	Graphene Oxide-Based Targeting of Extracellular Cathepsin D and Cathepsin L As A Novel Anti-Metastatic Enzyme Cancer Therapy. <i>Cancers</i> , 2019, 11, 319.	1.7	36
1015	GE11-PDA-Pt@USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy. <i>Biomaterials Science</i> , 2019, 7, 2076-2090.	2.6	34
1016	Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. <i>Drug Metabolism and Disposition</i> , 2019, 47, 665-672.	1.7	31
1017	Measuring and regulating oxygen levels in microphysiological systems: design, material, and sensor considerations. <i>Analyst, The</i> , 2019, 144, 3190-3215.	1.7	33
1018	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 71.	1.8	92
1019	Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-20.	1.0	52
1020	Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems. <i>Polymers</i> , 2019, 11, 630.	2.0	26
1021	Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide. <i>Molecular Pharmacology</i> , 2019, 95, 638-651.	1.0	11
1022	Drug Delivery to Hypoxic Tumors Targeting Carbonic Anhydrase IX. <i>ACS Symposium Series</i> , 2019, , 223-252.	0.5	1
1023	Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity. <i>European Journal of Pharmacology</i> , 2019, 853, 184-192.	1.7	19
1024	Reactivity and Transformation of Antimetastatic and Cytotoxic Rhodium(III)â€“Dimethyl Sulfoxide Complexes in Biological Fluids: An XAS Speciation Study. <i>Inorganic Chemistry</i> , 2019, 58, 4880-4893.	1.9	9
1025	Anticancer Drug Affects Metabolomic Profiles in Multicellular Spheroids: Studies Using Mass Spectrometry Imaging Combined with Machine Learning. <i>Analytical Chemistry</i> , 2019, 91, 5802-5809.	3.2	31
1026	The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells. <i>Reports on Progress in Physics</i> , 2019, 82, 064602.	8.1	157
1027	Larger tumors are associated with inferior progressionâ€“free survival of firstâ€“line EGFRâ€“tyrosine kinase inhibitors and a lower abundance of <i>EGFR</i> mutation in patients with advanced nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 686-694.	0.8	6
1028	Microphysiological Systems as Enabling Tools for Modeling Complexity in the Tumor Microenvironment and Accelerating Cancer Drug Development. <i>Advanced Functional Materials</i> , 2019, 29, 1807553.	7.8	32

#	ARTICLE	IF	CITATIONS
1029	Transferrin-Appended Nanocaplet for Transcellular siRNA Delivery into Deep Tissues. <i>Journal of the American Chemical Society</i> , 2019, 141, 2862-2866.	6.6	45
1030	GSK-3 β regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 46.	3.5	32
1031	Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy. , 2019, , 191-218.		3
1032	Ultrasound Hyperthermia Technology for Radiosensitization. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1025-1043.	0.7	78
1033	Multiple comparisons of three different sources of biomaterials in the application of tumor tissue engineering in vitro and in vivo. <i>International Journal of Biological Macromolecules</i> , 2019, 130, 166-176.	3.6	24
1034	Gold Nanoparticle-Decorated g-C ₃ N ₄ Nanosheets for Controlled Generation of Reactive Oxygen Species upon 670 nm Laser Illumination. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 10589-10596.	4.0	75
1035	Approaches to Targeting Cancer Stem Cells in Solid Tumors. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 421-427.	0.6	3
1036	Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad. <i>Laboratory Animal Research</i> , 2019, 35, 30.	1.1	21
1037	Therapeutic Inducers of Apoptosis in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1786.	1.7	44
1038	Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 46536-46547.	4.0	25
1039	Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. <i>Nature Nanotechnology</i> , 2019, 14, 1160-1169.	15.6	267
1040	Boyden chamber-based compartmentalized tumor spheroid culture system to implement localized anticancer drug treatment. <i>Biomicrofluidics</i> , 2019, 13, 054111.	1.2	4
1041	High-throughput three-dimensional spheroid tumor model using a novel stamp-like tool. <i>Journal of Tissue Engineering</i> , 2019, 10, 204173141988918.	2.3	37
1042	A mathematical model to study the effect of drug kinetics on the drug-induced resistance in tumor growth dynamics. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 332, 032015.	0.2	0
1043	Measuring gradients in body fluids " A tool for elucidating physiological processes, diagnosis and treatment of disease. <i>Clinica Chimica Acta</i> , 2019, 489, 233-241.	0.5	2
1044	Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades. <i>Drug Delivery and Translational Research</i> , 2019, 9, 379-393.	3.0	36
1045	M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition. <i>Toxicology and Applied Pharmacology</i> , 2019, 364, 77-82.	1.3	35
1046	3D cell coculture tumor model: A promising approach for future cancer drug discovery. <i>Process Biochemistry</i> , 2019, 78, 148-160.	1.8	37

#	ARTICLE	IF	CITATIONS
1047	High Content Screening Characterization of Head and Neck Squamous Cell Carcinoma Multicellular Tumor Spheroid Cultures Generated in 384-Well Ultra-Low Attachment Plates to Screen for Better Cancer Drug Leads. <i>Assay and Drug Development Technologies</i> , 2019, 17, 17-36.	0.6	35
1048	Hypoxia-tropic Protein Nanocages for Modulation of Tumor- and Chemotherapy-Associated Hypoxia. <i>ACS Nano</i> , 2019, 13, 236-247.	7.3	64
1049	Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 39-46.	2.5	47
1050	An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms. <i>British Journal of Radiology</i> , 2019, 92, 20180476.	1.0	17
1051	Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer-specific molecule. <i>Cancer Science</i> , 2019, 110, 761-770.	1.7	20
1052	A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats. <i>Pharmaceutical Research</i> , 2019, 36, 38.	1.7	10
1053	Utility of sheathless capillary electrophoresis-mass spectrometry for metabolic profiling of limited sample amounts. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1105, 10-14.	1.2	26
1054	Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 272-278.	2.5	59
1055	Perfluorocarbon-Loaded and Redox-Activatable Photosensitizing Agent with Oxygen Supply for Enhancement of Fluorescence/Photoacoustic Imaging Guided Tumor Photodynamic Therapy. <i>Advanced Functional Materials</i> , 2019, 29, 1806199.	7.8	127
1056	Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook. <i>Materials Today</i> , 2019, 26, 40-66.	8.3	89
1057	3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. <i>Biotechnology and Bioengineering</i> , 2019, 116, 206-226.	1.7	464
1058	Mechanosensitive TRPV4 channels stabilize VE-cadherin junctions to regulate tumor vascular integrity and metastasis. <i>Cancer Letters</i> , 2019, 442, 15-20.	3.2	39
1059	Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer. <i>Proteomics</i> , 2019, 19, e1800165.	1.3	37
1060	Composite Hydrogel Embedded with Porous Microspheres for Long-Term pH-Sensitive Drug Delivery. <i>Tissue Engineering - Part A</i> , 2019, 25, 172-182.	1.6	8
1061	Microporous cellulosic scaffold as a spheroid culture system modulates chemotherapeutic responses and stemness in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5244-5255.	1.2	6
1062	Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165339.	1.8	79
1063	Delivery of erlotinib for enhanced cancer treatment: An update review on particulate systems. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 55, 101348.	1.4	19
1064	Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia. <i>Molecular Imaging and Biology</i> , 2020, 22, 653-664.	1.3	1

#	ARTICLE	IF	CITATIONS
1065	Metabolic targeting of HIF-1 α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer. <i>Oncogene</i> , 2020, 39, 414-427.	2.6	47
1066	The Acidic Tumor Microenvironment as a Driver of Cancer. <i>Annual Review of Physiology</i> , 2020, 82, 103-126.	5.6	551
1067	A Tumor Microenvironment Destroyer for Efficient Cancer Suppression. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 450-462.	2.6	19
1068	Investigating Tumor Heterogeneity in Mouse Models. <i>Annual Review of Cancer Biology</i> , 2020, 4, 99-119.	2.3	42
1069	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. <i>Molecular Cancer Research</i> , 2020, 18, 644-656.	1.5	17
1070	A mitochondria-targeting nitroreductase fluorescent probe with large Stokes shift and long-wavelength emission for imaging hypoxic status in tumor cells. <i>Analytica Chimica Acta</i> , 2020, 1103, 202-211.	2.6	46
1071	Intratumoral distribution of YSNSG cyclopeptide in a mouse melanoma model using microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105201.	1.9	3
1072	Use of Oppositely Polarized External Magnets To Improve the Accumulation and Penetration of Magnetic Nanocarriers into Solid Tumors. <i>ACS Nano</i> , 2020, 14, 142-152.	7.3	59
1073	Strategies To Design and Synthesize Polymer-Based Stimuli-Responsive Drug-Delivery Nanosystems. <i>ChemBioChem</i> , 2020, 21, 1236-1253.	1.3	40
1074	Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165625.	1.8	54
1075	Glutamine deprivation counteracts hypoxia-induced chemoresistance. <i>Neoplasia</i> , 2020, 22, 22-32.	2.3	19
1076	The Comparative Cytotoxic Effects of <i>Apis mellifera</i> Crude Venom on MCF-7 Breast Cancer Cell Line in 2D and 3D Cell Cultures. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 1819-1828.	0.9	6
1077	Matrix Metalloproteinase-sensitive Multistage Nanogels Promote Drug Transport in 3D Tumor Model. <i>Theranostics</i> , 2020, 10, 91-108.	4.6	29
1078	Biomimetic Magnetite Nanoparticles as Targeted Drug Nanocarriers and Mediators of Hyperthermia in an Experimental Cancer Model. <i>Cancers</i> , 2020, 12, 2564.	1.7	33
1079	Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. <i>Current Opinion in Pharmacology</i> , 2020, 54, 36-43.	1.7	13
1080	Genetic alterations and clinical dimensions of oral cancer: a review. <i>Molecular Biology Reports</i> , 2020, 47, 9135-9148.	1.0	9
1081	Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer. <i>Biochemical Pharmacology</i> , 2020, 182, 114289.	2.0	18
1082	â€œNano-lymphaticâ€-photocatalytic water-splitting for relieving tumor interstitial fluid pressure and achieving hydrodynamic therapy. <i>Materials Horizons</i> , 2020, 7, 3266-3274.	6.4	26

#	ARTICLE	IF	CITATIONS
1083	Chemotaxis-based self-accumulation of surface-engineered mitochondria for cancer therapeutic improvement. <i>Nano Today</i> , 2020, 35, 100966.	6.2	10
1084	Evaluation of low-intensity pulsed ultrasound on doxorubicin delivery in 2D and 3D cancer cell cultures. <i>Scientific Reports</i> , 2020, 10, 16161.	1.6	8
1086	Mass Spectrometry Imaging Combined with Metabolomics Revealing the Proliferative Effect of Environmental Pollutants on Multicellular Tumor Spheroids. <i>Analytical Chemistry</i> , 2020, 92, 11341-11348.	3.2	33
1087	Modeling neoplastic disease with spheroids and organoids. <i>Journal of Hematology and Oncology</i> , 2020, 13, 97.	6.9	122
1088	A review on 1,1-bis(diphenylphosphino)methane bridged homo- and heterobimetallic complexes for anticancer applications: Synthesis, structure, and cytotoxicity. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112613.	2.6	18
1089	Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. <i>Molecular Cancer Research</i> , 2020, 18, 1500-1511.	1.5	13
1090	Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy. <i>Advanced Drug Delivery Reviews</i> , 2020, 163-164, 98-124.	6.6	77
1091	Manipulation of immune-vascular crosstalk: new strategies towards cancer treatment. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2018-2036.	5.7	42
1092	The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. <i>Cancers</i> , 2020, 12, 3226.	1.7	17
1093	pH-Sensitive Biomaterials for Drug Delivery. <i>Molecules</i> , 2020, 25, 5649.	1.7	104
1094	<p>Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5375-5392.	2.0	176
1095	The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology. <i>Frontiers in Veterinary Science</i> , 2020, 7, 598338.	0.9	9
1096	3D culture systems as models for solid tumors and cancer metabolism. , 2020, , 131-155.		0
1097	Development of pH/Glutathione-Responsive Theranostic Agents Activated by Glutathione S-Transferase I€ for Human Colon Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9271-9283.	2.9	18
1098	Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?. <i>Drug Discovery Today</i> , 2020, 25, 1651-1667.	3.2	20
1099	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
1100	Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem. <i>Molecular Pharmaceutics</i> , 2020, 17, 3151-3164.	2.3	19
1101	Impact of Galectins in Resistance to Anticancer Therapies. <i>Clinical Cancer Research</i> , 2020, 26, 6086-6101.	3.2	40

#	ARTICLE	IF	CITATIONS
1102	Stem cell programs in cancer initiation, progression, and therapy resistance. <i>Theranostics</i> , 2020, 10, 8721-8743.	4.6	208
1103	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. <i>Drug Resistance Updates</i> , 2020, 50, 100682.	6.5	160
1104	Fibrinolytic tissue plasminogen activator installed redox-active nanoparticles (t-PA@iRNP) for cancer therapy. <i>Biomaterials</i> , 2020, 259, 120290.	5.7	20
1105	EP4 receptor as a novel promising therapeutic target in colon cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153247.	1.0	17
1106	Exploring Diffusion and Cellular Uptake: Charged Gold Nanoparticles in an in Vitro Breast Cancer Model. <i>ACS Applied Bio Materials</i> , 2020, 3, 6992-7002.	2.3	21
1107	The construction of the novel magnetic prodrug Fe ₃ O ₄ @DOX and its antagonistic effects on hepatocarcinoma with low toxicity. <i>RSC Advances</i> , 2020, 10, 28965-28974.	1.7	6
1108	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. <i>Biology</i> , 2020, 9, 264.	1.3	7
1109	Chaperonin Hsp60 and Cancer Therapies. <i>Heat Shock Proteins</i> , 2020, , 31-52.	0.2	3
1110	<p>Modulation of Tumor Hypoxia by pH-Responsive Liposomes to Inhibit Mitochondrial Respiration for Enhancing Sonodynamic Therapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5687-5700.	3.3	17
1111	Bad neighbours: hypoxia and genomic instability in prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20200087.	1.0	23
1112	Nanoparticles Loaded with Wnt and YAP/Mevalonate Inhibitors in Combination with Paclitaxel Stop the Growth of TNBC Patientâ€Derived Xenografts and Diminish Tumorigenesis. <i>Advanced Therapeutics</i> , 2020, 3, 2000123.	1.6	1
1113	Co-inhibition of the TGF-Î² pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 5121-5132.	2.6	50
1114	Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 56712-56722.	4.0	17
1115	Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment. <i>Cancers</i> , 2020, 12, 3244.	1.7	111
1116	The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts. <i>Molecules</i> , 2020, 25, 5115.	1.7	3
1117	A new drug testing platform based on 3D tri-culture in lab-on-a-chip devices. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105542.	1.9	9
1118	Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	1.9	6
1119	Functionalization of Ti substrate with <sc>pH</sc>-responsive <sc>naringinâ€ZnO</sc> nanoparticles for the reconstruction of large bony after osteosarcoma resection. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 2190-2205.	2.1	24

#	ARTICLE	IF	CITATIONS
1120	Recent Advances in Activatable Organic Photosensitizers for Specific Photodynamic Therapy. <i>ChemPlusChem</i> , 2020, 85, 948-957.	1.3	53
1121	Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment. <i>Molecules</i> , 2020, 25, 2102.	1.7	13
1122	Three Birds with One Stone: Injectable CaC ₂ Nanobombs with Triple Effects for Minimally Invasive Tumor Chemical Ablation. <i>ACS Applied Bio Materials</i> , 2020, 3, 3809-3816.	2.3	2
1123	Preparation of Frozen Sections of Multicellular Tumor Spheroids Coated with Ice for Mass Spectrometry Imaging. <i>Analytical Chemistry</i> , 2020, 92, 7413-7418.	3.2	16
1124	Pathophysiological implications of hypoxia in human diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 63.	2.6	139
1125	Î²-Escin alleviates cobalt chloride-induced hypoxia-mediated apoptotic resistance and invasion via ROS-dependent HIF-1 α /TGF-Î²/MMPs in A549 cells. <i>Toxicology Research</i> , 2020, 9, 191-201.	0.9	10
1126	JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy. <i>Theranostics</i> , 2020, 10, 5763-5777.	4.6	14
1127	Targeting Glycosylation: A New Road for Cancer Drug Discovery. <i>Trends in Cancer</i> , 2020, 6, 757-766.	3.8	155
1128	Electrostatic driven transport enhances penetration of positively charged peptide surfaces through tumor extracellular matrix. <i>Acta Biomaterialia</i> , 2020, 113, 240-251.	4.1	15
1129	A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs. <i>Bioorganic Chemistry</i> , 2020, 101, 103975.	2.0	5
1130	<p>Emerging Antineoplastic Biogenic Gold Nanomaterials for Breast Cancer Therapeutics: A Systematic Review</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 3577-3595.	3.3	52
1131	Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting. <i>Theranostics</i> , 2020, 10, 6384-6398.	4.6	27
1132	Patient-derived xenografts as compatible models for precision oncology. <i>Laboratory Animal Research</i> , 2020, 36, 14.	1.1	34
1133	Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells. <i>Cancers</i> , 2020, 12, 1360.	1.7	17
1134	Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 1438-1452.	1.0	27
1135	Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models. <i>Materials Science and Engineering C</i> , 2020, 116, 111229.	3.8	30
1136	The role of single- and multi-walled carbon nanotube in breast cancer treatment. <i>Therapeutic Delivery</i> , 2020, 11, 653-672.	1.2	18
1137	Emerging Technologies for Local Cancer Treatment. <i>Advanced Therapeutics</i> , 2020, 3, 2000027.	1.6	37

#	ARTICLE	IF	CITATIONS
1138	The importance of spheroids in analyzing nanomedicine efficacy. <i>Nanomedicine</i> , 2020, 15, 1513-1525.	1.7	21
1139	Translational considerations in nanomedicine: The oncology perspective. <i>Advanced Drug Delivery Reviews</i> , 2020, 158, 140-157.	6.6	31
1140	Increased Acid-Producing Diet and Past Smoking Intensity Are Associated with Worse Prognoses among Breast Cancer Survivors: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1817.	1.0	16
1141	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. <i>Clinical Colorectal Cancer</i> , 2020, 19, 291-300.e5.	1.0	8
1142	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
1143	Discrete and continuum phenotype-structured models for the evolution of cancer cell populations under chemotherapy. <i>Mathematical Modelling of Natural Phenomena</i> , 2020, 15, 14.	0.9	20
1144	Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. <i>Molecular Neurobiology</i> , 2020, 57, 2461-2478.	1.9	219
1145	<i>p</i> -Pyridinyl oxime carbamates: synthesis, DNA binding, DNA photocleaving activity and theoretical photodegradation studies. <i>Beilstein Journal of Organic Chemistry</i> , 2020, 16, 337-350.	1.3	9
1146	Laser-assisted 3D bioprinting of exocrine pancreas spheroid models for cancer initiation study. <i>Biofabrication</i> , 2020, 12, 035001.	3.7	59
1147	Effects of molecular weight and structural conformation of multivalent-based elastin-like polypeptides on tumor accumulation and tissue biodistribution. <i>Nanotheranostics</i> , 2020, 4, 57-70.	2.7	9
1148	A cancer invasion model of cancer-associated fibroblasts aggregates combined with TGF- β 1 release system. <i>Regenerative Therapy</i> , 2020, 14, 196-204.	1.4	16
1149	Recellularized Colorectal Cancer Patient-Derived Scaffolds as In Vitro Pre-Clinical 3D Model for Drug Screening. <i>Cancers</i> , 2020, 12, 681.	1.7	32
1150	Vacuolar-ATPase proton pump inhibition in cancer therapy: Veterinary and human experience. , 2020, , 509-522.		0
1151	Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy. <i>Cancer Biology and Therapy</i> , 2020, 21, 560-569.	1.5	17
1152	Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line. <i>Cancer Biology and Therapy</i> , 2020, 21, 495-502.	1.5	5
1153	Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium <i>Lactococcus Lactis</i> . <i>Cancers</i> , 2020, 12, 438.	1.7	13
1154	3-Aryl-4-nitrobenzothiochromans S,S-dioxide: From Calcium-Channel Modulators Properties to Multidrug-Resistance Reverting Activity. <i>Molecules</i> , 2020, 25, 1056.	1.7	7
1155	Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer. , 2020, , 173-198.		1

#	ARTICLE	IF	CITATIONS
1156	Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging. <i>Cells</i> , 2020, 9, 1470.	1.8	0
1157	Image Analysis of 3D Conjunctival Melanoma Cell Cultures Following Electrochemotherapy. <i>Biomedicines</i> , 2020, 8, 158.	1.4	4
1158	In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer. <i>Biotechnology and Bioengineering</i> , 2020, 117, 3572-3590.	1.7	16
1159	[18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy. <i>Molecular Imaging and Biology</i> , 2020, 22, 1609-1620.	1.3	3
1160	Studies of nanoparticle delivery with in vitro bio-engineered microtissues. <i>Bioactive Materials</i> , 2020, 5, 924-937.	8.6	41
1161	TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 339.	1.7	39
1162	An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibody-Based Therapeutics in Overcoming Chemoresistance. <i>Biotechnology Journal</i> , 2020, 15, e1900439.	1.8	16
1163	Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 189, 110741.	2.5	13
1164	Active matter therapeutics. <i>Nano Today</i> , 2020, 31, 100836.	6.2	54
1165	Self-Delivery Nanomedicine for O ₂ -Economized Photodynamic Tumor Therapy. <i>Nano Letters</i> , 2020, 20, 2062-2071.	4.5	167
1166	Dual-response oxygen-generating MnO ₂ nanoparticles with polydopamine modification for combined photothermal-photodynamic therapy. <i>Chemical Engineering Journal</i> , 2020, 389, 124494.	6.6	166
1167	Tumour heterogeneity and the evolutionary trade-offs of cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 247-257.	12.8	111
1168	<p>Celastrol Self-Stabilized Nanoparticles for Effective Treatment of Melanoma</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 1205-1214.	3.3	14
1169	Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment. <i>Theranostics</i> , 2020, 10, 1884-1909.	4.6	30
1170	Towards extracellular matrix normalization for improved treatment of solid tumors. <i>Theranostics</i> , 2020, 10, 1960-1980.	4.6	68
1171	HemoSYS: A Toolkit for Image-based Systems Biology of Tumor Hemodynamics. <i>Scientific Reports</i> , 2020, 10, 2372.	1.6	5
1172	Applications and Perspectives of Cascade Reactions in Bacterial Infection Control. <i>Frontiers in Chemistry</i> , 2019, 7, 861.	1.8	16
1173	Size-adaptable and ligand (biotin)-shedddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity. <i>Journal of Controlled Release</i> , 2020, 320, 142-158.	4.8	36

#	ARTICLE	IF	CITATIONS
1174	Cryogenic 3D printing of porous scaffolds for <i>in situ</i> delivery of 2D black phosphorus nanosheets, doxorubicin hydrochloride and osteogenic peptide for treating tumor resection-induced bone defects. <i>Biofabrication</i> , 2020, 12, 035004.	3.7	68
1175	Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 2582-2594.	3.2	33
1176	Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines. <i>SLAS Discovery</i> , 2020, 25, 329-349.	1.4	13
1177	Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. <i>Cancer Cell International</i> , 2020, 20, 18.	1.8	77
1178	Emerging links between endosomal pH and cancer. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 519-534.	2.7	49
1179	pH-sensitive biomaterials for cancer therapy and diagnosis. , 2020, , 141-164.		1
1180	Reprogramming Tumor Microenvironment with Photothermal Therapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 1268-1278.	1.8	66
1181	In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses. <i>Cancer Gene Therapy</i> , 2020, 27, 910-922.	2.2	9
1182	Combination therapy based on nano codelivery for overcoming cancer drug resistance. <i>Medicine in Drug Discovery</i> , 2020, 6, 100024.	2.3	66
1183	Protein-drug conjugate programmed by pH-reversible linker for tumor hypoxia relief and enhanced cancer combination therapy. <i>International Journal of Pharmaceutics</i> , 2020, 582, 119321.	2.6	26
1184	Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. , 2020, , 371-404.		6
1185	Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 308.	1.3	27
1186	Anti-Estrogenic Activity of Guajadial Fraction, from Guava Leaves (<i>Psidium guajava</i> L.). <i>Molecules</i> , 2020, 25, 1525.	1.7	13
1187	Alginate Microencapsulation for Three-Dimensional In Vitro Cell Culture. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2864-2879.	2.6	41
1188	Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. <i>Seminars in Cancer Biology</i> , 2021, 69, 52-68.	4.3	125
1189	An azo dye for photodynamic therapy that is activated selectively by two-photon excitation. <i>Chemical Science</i> , 2021, 12, 427-434.	3.7	33
1190	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1129-1147.	5.7	47
1191	Recent advances in graphene-family nanomaterials for effective drug delivery and phototherapy. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 119-138.	2.4	15

#	ARTICLE	IF	CITATIONS
1192	Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: reversed by artesunate. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 624-632.	2.8	9
1193	Functional CT Contrast Nanoagents for the Tumor Microenvironment. <i>Advanced Healthcare Materials</i> , 2021, 10, e2000912.	3.9	17
1194	Designing Hypoxia-Responsive Nanotheranostic Agents for Tumor Imaging and Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001277.	3.9	39
1195	Associations of self-reported obstructive sleep apnea with total and site-specific cancer risk in older women: a prospective study. <i>Sleep</i> , 2021, 44, .	0.6	17
1196	Three-dimensional multicellular cell culture for anti-melanoma drug screening: focus on tumor microenvironment. <i>Cytotechnology</i> , 2021, 73, 35-48.	0.7	8
1197	Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays. <i>Drug Discovery Today</i> , 2021, 26, 455-473.	3.2	2
1198	Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. <i>International Journal of Biological Macromolecules</i> , 2021, 168, 22-37.	3.6	23
1199	A sulfur dioxide polymer prodrug showing combined effect with doxorubicin in combating subcutaneous and metastatic melanoma. <i>Bioactive Materials</i> , 2021, 6, 1365-1374.	8.6	29
1200	Role of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu. <i>International Journal of Sports Medicine</i> , 2021, 42, 389-406.	0.8	9
1201	<i>In situ</i> oxygenating and 808 nm light-sensitized nanocomposite for multimodal imaging and mitochondria-assisted cancer therapy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 131-146.	2.9	14
1202	Anticancer drug-loaded mesenchymal stem cells for targeted cancer therapy. <i>Journal of Controlled Release</i> , 2021, 329, 1090-1101.	4.8	41
1203	Docetaxel-dasatinib combination: A strategy to overcome unfavorable treatment outcomes due to dose reduction. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 61, 102085.	1.4	1
1204	Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. <i>European Radiology</i> , 2021, 31, 2242-2251.	2.3	11
1205	Emerging theranostic silver and gold nanobiomaterials for breast cancer: Present status and future prospects. , 2021, , 439-456.		35
1206	Fabrication of Tunable 3D Cellular Structures in High Volume Using Magnetic Levitation Guided Assembly. <i>ACS Applied Bio Materials</i> , 2021, 4, 1794-1802.	2.3	8
1207	An overview of polymeric nanomicelles in clinical trials and on the market. <i>Chinese Chemical Letters</i> , 2021, 32, 243-257.	4.8	69
1208	Patent survey on chemosensitizers (2015-2019). , 2021, , 129-146.		0
1209	3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 243-270.	0.8	14

#	ARTICLE	IF	CITATIONS
1210	Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. <i>Molecules</i> , 2021, 26, 717.	1.7	11
1211	An Interactive Pipeline for Quantitative Histopathological Analysis of Spatially Defined Drug Effects in Tumors. <i>Journal of Pathology Informatics</i> , 2021, 12, 34.	0.8	6
1212	A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. <i>Cancers</i> , 2021, 13, 227.	1.7	48
1213	Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells. <i>Lab on A Chip</i> , 2021, 21, 746-754.	3.1	17
1214	Proton pump inhibitors and other pH-buffering agents. , 2021, , 47-62.		0
1215	Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. <i>Epigenomics</i> , 2021, 13, 129-144.	1.0	7
1216	The acoustic droplet printing of functional tumor microenvironments. <i>Lab on A Chip</i> , 2021, 21, 1604-1612.	3.1	46
1217	A New Mathematical Model for Controlling Tumor Growth Based on Microenvironment Acidity and Oxygen Concentration. <i>BioMed Research International</i> , 2021, 2021, 1-18.	0.9	10
1218	Epithelial and Immune Cell Responses to <i>Helicobacter pylori</i> That Shape the Gastric Tumor Microenvironment. <i>Physiology in Health and Disease</i> , 2021, , 155-197.	0.2	0
1219	Exosomes derived from hypoxic glioma deliver miR-1246 and miR-10b-5p to normoxic glioma cells to promote migration and invasion. <i>Laboratory Investigation</i> , 2021, 101, 612-624.	1.7	28
1220	The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. <i>Cancer Cell International</i> , 2021, 21, 62.	1.8	296
1221	Therapeutic response differences between 2D and 3D tumor models of magnetic hyperthermia. <i>Nanoscale Advances</i> , 2021, 3, 3663-3680.	2.2	11
1222	In Vitro Assays for Nanoparticle–Cancer Cell Interaction Studies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 223-242.	0.8	1
1223	Microfluidic Reconstitution of Tumor Microenvironment for Nanomedical Applications. <i>Advanced Healthcare Materials</i> , 2021, 10, 2002122.	3.9	4
1224	Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2103-2121.	2.0	23
1225	CEST MRI trackable nanoparticle drug delivery systems. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 024103.	1.7	10
1228	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. <i>Cell Reports</i> , 2021, 34, 108726.	2.9	27
1229	Solvability of Solid Tumor Invasion Model. <i>Results in Mathematics</i> , 2021, 76, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
1230	Initial Identification of UDP-Glucose Dehydrogenase as a Prognostic Marker in Breast Cancer Patients, Which Facilitates Epirubicin Resistance and Regulates Hyaluronan Synthesis in MDA-MB-231 Cells. <i>Biomolecules</i> , 2021, 11, 246.	1.8	21
1231	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614332.	1.3	33
1232	3D Cell Culture: Recent Development in Materials with Tunable Stiffness. <i>ACS Applied Bio Materials</i> , 2021, 4, 2233-2250.	2.3	45
1233	Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. <i>Frontiers in Oncology</i> , 2020, 10, 610513.	1.3	17
1234	A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 7.	2.3	29
1235	Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. <i>Journal of Personalized Medicine</i> , 2021, 11, 124.	1.1	68
1236	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664816.	1.8	17
1237	Drug penetration in pediatric brain tumors: Challenges and opportunities. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28983.	0.8	10
1238	Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1477.	1.7	19
1239	Recent Advancements in Nanomedicine for α -Cold β ™ Tumor Immunotherapy. <i>Nano-Micro Letters</i> , 2021, 13, 92.	14.4	41
1240	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641469.	1.8	76
1241	Metabolic engineering of probiotic <i>Escherichia coli</i> for cytolytic therapy of tumors. <i>Scientific Reports</i> , 2021, 11, 5853.	1.6	25
1242	An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs. <i>ACS Sensors</i> , 2021, 6, 823-832.	4.0	28
1243	Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1008-1018.	1.9	1
1244	Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. <i>Anticancer Research</i> , 2021, 41, 1683-1691.	0.5	7
1245	Clinical implication of aquaporin 9 in non-small cell lung cancer patients: its expression and relationship with clinical features and prognosis. <i>Irish Journal of Medical Science</i> , 2021, , 1.	0.8	3
1246	Leveraging microenvironmental synthetic lethality to treat cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
1247	Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2021, 48, 3695-3717.	1.0	12

#	ARTICLE	IF	CITATIONS
1248	Nanomedicines for combating multidrug resistance of cancer. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1715.	3.3	14
1249	Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. Nano Convergence, 2021, 8, 12.	6.3	43
1250	Mild Magnetic Hyperthermia-Activated Innate Immunity for Liver Cancer Therapy. Journal of the American Chemical Society, 2021, 143, 8116-8128.	6.6	87
1251	Enhanced tumour penetration and prolonged circulation in blood of polyzwitterionâ€“drug conjugates with cell-membrane affinity. Nature Biomedical Engineering, 2021, 5, 1019-1037.	11.6	148
1252	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3765.	1.8	136
1254	Measuring and Modelling the Epithelial- Mesenchymal Hybrid State in Cancer: Clinical Implications. Cells Tissues Organs, 2022, 211, 110-133.	1.3	28
1255	Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology (Dordrecht), 2021, 44, 715-737.	2.1	109
1256	Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery. Current Medicinal Chemistry, 2021, 28, 1508-1534.	1.2	20
1257	Karyotype Aberrations in Action: The Evolution of Cancer Genomes and the Tumor Microenvironment. Genes, 2021, 12, 558.	1.0	13
1258	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials, 2021, 14, 2440.	1.3	14
1259	Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers, 2021, 13, 2279.	1.7	10
1260	Glioma-Derived Extracellular Vesicles â€“ Far More Than Local Mediators. Frontiers in Immunology, 2021, 12, 679954.	2.2	11
1261	Advances in development and application of human organoids. 3 Biotech, 2021, 11, 257.	1.1	31
1262	Nanomaterials for cancer therapy: current progress and perspectives. Journal of Hematology and Oncology, 2021, 14, 85.	6.9	456
1263	Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4. Cell Death Discovery, 2021, 7, 94.	2.0	16
1264	Sensitive High-Throughput Assays for Tumour Burden Reveal the Response of a Drosophila melanogaster Model of Colorectal Cancer to Standard Chemotherapies. International Journal of Molecular Sciences, 2021, 22, 5101.	1.8	5
1265	Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers, 2021, 13, 2632.	1.7	14
1267	Characterization and quantification of necrotic tissues and morphology in multicellular ovarian cancer tumor spheroids using optical coherence tomography. Biomedical Optics Express, 2021, 12, 3352.	1.5	14

#	ARTICLE	IF	CITATIONS
1268	Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2295.	1.0	28
1269	Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function. <i>Frontiers in Immunology</i> , 2021, 12, 646384.	2.2	10
1270	The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 656229.	1.3	18
1271	Recent advances in liposome formulations for breast cancer therapeutics. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5225-5243.	2.4	41
1272	A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy. <i>Cancers</i> , 2021, 13, 2818.	1.7	75
1273	Targeting tumor vascularization: promising strategies for vascular normalization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2489-2505.	1.2	32
1274	An Overview of Advanced In Vitro Corneal Models: Implications for Pharmacological Testing. <i>Tissue Engineering - Part B: Reviews</i> , 2021, , .	2.5	2
1275	In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. <i>Journal of Controlled Release</i> , 2021, 334, 164-177.	4.8	19
1276	Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. <i>Drug Discovery Today</i> , 2021, 26, 1369-1381.	3.2	6
1277	Autologous tumor antigens and boron nanosheet-based nanovaccines for enhanced photo-immunotherapy against immune desert tumors. <i>Nanophotonics</i> , 2021, 10, 2519-2535.	2.9	8
1278	A Focus on "Bio-Bio" in Bio-Nanoscience: The Impact of Biological Factors on Nanomaterial Interactions. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100574.	3.9	23
1279	Long Distance From Microvessel to Cancer Cell Predicts Poor Prognosis in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 632352.	1.3	2
1280	The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689132.	2.2	55
1281	3D Modeling of Epithelial Tumors—The Synergy between Materials Engineering, 3D Bioprinting, High-Content Imaging, and Nanotechnology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6225.	1.8	13
1282	Effects of Irinotecan on Tumor Vasculature and Oxygenation: An <i>in vivo</i> Study on Colorectal Cancer Model. <i>IEEE Journal of Selected Topics in Quantum Electronics</i> , 2021, 27, 1-8.	1.9	9
1283	Core-Shell Plasmonic Nanomaterials toward: Dual-Mode Imaging Analysis of Glutathione and Enhanced Chemodynamic Therapy. <i>Analytical Chemistry</i> , 2021, 93, 10317-10325.	3.2	15
1284	Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents. <i>ACS Omega</i> , 2021, 6, 19252-19268.	1.6	5
1285	Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4527-4544.	3.3	7

#	ARTICLE	IF	CITATIONS
1286	Multifunctional Traceable Liposomes with Temperature-Triggered Drug Release and Neovasculture-Targeting Properties for Improved Cancer Chemotherapy. <i>Molecular Pharmaceutics</i> , 2021, 18, 3342-3351.	2.3	16
1287	Downregulation of tumor-derived exosomal miR-34c induces cancer-associated fibroblast activation to promote cholangiocarcinoma progress. <i>Cancer Cell International</i> , 2021, 21, 373.	1.8	13
1288	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
1289	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 741-757.	1.8	29
1290	Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice. <i>Pharmaceutics</i> , 2021, 13, 1021.	2.0	16
1291	Imitating Hypoxia and Tumor Microenvironment with Immune Evasion by Employing Three Dimensional <i>In vitro</i> Cellular Models: Impressive Tool in Drug Discovery. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 80-91.	0.8	7
1292	Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?. <i>Cancers</i> , 2021, 13, 3466.	1.7	55
1293	Hybrid nano- and microgels doped with photoacoustic contrast agents for cancer theranostics. <i>View</i> , 2021, 2, 20200176.	2.7	7
1294	A Nuclear-Directed Ribonuclease Variant Targets Cancer Stem Cells and Inhibits Migration and Invasion of Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 4350.	1.7	2
1295	Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113920.	6.6	18
1296	Antibody Conjugates for Sarcoma Therapy: How Far along Are We?. <i>Biomedicines</i> , 2021, 9, 978.	1.4	12
1297	The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 441-449.	1.7	3
1298	Avances en citometría de masas y aplicabilidad en patología digital para estudios clínico-traslacionales en oncología. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 17-29.	0.1	0
1299	Targeted Toxins for the Treatment of Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 986.	1.4	5
1300	Convection enhanced delivery of light responsive antigen capturing oxygen generators for chemo-phototherapy triggered adaptive immunity. <i>Biomaterials</i> , 2021, 275, 120974.	5.7	12
1301	Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. <i>ELife</i> , 2021, 10, .	2.8	17
1302	Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	3
1303	Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells. <i>Life Sciences</i> , 2021, 278, 119554.	2.0	5

#	ARTICLE	IF	CITATIONS
1304	Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1 α Expression. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	3
1305	Magnetic systems for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2172-2196.	5.7	40
1306	Bloodâ€“Brain Barrier, Cell Junctions, and Tumor Microenvironment in Brain Metastases, the Biological Prospects and Dilemma in Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 722917.	1.8	13
1307	Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102681.	1.4	9
1308	Tissue Architecture Influences the Biological Effectiveness of Boron Neutron Capture Therapy in In Vitro/In Silico Three-Dimensional Self-Assembly Cell Models of Pancreatic Cancers. <i>Cancers</i> , 2021, 13, 4058.	1.7	4
1309	Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing. <i>Frontiers in Pharmacology</i> , 2021, 12, 709343.	1.6	6
1310	Neutrally charged self-assembling peptide hydrogel recapitulates in vitro mechanisms of breast cancer progression. <i>Materials Science and Engineering C</i> , 2021, 127, 112200.	3.8	19
1311	Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines. <i>Open Biology</i> , 2021, 11, 210161.	1.5	2
1312	The importance of understanding the infectious microenvironment. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e88-e92.	4.6	78
1313	Viability of Nanostructured Lipid Carrier System in Overcoming the Barriers Associated with Chemotherapeutic Delivery. <i>Current Nanoscience</i> , 2021, 17, .	0.7	1
1314	Spatially resolved quantification of drug metabolism and efficacy in 3D paper-based tumor mimics. <i>Analytica Chimica Acta</i> , 2021, 1186, 339091.	2.6	5
1315	Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 721959.	1.3	15
1316	Oxygen transport to mammalian cell and bacteria using nano-sized liposomes encapsulating oxygen molecules. <i>Journal of Bioscience and Bioengineering</i> , 2021, 132, 657-665.	1.1	5
1317	In situ delivery of biobutyrate by probiotic <i>Escherichia coli</i> for cancer therapy. <i>Scientific Reports</i> , 2021, 11, 18172.	1.6	19
1318	Metal peroxides for cancer treatment. <i>Bioactive Materials</i> , 2021, 6, 2698-2710.	8.6	46
1319	Reductantâ€“Free Synthesis of MnO ₂ Nanosheetâ€“Decorated Hybrid Nanoplatfom for Magnetic Resonance Imagingâ€“Monitored Tumor Microenvironmentâ€“Responsive Chemodynamic Therapy and Nearâ€“Infraredâ€“Mediated Photodynamic Therapy. <i>Small Structures</i> , 2021, 2, 2100116.	6.9	20
1320	Preparation of novel cinnamaldehyde derivativeâ€“BSA nanoparticles with high stability, good cell penetrating ability, and promising anticancer activity. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021, 624, 126765.	2.3	13
1321	Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma. <i>Acta Biomaterialia</i> , 2021, 131, 555-571.	4.1	31

#	ARTICLE	IF	CITATIONS
1322	Multiplex gene quantification as digital markers for extremely rapid evaluation of chemo-drug sensitivity. <i>Patterns</i> , 2021, 2, 100360.	3.1	4
1323	Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. <i>Cell Chemical Biology</i> , 2021, 28, 1258-1270.e13.	2.5	21
1324	Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. <i>Oral Oncology</i> , 2021, 120, 105420.	0.8	20
1325	CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response. <i>Nucleic Acids Research</i> , 2022, 50, D1184-D1199.	6.5	26
1326	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 286.	3.5	18
1327	Method of Tumor Pathological Micronecrosis Quantification Via Deep Learning From Label Fuzzy Proportions. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021, 25, 3288-3299.	3.9	9
1328	Acid-sensitive and L61-crosslinked hyaluronic acid nanogels for overcoming tumor drug-resistance. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 11-23.	3.6	14
1329	Cashing in on ferroptosis against tumor cells: Usher in the next chapter. <i>Life Sciences</i> , 2021, 285, 119958.	2.0	14
1330	Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 168, 110-121.	2.0	2
1331	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48
1332	Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 383-398.	2.4	25
1333	Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers. , 2021, , 75-106.		0
1334	Advances of smart nano-drug delivery systems in osteosarcoma treatment. <i>Journal of Materials Chemistry B</i> , 2021, 9, 5439-5450.	2.9	20
1335	Hypoxia-Triggered Self-Assembly of Ultrasmall Iron Oxide Nanoparticles to Amplify the Imaging Signal of a Tumor. <i>Journal of the American Chemical Society</i> , 2021, 143, 1846-1853.	6.6	91
1336	Barriers to Drug Delivery in Cancer: Clinical Implications. , 2009, , 81-104.		1
1337	The Complexity of the HIF-1-Dependent Hypoxic Response in Breast Cancer Presents Multiple Avenues for Therapeutic Intervention. , 2009, , 521-558.		3
1338	Multidrug Resistance in Solid Tumor and Its Reversal. , 2009, , 121-148.		7
1339	Therapeutic Applications of Nitric Oxide for Malignant Tumor in Animal Models and Human Studies. , 2010, , 419-441.		6

#	ARTICLE	IF	CITATIONS
1340	Biological Role, Properties, and Therapeutic Applications of the Reduced Folate Carrier (RFC-SLC19A1) and the Proton-Coupled Folate Transporter (PCFT-SLC46A1). , 2011, , 1-34.		3
1341	Discovery of Novel Antifolate Inhibitors of De Novo Purine Nucleotide Biosynthesis with Selectivity for High Affinity Folate Receptors and the Proton-Coupled Folate Transporter Over the Reduced Folate Carrier for Cellular Entry. , 2011, , 119-134.		3
1342	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology. , 2013, , 187-206.		1
1343	Resistance to Anthracyclines and Taxanes in Breast Cancer. , 2013, , 227-247.		3
1344	Cancer Hypoxia and the Tumour Microenvironment as Effectors of Cancer Metabolism. SpringerBriefs in Systems Biology, 2014, , 7-14.	0.1	2
1345	Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model. The IMA Volumes in Mathematics and Its Applications, 2015, , 1-34.	0.5	16
1346	Cellular Resistance to Oxaliplatin and Drug Accumulation Defects. , 2009, , 115-124.		4
1347	Hsp60 in Cancer Immunity: Biological Basis, Diagnostic Potential and Therapeutic Opportunities. Heat Shock Proteins, 2019, , 117-134.	0.2	3
1348	Nanocarriers as Potential Targeted Drug Delivery for Cancer Therapy. Environmental Chemistry for A Sustainable World, 2020, , 51-88.	0.3	15
1349	Design of Inhibitors of the Human Fibroblast Activation Protein $\alpha 1$ as a Strategy to Hinder Metastasis and Angiogenesis. Engineering Materials, 2020, , 277-303.	0.3	1
1350	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
1351	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 45-64.	0.1	1
1352	Physiological Mechanisms of Treatment Resistance. Medical Radiology, 2009, , 273-290.	0.0	24
1353	Pathophysiology of Solid Tumors. Medical Radiology, 2009, , 51-92.	0.0	43
1354	Contribution of pH Alterations to the Tumor Microenvironment. , 2015, , 173-196.		3
1355	Mass Transport via Cellular Barriers and Endocytosis. Fundamental Biomedical Technologies, 2011, , 3-55.	0.2	4
1356	Computed tomography and photoacoustic imaging guided photodynamic therapy against breast cancer based on mesoporous platinum with insitu oxygen generation ability. Acta Pharmaceutica Sinica B, 2020, 10, 1719-1729.	5.7	16
1357	Aldolase triggers metabolic reprogramming in colorectal cancer in hypoxia and stiff desmoplastic microenvironments. Colloids and Surfaces B: Biointerfaces, 2020, 190, 110969.	2.5	7

#	ARTICLE	IF	CITATIONS
1358	Advances in liposomal drug delivery to cancer: An overview. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 56, 101549.	1.4	113
1359	NIR-dye based mucoadhesive nanosystem for photothermal therapy in breast cancer cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 208, 111901.	1.7	16
1360	The impact of competition between cancer cells and healthy cells on optimal drug delivery. <i>Mathematical Modelling of Natural Phenomena</i> , 2020, 15, 42.	0.9	5
1361	Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. <i>Nanotechnology</i> , 2021, 32, 062001.	1.3	10
1362	A Co-Culture System of Three-Dimensional Tumor-Associated Macrophages and Three-Dimensional Cancer-Associated Fibroblasts Combined with Biomolecule Release for Cancer Cell Migration. <i>Tissue Engineering - Part A</i> , 2020, 26, 1272-1282.	1.6	29
1366	Long-term fluorescence lifetime imaging of a genetically encoded sensor for caspase-3 activity in mouse tumor xenografts. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	11
1367	Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. <i>Journal of Clinical Investigation</i> , 2009, 119, 865-875.	3.9	59
1368	Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. <i>Journal of Clinical Investigation</i> , 2011, 121, 1075-1087.	3.9	46
1369	The impact of hypoxia on tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2016, 126, 3672-3679.	3.9	401
1370	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 589-606.	3.9	105
1371	Leveraging and manufacturing in vitro multicellular spheroid-based tumor cell model as a preclinical tool for translating dysregulated tumor metabolism into clinical targets and biomarkers. <i>Bioresources and Bioprocessing</i> , 2020, 7, .	2.0	12
1372	Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway. <i>Medical Science Monitor</i> , 2016, 22, 4644-4650.	0.5	26
1373	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. <i>PLoS Biology</i> , 2018, 16, e2002930.	2.6	47
1374	Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. <i>PLoS Computational Biology</i> , 2016, 12, e1005077.	1.5	20
1375	Increased Fibrosis and Interstitial Fluid Pressure in Two Different Types of Syngeneic Murine Carcinoma Grown in Integrin β 3-Subunit Deficient Mice. <i>PLoS ONE</i> , 2012, 7, e34082.	1.1	13
1376	Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere [®] . <i>PLoS ONE</i> , 2013, 8, e62630.	1.1	118
1377	Tumor Environmental Factors Glucose Deprivation and Lactic Acidosis Induce Mitotic Chromosomal Instability – An Implication in Aneuploid Human Tumors. <i>PLoS ONE</i> , 2013, 8, e63054.	1.1	38
1378	Differential Effects of Cold Atmospheric Plasma in the Treatment of Malignant Glioma. <i>PLoS ONE</i> , 2015, 10, e0126313.	1.1	63

#	ARTICLE	IF	CITATIONS
1379	Expression of HIF-1 α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. PLoS ONE, 2015, 10, e0129356.	1.1	34
1380	Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS ONE, 2015, 10, e0129433.	1.1	24
1381	Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids. PLoS ONE, 2015, 10, e0137920.	1.1	34
1382	Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro. PLoS ONE, 2016, 11, e0150675.	1.1	12
1383	Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins. PLoS ONE, 2016, 11, e0158116.	1.1	55
1384	Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PLoS ONE, 2017, 12, e0169797.	1.1	25
1385	Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS ONE, 2017, 12, e0183662.	1.1	49
1386	Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma. PLoS ONE, 2018, 13, e0190970.	1.1	8
1387	Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 585-599.	1.6	16
1388	Multidrug Resistance in Hepatocellular Carcinoma. , 0, , 141-158.		9
1389	P-glycoprotein transporter in drug development. EXCLI Journal, 2016, 15, 113-8.	0.5	24
1390	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes and Cancer, 2017, 7, 340-354.	0.6	20
1391	Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget, 2016, 7, 66586-66594.	0.8	53
1392	The anti-fibrotic effect of CV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget, 2016, 7, 75081-75093.	0.8	11
1393	Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget, 2016, 7, 77565-77575.	0.8	12
1394	Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment. Oncotarget, 2017, 8, 1725-1736.	0.8	154
1395	Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget, 2017, 8, 47518-47532.	0.8	39
1396	Chromosomal instability and acquired drug resistance in multiple myeloma. Oncotarget, 2017, 8, 78234-78244.	0.8	21

#	ARTICLE	IF	CITATIONS
1397	Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression. <i>Oncotarget</i> , 2018, 9, 36585-36602.	0.8	16
1398	CD44+/EPCAM+ cells detect a subpopulation of ALDH ^{high} cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?. <i>Oncotarget</i> , 2020, 11, 1545-1555.	0.8	22
1399	Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer. <i>Oncotarget</i> , 2015, 6, 13803-13821.	0.8	35
1400	Enhanced antitumor efficacy of ultrasonic cavitation with up-sized microbubbles in pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 20241-20251.	0.8	14
1401	Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. <i>Oncotarget</i> , 2015, 6, 15752-15771.	0.8	97
1402	IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules. <i>Oncotarget</i> , 2015, 6, 27651-27660.	0.8	62
1403	Multistep, effective drug distribution within solid tumors. <i>Oncotarget</i> , 2015, 6, 39564-39577.	0.8	22
1404	CEST theranostics: label-free MR imaging of anticancer drugs. <i>Oncotarget</i> , 2016, 7, 6369-6378.	0.8	49
1405	Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. <i>Oncotarget</i> , 2016, 7, 35703-35723.	0.8	30
1406	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. <i>Current Pharmaceutical Design</i> , 2016, 22, 4360-4373.	0.9	53
1407	Cancer-on-a-chip for Drug Screening. <i>Current Pharmaceutical Design</i> , 2019, 24, 5407-5418.	0.9	10
1408	Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2019, 22, 483-495.	0.6	6
1409	Engineered Inorganic Nanoparticles for Drug Delivery Applications. <i>Current Drug Metabolism</i> , 2013, 14, 518-530.	0.7	58
1410	Dual Role of Mitophagy in Cancer Drug Resistance. <i>Anticancer Research</i> , 2018, 38, 617-621.	0.5	66
1411	Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e13464.	0.5	20
1412	A clinical trial can determine the course of DDS development. <i>Drug Delivery System</i> , 2014, 29, 39-50.	0.0	1
1413	Overcoming Hypoxia-Induced Chemoresistance in Cancer Using a Novel Glycoconjugate of Methotrexate. <i>Pharmaceuticals</i> , 2021, 14, 13.	1.7	9
1414	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. <i>World Journal of Gastroenterology</i> , 2018, 24, 3222-3238.	1.4	77

#	ARTICLE	IF	CITATIONS
1415	Wnt/ β -catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review). <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	23
1416	Towards an advanced cell-based in vitro glioma model system. <i>AIMS Genetics</i> , 2018, 05, 091-112.	1.9	14
1417	Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases. <i>Mathematical Biosciences and Engineering</i> , 2016, 13, 1185-1206.	1.0	26
1418	Tumor microenvironment and nanotherapeutics. <i>Translational Cancer Research</i> , 2013, 2, 309-319.	0.4	77
1419	Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1117-1127.	1.3	19
1420	Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 172.	0.8	6
1421	Positron emission tomography to assess hypoxia and perfusion in lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 824.	0.9	10
1422	Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. <i>Chinese Journal of Cancer</i> , 2014, 33, 80-86.	4.9	128
1423	Topics on Drug Metabolism. , 2012, , .		9
1424	Cell cycle progression in glioblastoma cells is unaffected by pathophysiological levels of hypoxia. <i>PeerJ</i> , 2016, 4, e1755.	0.9	17
1425	Oral biomaterials for intestinal regulation. <i>Engineered Regeneration</i> , 2021, 2, 116-132.	3.0	6
1426	Tumor Microenvironmentâ€“Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 253-269.	0.8	11
1427	JAK2 regulates paclitaxel resistance in triple negative breast cancers. <i>Journal of Molecular Medicine</i> , 2021, 99, 1783-1795.	1.7	17
1428	Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy. <i>Journal of Mathematical Biology</i> , 2021, 83, 47.	0.8	9
1429	Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 113930.	2.6	5
1430	Gastrointestinal cancer organoidsâ€”applications in basic and translational cancer research. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1459-1470.	3.2	15
1431	Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 114004.	6.6	55
1432	Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. <i>Cell Reports</i> , 2021, 37, 109852.	2.9	8

#	ARTICLE	IF	CITATIONS
1433	Tumor Microenvironment Modulating Functional Nanoparticles for Effective Cancer Treatments. Tissue Engineering and Regenerative Medicine, 2022, 19, 205-219.	1.6	14
1434	Ultrasound-Mediated Drug Delivery With a Clinical Ultrasound System: In Vitro Evaluation. Frontiers in Pharmacology, 2021, 12, 768436.	1.6	12
1435	Erythrocyte Membrane Camouflaged Metal-Organic Framework Nanodrugs for Remodeled Tumor Microenvironment and Enhanced Tumor Chemotherapy. Advanced Functional Materials, 2022, 32, 2107791.	7.8	39
1436	Effects of Tumor Microenvironment on Hyperthermia, Photodynamic and Nanotherapy. , 2009, , 181-201.		1
1437	Cancer in Context: Importance of the Tumor Microenvironment. , 2010, , 43-63.		0
1438	Translating In Vitro Cell Lines Result into Clinical Practice. , 2010, , 183-191.		0
1439	Chapter 7. Mesenchymal Stromal/Stem Cells from Tissue Repair to Destruction of Tumor Cells. , 2010, , 141-158.		0
1440	Glioblastoma: Role of Galectin-1 in Chemoresistance. , 2011, , 261-267.		0
1441	Targeting Tumor Associated Fibroblasts Tumor Associated Fibroblasts and Chemotherapy. , 2011, , 403-418.		0
1442	Pathophysiological Barriers Impeding the Delivery of Heat Shock Protein (HSP)-Based Macromolecules and Nanotherapeutics to Solid Tumors. Heat Shock Proteins, 2012, , 185-199.	0.2	1
1443	Vacuolar H(+)-ATPase in Cancer Cells: Structure and Function. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	0
1444	Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma. , 2013, , 161-181.		0
1445	Chemotherapy Increases Aggressiveness of Prostate Cancer via Epithelial Mesenchymal Transition. Cell Biology: Research & Therapy, 2013, 02, .	0.2	2
1446	Sphingosine-1-Phosphate in Hypoxic Signaling. , 2014, , 199-217.		0
1447	Intravital Microscopy for Molecular Imaging in Cancer Research. , 2014, , 233-262.		0
1448	Case Study: Systems Biology of Chemotherapy Resistance in Hypoxic Cancer. SpringerBriefs in Systems Biology, 2014, , 49-61.	0.1	0
1449	Angiogenesis Inhibition in Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 203-231.	0.0	0
1452	Glucose Intolerance During Adjuvant Chemotherapy for Breast Cancer. Journal of Cancer Prevention & Current Research, 2016, 6, .	0.1	0

#	ARTICLE	IF	CITATIONS
1454	Virotherapies in Pancreatic Cancer. , 2018, , 309-322.		0
1456	THE BI-DIRECTIONAL MIGRATION OF A DYE TRACER INJECTED AT THE EDGE OF PRIMARY OR SECONDARY LUNG TUMORS DURING SURGERY (INITIAL STUDY ON 33 PATIENTS AND CLINICAL IMPLICATIONS). Inter Collegas, 2017, 4, 106-119.	0.0	0
1460	Two-dimensional and three-dimensional cell culture models in vitro: pros and cons. Bulletin of Siberian Medicine, 2018, 17, 188-196.	0.1	6
1461	Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. , 2019, , 57-89.		3
1463	Cancer Drug Resistance. , 2019, , 77-85.		0
1464	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
1465	Effect of tirapazamine on selected kidney parameters in rats treated with cisplatin. Current Issues in Pharmacy and Medical Sciences, 2019, 32, 18-22.	0.1	0
1468	Tissue dynamics spectroscopic imaging: functional imaging of heterogeneous cancer tissue. Journal of Biomedical Optics, 2020, 25, .	1.4	5
1469	A Two-Photon Microimaging-Microdevice System for Four-Dimensional Imaging of Local Drug Delivery in Tissues. International Journal of Molecular Sciences, 2021, 22, 11752.	1.8	5
1470	The role of exogenous epidermal growth factor on Ki-67 proliferation marker expression in the submandibular salivary gland of albino rats receiving doxorubicin. F1000Research, 2020, 9, 1393.	0.8	7
1471	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. BioEssays, 2021, 43, 2000272.	1.2	5
1472	CancÃ©rogenÃ©se et maladie cancÃ©reuse. , 2020, , 31-35.e1.		0
1473	Triculture Model of In Vitro BBB and its Application to Study BBB-Associated Chemosensitivity and Drug Delivery in Glioblastoma. Advanced Functional Materials, 2022, 32, 2106860.	7.8	27
1474	Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration. Advanced Drug Delivery Reviews, 2022, 180, 114031.	6.6	14
1475	The Biology and Function of Extracellular Vesicles in Cancer Development. Frontiers in Cell and Developmental Biology, 2021, 9, 777441.	1.8	28
1476	Multicellular Ovarian Cancer Model for Evaluation of Nanovector Delivery in Ascites and Metastatic Environments. Pharmaceutics, 2021, 13, 1891.	2.0	6
1479	A feasibility study to evaluate early treatment response of brain metastases one week after stereotactic radiosurgery using perfusion weighted imaging. PLoS ONE, 2020, 15, e0241835.	1.1	3
1480	A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data. GigaScience, 2020, 9, .	3.3	5

#	ARTICLE	IF	CITATIONS
1481	A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia. <i>IScience</i> , 2020, 23, 101536.	1.9	16
1484	Kinetic modeling in PET imaging of hypoxia. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 490-506.	1.0	17
1485	Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 830-43.	1.4	22
1486	Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 8369-76.	1.3	25
1488	Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling. <i>American Journal of Cancer Research</i> , 2017, 7, 2333-2349.	1.4	13
1489	Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2018, 8, 354-365.	1.4	22
1490	Why we do what we do. A brief analysis of cancer therapies. <i>EXCLI Journal</i> , 2020, 19, 1401-1413.	0.5	1
1492	Supramolecular Dual Drug Nanomicelles for Circumventing Multidrug Resistance. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 5515-5523.	2.6	6
1493	Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 5-16.	0.1	1
1495	Development of a Microfluidic Device to Form a Long Chemical Gradient in a Tissue from Both Ends with an Analysis of Its Appearance and Content. <i>Micromachines</i> , 2021, 12, 1482.	1.4	3
1497	Stromal Barrier-Dismantled Nanodril-Like and Cancer Cell-Targeted pH-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin. <i>ACS Biomaterials Science and Engineering</i> , 2021, , .	2.6	2
1498	Impact of Collagen Triple Helix Structure on Melanoma Cell Invadopodia Formation and Matrix Degradation upon BRAF Inhibitor Treatment. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101592.	3.9	2
1499	Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 782766.	1.3	29
1500	Evolution under Spatially Heterogeneous Selection in Solid Tumors. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	5
1501	Current developments in modelling the tumour microenvironment in vitro: Incorporation of biochemical and physical gradients. <i>Organs-on-a-Chip</i> , 2021, 3, 100012.	1.8	7
1502	Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins. <i>Frontiers in Oncology</i> , 2021, 11, 761107.	1.3	20
1503	Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring. <i>Cancers</i> , 2021, 13, 5682.	1.7	11
1504	Modulating undruggable targets to overcome cancer therapy resistance. <i>Drug Resistance Updates</i> , 2022, 60, 100788.	6.5	15

#	ARTICLE	IF	CITATIONS
1505	Application of nanogels as drug delivery systems in multicellular spheroid tumor model. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 68, 103109.	1.4	20
1506	The multifaceted role of Matricellular Proteins in health and cancer, as biomarkers and therapeutic targets. <i>Gene</i> , 2022, 815, 146137.	1.0	11
1508	Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters. <i>Cancers</i> , 2022, 14, 499.	1.7	0
1509	Advances in antitumor nanomedicine based on functional metal-organic frameworks beyond drug carriers. <i>Journal of Materials Chemistry B</i> , 2022, 10, 676-699.	2.9	12
1510	Integration of Au Nanosheets and GdOF:Yb,Er for NIR-I and NIR-II Light-Activated Synergistic Theranostics. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 3809-3824.	4.0	13
1511	Caveolae-Associated Molecules, Tumor Stroma, and Cancer Drug Resistance: Current Findings and Future Perspectives. <i>Cancers</i> , 2022, 14, 589.	1.7	8
1512	Tumor-Acidity and Bioorthogonal Chemistry-Mediated On-Site Size Transformation Clustered Nanosystem to Overcome Hypoxic Resistance and Enhance Chemoimmunotherapy. <i>ACS Nano</i> , 2022, 16, 721-735.	7.3	41
1513	Recent developments of iron-based nanosystems as enzyme-mimicking surrogates of interest in tumor microenvironment treatment. , 2022, , 237-265.		0
1514	Mathematical modeling of therapeutic neural stem cell migration in mouse brain with and without brain tumors. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 2592-2615.	1.0	5
1515	Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies exemplified by polyunsaturated fatty acids and other ROS-modulating agents. <i>Drug Delivery and Translational Research</i> , 2022, 12, 2303-2334.	3.0	7
1516	Extracellular Vesicles Mediate the Intercellular Exchange of Nanoparticles. <i>Advanced Science</i> , 2022, 9, e2102441.	5.6	11
1517	Exosomes derived from $\hat{1}3\hat{1}$ -T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment. , 2022, 10, e003832.		24
1518	A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8+ T cell immune response. <i>Journal of Theoretical Biology</i> , 2022, 538, 111028.	0.8	12
1519	New Pyridinium Salt Derivatives of 2-(Hydrazinocarbonyl)-3-phenyl-1H-indole-5- sulfonamide as Selective Inhibitors of Tumour-Related Human Carbonic Anhydrase Isoforms IX and XII. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2637-2646.	0.9	6
1521	Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. <i>Frontiers in Endocrinology</i> , 2021, 12, 710009.	1.5	5
1522	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 422.	7.1	57
1523	Real-Time Monitoring the Efficacy of 7-Hydroxycoumarin to Cells Cultured on Microfluidics in Different Extracellular Ph Environments by Chip-Mass Spectrometry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1524	Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability <i>in vivo</i> and <i>in vitro</i>. <i>Nanotheranostics</i> , 2022, 6, 270-285.	2.7	10

#	ARTICLE	IF	CITATIONS
1525	Liposomal Delivery System. <i>Materials Horizons</i> , 2022, , 109-134.	0.3	1
1526	Metabolism in tumor-associated macrophages. <i>International Review of Cell and Molecular Biology</i> , 2022, 367, 65-100.	1.6	10
1527	Carrier Free O ₂ Economizer for Photodynamic Therapy Against Hypoxic Tumor by Inhibiting Cell Respiration. <i>Small</i> , 2022, 18, e2107467.	5.2	19
1528	In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired resistance derive from quiescent residual cancer cells that overexpress <sc>CRYAB</sc>, <sc>CEACAM6,</sc> and <sc>SOX2</sc>. <i>Journal of Pathology</i> , 2022, 257, 367-378.	2.1	11
1529	GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. <i>Diagnostics</i> , 2022, 12, 676.	1.3	6
1530	Antibody mutations favoring <sc>pH</sc>-dependent binding in solid tumor microenvironments: Insights from large-scale structure-based calculations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 1538-1546.	1.5	4
1531	TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells. <i>Cell Death and Disease</i> , 2022, 13, 285.	2.7	21
1532	Juglone and KPT6566 Suppress the Tumorigenic Potential of CD44+CD133+ Tumor-Initiating Caco-2 Cells In Vitro and In Vivo. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 861045.	1.8	5
1533	The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3052-3063.	1.1	16
1534	Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates. <i>Oncotarget</i> , 2022, 13, 553-575.	0.8	6
1535	Assessing the Future of Solid Tumor Immunotherapy. <i>Biomedicines</i> , 2022, 10, 655.	1.4	34
1536	Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 953-967.	3.3	7
1537	Current Nano-Strategies to Target Tumor Microenvironment to Improve Anti-Tumor efficiency. <i>OpenNano</i> , 2022, , 100042.	1.8	1
1538	In vitro 3D cocultured tumor-vascular barrier model based on alginate hydrogel and Transwell system for anti-cancer drug evaluation. <i>Tissue and Cell</i> , 2022, 76, 101796.	1.0	2
1539	Breaking through the barrier: Modelling and exploiting the physical microenvironment to enhance drug transport and efficacy. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114183.	6.6	10
1540	Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [18F]FMISO. <i>Nuclear Medicine and Biology</i> , 2022, 108-109, 85-92.	0.3	3
1541	Real-time monitoring the efficacy of 7-hydroxycoumarin to cells cultured on microfluidics in different extracellular pH environments by chip-mass spectrometry. <i>Talanta</i> , 2022, 243, 123331.	2.9	8
1542	The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux. <i>Cancer Letters</i> , 2022, 535, 215639.	3.2	5

#	ARTICLE	IF	CITATIONS
1543	Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition. <i>Cancers</i> , 2021, 13, 6124.	1.7	7
1544	Ultrasound Strain Elastography and Contrast-Enhanced Ultrasound in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: A Nomogram Integrating Ki-67 and Ultrasound Features. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 2191-2201.	0.8	2
1545	Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13297.	1.8	8
1546	Improving Cancer Detection and Treatment by pH-Sensitive Peptide Nanoparticle Drug Delivery Platform: Pharmacokinetics, Toxicity, and Immunogenicity Profile. <i>Advanced NanoBiomed Research</i> , 2022, 2, 2100081.	1.7	3
1548	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. <i>Pharmaceutics</i> , 2022, 14, 41.	2.0	27
1549	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?. <i>Frontiers in Oncology</i> , 2021, 11, 718590.	1.3	14
1550	Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. <i>Pharmaceutics</i> , 2022, 14, 866.	2.0	17
1551	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. <i>Science China Technological Sciences</i> , 2022, 65, 1011-1028.	2.0	7
1552	Overcoming Hypoxia-Induced Drug Resistance via Promotion of Drug Uptake and Reoxygenation by Acousto-Mechanical Oxygen Delivery. <i>Pharmaceutics</i> , 2022, 14, 902.	2.0	3
1553	Quantification of vascular networks in photoacoustic mesoscopy. <i>Photoacoustics</i> , 2022, 26, 100357.	4.4	13
1562	Folic Acid-Functionalized Carbon Dot-Enabled Starvation Therapy in Synergism with Paclitaxel against Breast Cancer. <i>ACS Applied Bio Materials</i> , 2022, 5, 2389-2402.	2.3	8
1564	Glioblastoma-Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment. <i>Pharmaceutics</i> , 2022, 14, 1002.	2.0	17
1565	Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, 181.	2.4	33
1566	Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer. <i>Current Oncology</i> , 2022, 29, 3232-3241.	0.9	10
1567	Proton Pump Inhibitors Enhance the Antitumor Effect of Chemotherapy for Esophageal Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2395.	1.7	5
1568	PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. <i>Neoplasia</i> , 2022, 30, 100793.	2.3	6
1569	Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. <i>Chinese Chemical Letters</i> , 2023, 34, 107518.	4.8	124
1571	Hydrogen Sulfide Biology and Its Role in Cancer. <i>Molecules</i> , 2022, 27, 3389.	1.7	47

#	ARTICLE	IF	CITATIONS
1572	A pH-sensor scaffold for mapping spatiotemporal gradients in three-dimensional in vitro tumour models. <i>Biosensors and Bioelectronics</i> , 2022, 212, 114401.	5.3	6
1573	The HIF-1 α as a Potent Inducer of the Hallmarks in Gastric Cancer. <i>Cancers</i> , 2022, 14, 2711.	1.7	9
1574	Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. <i>Drug Delivery</i> , 2022, 29, 1743-1753.	2.5	4
1575	Passiflora mollissima Seed Extract Induced Antiproliferative and Cytotoxic Effects on CAL 27 Spheroids. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2022, 2022, 1-15.	0.7	1
1576	Targeting the Ezrin Adaptor Protein Sensitizes Metastatic Breast Cancer Cells to Chemotherapy and Reduces Neoadjuvant Therapy-induced Metastasis. <i>Cancer Research Communications</i> , 2022, 2, 456-470.	0.7	3
1577	Boosting Anti-tumour Immunity Using Adjuvant Apigenin. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 266-277.	0.9	8
1578	Trends in Nanotechnology to improve therapeutic efficacy across special structures. <i>OpenNano</i> , 2022, 7, 100049.	1.8	11
1580	Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 612-24.	0.9	4
1581	Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system. <i>Drug Delivery and Translational Research</i> , 2023, 13, 135-163.	3.0	59
1582	miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review). <i>Oncology Reports</i> , 2022, 48, .	1.2	5
1583	Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer. <i>Cancer Science</i> , 0, , .	1.7	1
1584	Self-assembled Cupric Oxide Nanoclusters for Highly efficient chemodynamic therapy. <i>Chemistry - an Asian Journal</i> , 2022, 17, .	1.7	3
1585	Macromolecular crowding in the development of a three-dimensional organotypic human breast cancer model. <i>Biomaterials</i> , 2022, 287, 121642.	5.7	3
1586	The dynamic roles of the bladder tumour microenvironment. <i>Nature Reviews Urology</i> , 2022, 19, 515-533.	1.9	24
1587	Vascular damage in tumors: a key player in stereotactic radiation therapy?. <i>Trends in Cancer</i> , 2022, , .	3.8	2
1588	Fluorescent Probes for Sensing and Imaging Biological Hydrogen Sulfide. <i>Analysis & Sensing</i> , 2022, 2, .	1.1	1
1589	Progressing Towards a Human-Centric Approach in Cancer Research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1590	A thermo-sensitive hydrogel composed of methylcellulose/hyaluronic acid/silk fibrin as a biomimetic extracellular matrix to simulate breast cancer malignancy. <i>European Polymer Journal</i> , 2022, 176, 111421.	2.6	4

#	ARTICLE	IF	CITATIONS
1591	Stimuli-responsive polyprodrug for cancer therapy. <i>Materials Today Advances</i> , 2022, 15, 100266.	2.5	4
1592	Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies. <i>Neoplasia</i> , 2022, 32, 100825.	2.3	1
1593	Recent advances in smart nanoplatfoms for tumor non-interventional embolization therapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	6
1594	Synergetic treatment of oxygen microcapsules and lenvatinib for enhanced therapy of HCC by alleviating hypoxia condition and activating anti-tumor immunity. <i>Chinese Chemical Letters</i> , 2023, 34, 107738.	4.8	3
1595	Transcriptomic Profiling Analysis of Castration-Resistant Prostate Cancer Cell Lines Treated with Chronic Intermittent Hypoxia. <i>Cancers</i> , 2022, 14, 3959.	1.7	0
1596	AMPK β 2/HNF4A/BORIS/GLUT4 pathway promotes hepatocellular carcinoma cell invasion and metastasis in low glucose microenviroment. <i>Biochemical Pharmacology</i> , 2022, 203, 115198.	2.0	8
1597	In situ forming oxygen/ROS-responsive niche-like hydrogel enabling gelation-triggered chemotherapy and inhibition of metastasis. <i>Bioactive Materials</i> , 2023, 21, 86-96.	8.6	10
1598	Progress in research and development of temozolomide brain-targeted preparations: a review. <i>Journal of Drug Targeting</i> , 2023, 31, 119-133.	2.1	3
1599	Increased Drug Loading Enhances the Activity of Ellipticine in Poly(<i>N</i> -(2-hydroxypropyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Chemistry and Physics, 2023, 224, .	1.1	2
1600	iRGD-grafted N-trimethyl chitosan-coated protein nanotubes enhanced the anticancer efficacy of curcumin and melittin. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 348-359.	3.6	8
1601	Manganese oxide nano-platfoms in cancer therapy: Recent advances on the development of synergistic strategies targeting the tumor microenvironment. <i>Applied Materials Today</i> , 2022, 29, 101628.	2.3	14
1602	Magnetotactic bacteria AMB-1 with active deep tumor penetrability for magnetic hyperthermia of hypoxic tumors. <i>Biomaterials Science</i> , 2022, 10, 6510-6516.	2.6	4
1603	Development of a series of flurbiprofen and zaltoprofen platinum(<i>iv</i>) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA. <i>Dalton Transactions</i> , 2022, 51, 12604-12619.	1.6	9
1604	Glycosylation on Spermatozoa, a Promise for the Journey to the Oocyte. <i>Biochemistry</i> , 0, , .	0.8	0
1605	Tumor acidity: From hallmark of cancer to target of treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	35
1606	Advances in research on glioma microenvironment and immunotherapeutic targets. , 0, , 14-29.		0
1607	Tumor Distribution by Quantitative Mass Spectrometry Imaging of the Inhibitor of Apoptosis Protein Antagonist Xevinapant in Patients with Resectable Squamous Cell Carcinoma of the Head and Neck (EudraCT Number: 2014-004655-31). <i>Analytical Chemistry</i> , 2022, 94, 12333-12341.	3.2	3
1608	Interleukin-17A mRNA Expression is Associated with the Prognosis of Patients with Colorectal Cancer: A Pooled Meta-Analysis. , 2022, 33, 995-1003.		1

#	ARTICLE	IF	CITATIONS
1609	Ameliorating the antitumor activity of gemcitabine against breast tumor using β -integrin-targeting lipid nanoparticles. Drug Development and Industrial Pharmacy, 0, , 1-13.	0.9	0
1610	Characteristic of Molecular Subtypes in Lung Squamous Cell Carcinoma Based on Autophagy-Related Genes and Tumor Microenvironment Infiltration. Journal of Oncology, 2022, 2022, 1-18.	0.6	0
1611	PRP-1, a toll-like receptor ligand, upregulates the unfolded protein response in human chondrosarcoma cells. Cancer Treatment and Research Communications, 2022, 33, 100644.	0.7	1
1612	Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade. Cancer Discovery, 2022, 12, 2774-2799.	7.7	22
1613	Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance. Current Medicinal Chemistry, 2023, 30, 3335-3355.	1.2	4
1614	The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients. Pharmacogenomics and Personalized Medicine, 0, Volume 15, 817-825.	0.4	0
1615	Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation. International Journal of Molecular Sciences, 2022, 23, 11222.	1.8	9
1616	Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. Pharmaceutics, 2022, 14, 1990.	2.0	17
1617	Low Intensity Focused Ultrasound Ignited α -Deep-Penetration Nanobomb (DPNB) for Tetramodal Imaging Guided Hypoxia-Tolerant Sonodynamic Therapy Against Hypoxic Tumors. International Journal of Nanomedicine, 0, Volume 17, 4547-4565.	3.3	7
1618	Crosstalk between Hypoxia and Extracellular Matrix in the Tumor Microenvironment in Breast Cancer. Genes, 2022, 13, 1585.	1.0	20
1619	Bench to Bedside: New Therapeutic Approaches with Extracellular Vesicles and Engineered Biomaterials for Targeting Therapeutic Resistance of Cancer Stem Cells. ACS Biomaterials Science and Engineering, 2022, 8, 4673-4696.	2.6	1
1620	<i>MYC</i> and therapy resistance in cancer: risks and opportunities. Molecular Oncology, 2022, 16, 3828-3854.	2.1	20
1621	Anti-EGFR Targeted Multifunctional I-131 Radio-Nanotherapy for Treating Osteosarcoma: In Vitro 3D Tumor Spheroid Model. Nanomaterials, 2022, 12, 3517.	1.9	6
1622	Nanoscale CaO ₂ materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model. Acta Biomaterialia, 2022, 154, 536-548.	4.1	12
1623	Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. Frontiers in Immunology, 0, 13, .	2.2	11
1624	Physiology of chemokines in the cancer microenvironment. American Journal of Physiology - Cell Physiology, 2023, 324, C167-C182.	2.1	10
1625	An Overview of Recent Advancements on Manganese-Based Nanostructures and Their Application for ROS-Mediated Tumor Therapy. , 2022, 4, 2415-2433.		2
1626	Nanomodulation and nanotherapeutics of tumor-microenvironment. OpenNano, 2022, 8, 100099.	1.8	0

#	ARTICLE	IF	CITATIONS
1627	Nanoparticle-assisted targeting of the tumour microenvironment. <i>OpenNano</i> , 2022, 8, 100097.	1.8	2
1628	New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113909.	2.5	3
1629	STRATEGIE WALKI ZE ZJAWISKIEM OPORNOŚCI WIELOLEKOWEJ NOWOTWORĂ“W. , 2012, 10, 1-8.		0
1630	CD3â€ˆcellâ€ˆengager (TCE) therapies to overcome solid tumors: Beyond BiTEs. , 2022, 1, .		1
1631	Immune cellâ€ˆcamouflaged surface-engineered nanotherapeutics for cancer management. <i>Acta Biomaterialia</i> , 2023, 155, 57-79.	4.1	8
1632	Roles of m⁶A modification in oral cancer (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
1633	The Therapeutic Potential of Chemo/Thermotherapy with Magnetoliposomes for Cancer Treatment. <i>Pharmaceutics</i> , 2022, 14, 2443.	2.0	9
1634	Strategies to improve drug penetration into tumor microenvironment by nanoparticles: Focus on nanozymes. <i>OpenNano</i> , 2022, 8, 100100.	1.8	1
1635	Establishment of a threeâ€ˆdimensional triculture model on the novel AXTEXâ€ˆ4Dâ„¢ platform. <i>Oncology Reports</i> , 2022, 49, .	1.2	2
1637	Evolution of the Solid Human Tumor Cells Properties in Various Experimental Systems in Vitro. <i>Journal of Hematology and Oncology Research</i> , 2021, 4, 9-29.	1.8	1
1638	Tumor microenvironment-responsive Zn/Cu nanoparticles for enhanced chemodynamic therapy. <i>Smart Materials in Medicine</i> , 2023, 4, 286-293.	3.7	8
1639	Active therapy based on the byproducts of micro/nanomotors. <i>Nanoscale</i> , 0, , .	2.8	4
1640	Focus on mast cells in the tumor microenvironment: Current knowledge and future directions. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188845.	3.3	11
1641	Cell cultures of human CNS tumors as in vitro model for individualized therapeutic approach. <i>Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko</i> , 2022, 86, 84.	0.1	0
1642	Gallium-68â€ˆlabeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. <i>Clinical Cancer Research</i> , 2023, 29, 581-591.	3.2	8
1643	Modern view on the treatment of oncological diseases by endovascular methods. <i>Translational Medicine</i> , 2022, 9, 33-40.	0.1	2
1644	Organismâ€ˆGenerated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy. <i>Advanced Science</i> , 2023, 10, .	5.6	5
1645	The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
1646	Phenotypic Evaluation of Nucleoside Analogues against Trypanosoma cruzi Infection: In Vitro and In Vivo Approaches. <i>Molecules</i> , 2022, 27, 8087.	1.7	7
1647	Recent Advances of Organ-on-a-Chip in Cancer Modeling Research. <i>Biosensors</i> , 2022, 12, 1045.	2.3	14
1648	Monitor Tumor pH and Response Longitudinally during Treatment Using CEST MRI-Detectable Alginate Microbeads. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 54401-54410.	4.0	4
1649	Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect. <i>British Journal of Cancer</i> , 2023, 128, 715-725.	2.9	14
1650	Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC. <i>Molecular Cancer</i> , 2022, 21, .	7.9	4
1651	EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1652	Drug Self-Delivery Systems: Molecule Design, Construction Strategy, and Biological Application. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	12
1653	Hypoxia-responsive nanomaterials for tumor imaging and therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1654	Lymphatic Mechanoregulation in Development and Disease. <i>Biology of Extracellular Matrix</i> , 2023, , 277-311.	0.3	0
1655	Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1657	Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	6
1658	Biomaterial-based in vitro 3D modeling of glioblastoma multiforme. , 2023, 1, 177-194.		2
1659	Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI. <i>Pharmaceutics</i> , 2023, 15, 120.	2.0	1
1660	Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments. <i>Molecules</i> , 2023, 28, 273.	1.7	9
1661	Reconstructing Tumor Microenvironment Using Photoresponsive Cyanobacteria to Reversal Chemoresistance for Robust Chemotherapy. <i>Small Structures</i> , 2023, 4, .	6.9	1
1662	CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. <i>Molecular Cancer</i> , 2023, 22, .	7.9	65
1663	Cellular Invasion Assay for the Real-Time Tracking of Individual Cells in Spheroid or Tumor-like Mimics. <i>Analytical Chemistry</i> , 2023, 95, 3054-3061.	3.2	3
1664	Porous Carbon Materials Enhanced the Therapeutic Efficacy of Anticancer Drugs. <i>Materials Horizons</i> , 2023, , 939-954.	0.3	0

#	ARTICLE	IF	CITATIONS
1665	Facile construction of a 3D tumor model with multiple biomimetic characteristics using a micropatterned chip for large-scale chemotherapy investigation. <i>Lab on A Chip</i> , 2023, 23, 2161-2174.	3.1	2
1666	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4
1667	The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1668	The effect of SMAD4 on the prognosis and immune response in hypopharyngeal carcinoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
1669	Identification of endothelial-related molecular subtypes for bladder cancer patients. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7
1670	Unsung versatility of elastin-like polypeptide inspired spheroid fabrication: A review. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123664.	3.6	3
1671	Acoustic and Magnetic Stimuli-Based Three-Dimensional Cell Culture Platform for Tissue Engineering. <i>Tissue Engineering and Regenerative Medicine</i> , 2023, 20, 563-580.	1.6	3
1672	Current therapy and drug resistance in metastatic castration-resistant prostate cancer. <i>Drug Resistance Updates</i> , 2023, 68, 100962.	6.5	30
1673	The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114504.	2.5	5
1674	CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer. <i>European Journal of Cell Biology</i> , 2023, 102, 151299.	1.6	4
1675	Effect of paclitaxel priming on doxorubicin penetration in a multicellular layer model of human colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 647, 30-36.	1.0	1
1676	Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103920.	2.0	18
1677	Role of hypoxia-inducible factor-1 α and survivin in enhancing radiosensitivity of breast cancer. <i>Journal of Radiation Research and Applied Sciences</i> , 2023, 16, 100530.	0.7	2
1678	Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1679	The hypoxia-inducible factor-1 α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
1680	Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 257-266.	1.8	4
1681	RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer. <i>Cells</i> , 2023, 12, 685.	1.8	2
1682	Personalized Oncology by In Vivo Chemical Imaging: Photoacoustic Mapping of Tumor Oxygen Predicts Radiotherapy Efficacy. <i>ACS Nano</i> , 2023, 17, 4396-4403.	7.3	6

#	ARTICLE	IF	CITATIONS
1683	Expression Dynamics of CA IX Epitope in Cancer Cells under Intermittent Hypoxia Correlates with Extracellular pH Drop and Cell Killing by Ureido-Sulfonamide CA IX Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4595.	1.8	3
1684	Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction. <i>JCO Precision Oncology</i> , 2023, , .	1.5	2
1685	Microenvironmental elements singularity synergistically regulate the behavior and chemosensitivity of endometrioid carcinoma. <i>Human Cell</i> , 2023, 36, 1147-1159.	1.2	1
1686	Future Prospective and Challenges in the Treatment of Cancer. , 2023, , 382-394.		0
1687	Application prospect of calcium peroxide nanoparticles in biomedical field. <i>Reviews on Advanced Materials Science</i> , 2023, 62, .	1.4	6
1689	IFN γ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins. <i>International Journal of Biological Sciences</i> , 2023, 19, 1490-1508.	2.6	0
1690	Alleviating the hypoxic tumor microenvironment with MnO ₂ -coated CeO ₂ nanoplatform for magnetic resonance imaging guided radiotherapy. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	8
1691	Photodynamic and photothermal therapy using PLGA nanoparticles. , 2023, , 357-391.		1
1692	Crosstalk between triple negative breast cancer and microenvironment. <i>Oncotarget</i> , 2023, 14, 284-293.	0.8	2
1693	Evaluating the tumor stratification with a lysosomal pH sensitive-probe by fluorescence lifetime imaging. <i>Chinese Chemical Letters</i> , 2024, 35, 108408.	4.8	2
1694	Rational Molecular Designing of Aggregation-Enhanced Emission (AEE) Active Red-Emitting Iridium(III) Complexes: Effect of Lipophilicity and Nanoparticle Encapsulation on Photodynamic Therapy Efficacy. <i>ACS Applied Bio Materials</i> , 2023, 6, 1445-1459.	2.3	3
1695	Multifaceted Roles of Copper Ions in Anticancer Nanomedicine. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	10
1696	Investigating the spatial interaction of immune cells in colon cancer. <i>IScience</i> , 2023, 26, 106596.	1.9	2
1697	Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	1
1698	Vehicles for Delivery of Therapeutic Agent for Cancer Therapy. <i>Biological and Medical Physics Series</i> , 2023, , 719-753.	0.3	0
1700	Hypoxia and Its Biological Implications for Cancer Therapy. , 2023, , 1-18.		0
1701	Advanced 3D Models of Human Brain Tissue Using Neural Cell Lines: State-of-the-Art and Future Prospects. <i>Cells</i> , 2023, 12, 1181.	1.8	5
1702	Robust formation of optimal single spheroids towards cost-effective <i>in vitro</i> three-dimensional tumour models. <i>FEBS Open Bio</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1704	Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.4	1
1710	Radiation Therapies in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 59-77.	0.2	0
1726	Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. , 2023, , 149-165.		1
1728	Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 959-1020.	2.7	1
1750	Modeling and Simulation of Bio-Inspired Nanorobotic Drug Delivery System. <i>Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering</i> , 2023, , 64-76.	0.2	0
1766	Drug from Marine Sampling to Factory. <i>Marine Ecology</i> , 2023, , 355-393.	0.1	0
1780	Nanomedicines in Treatment of Cancer. <i>Learning Materials in Biosciences</i> , 2023, , 183-211.	0.2	0